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I  
ABSTRACT 
School of Medicine 
Doctor of Philosophy 
 
THE EFFECT OF MANIPULATING APOPTOTIC CELL 
UPTAKE ON THEIR IMMUNOGENICITY 
 
By Kathrine Elizabeth Attfield 
 
Failure of the immune system to differentiate between apoptotic tumour 
cells and cells rendered apoptotic as part of homeostasis prevents a 
successful response being mounted against tumours.  Apoptotic cells are 
cleared rapidly by professional phagocytes thus preventing the release of 
potentially inflammatory or immunogenic material into the surrounding 
environment.  In addition, macrophages release immuno-suppressive 
cytokines such as tumour growth factor β (TGF-β) and interleukin-10 (IL-
10) that dampen the initiation of cytotoxic T cell (CTL) immunity and 
render T cells tolerant.  It was hypothesised that manipulation of this 
clearance pathway, which is normally employed to prevent autoimmunity, 
may alleviate immuno-suppression of apoptotic tumour cells and promote 
the expansion of a tumour antigen-specific T cell response. 
  
Milk fat globule – epidermal growth factor 8 (MFG-E8) is a glycoprotein 
secreted by activated macrophages and immature dendritic cells.  It 
facilitates the uptake of apoptotic cells by acting as a bridging molecule 
between integrins on the phagocyte and phosphatidylserine (PS) on the 
apoptotic cell surface.  Here, two recombinant dominant-negative MFG-E8 
proteins were generated: one which is shown to inhibit PS-dependent 
apoptotic cell uptake by macrophages by over 40% (DN-MFG-E8), and a 
second which re-directed apoptotic cells through Fcγ receptors and 
conferred enhanced phagocytosis by both macrophages and immature 
dendritic cells (DN-MFG-E8-Fc) in a dose-dependent manner. 
 
Cross-presentation of cell-associated antigen by bone marrow-derived 
dendritic cells (BMDCs) was determined by CD8+ T cell proliferation 
assays in vitro and in vivo.  Loading BMDCs with apoptotic cells via a PS-
independent pathway or through Fcγ receptors (FcγRs) reduced their ability 
to induce CD8+ T cell proliferation in vivo, suggesting the blockade of a 
mechanism which is intrinsic for DC maturation or migration.  Similarly, 
the balance between activating and inhibitory FcγRs proved essential for 
effective DC maturation.  Apoptotic cells treated with DN-MFG-E8-Fc 
protein resulted in upregulation of costimulatory molecules, CD86 and 
CD70, when BMDCs were deficient for the inhibitory FcγR, FcγRIIb.   
 
Additionally, the immunosuppressive effect of apoptotic cells on antibody 
production proved dependent on the exposure of PS; whereby both DN-
MFG-E8 and DN-MFG-E8-Fc proteins were shown to alleviate this 
suppression. 
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Chapter 1 
 
Introduction      
 
1.1   Overview 
With the ever aging population in the Western world, cancer has inevitably 
become one of the most common causes of death, second only to 
cardiovascular disease.  Environmental and genetic factors contribute to 
DNA damage or mutations; consequently there is elevated survival and 
proliferation of abnormal cell populations caused by their ability to evade 
or over-ride normal cell growth-regulating mechanisms.  Thus far, 
treatments for cancer include surgery, chemotherapy, radiation therapy and 
immunotherapy.  The success of each is highly variable and as yet there is 
no known universal cure.   
 
One of the key aims in current cancer research is to understand the manner 
in which cancer cells evade recognition by the immune system.  The 
fundamental problem when treating cancer is its inability to be 
distinguished by the immune system as a component other than self.   
Current antibody therapies exist to target tumour cells specific for certain 
markers (antigens) [1].  The results to date are encouraging but far from 
absolute.  Further understanding of the immune response to cancer and the 
manners in which the immune system can be manipulated is therefore 
imperative. 
 
 
 
 
 
 
 
 
 
1  
1.2   The immune system 
The environment challenges our immune system on a continuous basis 
with an endless array of infectious microbes – viruses, fungi, protozoa, and 
multi-cellular parasites.  Their successful infection into a host organism 
will in many cases lead to disease, some of which may prove fatal.   
Fortunately however, the immune system is highly effective in ensuring 
that most infections are short-lived and that any permanent damage is 
minimal.  An immune response can be defined in two steps; firstly, the 
immune system must recognise the pathogen or foreign material and 
secondly it must then initiate an immune response in which to eliminate it 
[2]. 
 
1.2.1  Innate immunity 
Innate immunity is regarded as a defence barrier which comprises of 
‘basic’ mechanisms aimed non-specifically at invading pathogens.  The 
innate immune response is short lived and does not generate long-lasting 
protective immunity against foreign antigen; it serves to limit infection and 
to facilitate activation of the adaptive immune response (see section 1.2.2).  
Innate immunity is considered to comprise of four general defence barriers; 
anatomic (skin and mucous membranes), physiologic (temperature, low 
pH, and chemical mediators), phagocytic (ingestion of extracellular 
particulate material through phagocytosis by blood monocytes, neutrophils 
and macrophages) and inflammation (which allows an influx of phagocytes 
into the infected site).  If an infectious organism eludes innate mechanisms 
or is not cleared by them, the host is equipped to surmount the infection 
through successive activation of the adaptive immune system. 
  
1.2.2  Adaptive immunity 
The adaptive immune system is found exclusively in vertebrates and is 
capable of mounting a reaction against a specific antigenic challenge.  The 
success and specificity of adaptive immunity is owing to its four attributes; 
antigenic specificity, diversity, immunologic memory, and self/non-self 
recognition.    
2  
 
An effective immune response against a specific antigenic challenge is 
mediated by two major groups of cells: lymphocytes and antigen 
presenting cells (APCs).  Both B and T lymphocytes are the key mediators 
of the immune system; however their function is dictated largely by antigen 
presenting cells, namely dendritic cells (DCs).  Innate signalling precedes 
and is essential for the generation of both T and B cell responses and it is 
acknowledged that dendritic cells provide the crucial connection between 
innate and adaptive immunity [3].  There are multiple innate pathways that 
activate DCs, most likely so that infection can be detected at an early stage, 
ensuring that the pathogen has limited time in which to become established 
[4]. 
 
B cells are the precursors of antibody-secreting cells that can directly 
recognise native antigen through their B cell receptors.  T lymphocytes 
however will only recognise antigen via its T cell receptor when it is 
presented to them by an antigen presenting cell through a major 
histocompatibilty complex [5].    
 
1.2.3  Role of the immune system in cancer 
Cancer immunosurveillance: the concept that the immune system can 
recognise and eliminate the development of tumours in the absence of 
external intervention; a hypothesis which has been in the scientific 
community since its first proposal by Paul Ehrlich in 1909 (reviewed in 
[6]). His work was then later revised by Burnett and Thomas ([7] and 
reviewed in [6]), 50 years later, who suggested that the immune system 
continuously surveys the body for the presence of abnormal cells, and can 
eradicate precancerous or cancerous cells through a “surveillance” 
mechanism.    
Only until recently has the technology been available to test this theory. 
Through studying mice with targeted deletion of specific genes and the use 
of monoclonal antibodies (mAbs) against immune components, it has 
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become clear that the immune system has the capacity to both protect from 
and promote tumour growth; re-classifying this hypothesis as cancer 
immunoediting. 
The idea of cancer immunoediting states that there are three phases in the 
evolution of a tumour; elimination, equilibrium, and escape [8].  This 
theory suggests that most tumours have evolved the ability to evade the 
immune system by the time that they become clinically detectable. 
 
 
 
Figure 1.1 Some of the immunological factors that affect tumour development.   
(diagram from N. Bhardwaj. Harnessing the immune system to treat cancer. Journal of 
Clinical Investigation. 2007 [6]) 
Elimination  - The involvement of both the innate and adaptive arms of 
the immune system promote the elimination of cancerous cells.  Studies to 
support this have shown that RAG2-deficient mice (which do not have T or 
B cells) spontaneously develop adenomas of the intestine and lung.   
Additionally, interferon-γ (IFN-γ)-deficient mice also have a higher 
incidence of tumour development [9].  Additionally, the role of NK and 
NKT cells as effectors of immune surveillance was originally established 
when C57BL/6 mice were depleted of both cell types by using an anti-
NK1.1 antibody.  These mice were 2 to 3 times more susceptible to 
developing tumours compared to non-treated mice [10].  Another study to 
support this showed that mice treated with the NKT cell-activating ligand 
α-galactosylceramide after treatment with tumour-inducing agents, showed 
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a reduced incidence of tumours and had a longer latency period of tumour 
formation compared to the control [11].  
Equilibrium -  As a result of tumour elimination, the selection and 
sculpting of tumour cells around the immune response promotes the 
generation of tumour cell variants which decrease their immunogenicity 
and thus are able to become resistant to immune effector cells. Again, 
evidence to support this originates from studies where the transfer of 
tumour cells into wild-type mice that re-emerge during the equilibrium 
phase results in their rejection, however grow progressively in syngeneic 
immunodeficient mice [12]. 
  
Escape     - When this balance is finally tipped in favour of the tumour, its 
ability to escape immune recognition is accomplished by the induction of 
tumour-derived soluble factors into the tumour microenvironment.  Firstly, 
tumours are able to inhibit antigen presenting cell (APC) maturation, thus 
rendering T cells tolerant due to the absence of the necessary costimulatory 
molecules (described further in section 1.3).  T cells are also able to be 
rendered functionally anergic by factors secreted by the tumour.  An 
example of this is indolemine-2,3, dioxygenase (IDO); an enzyme involved 
in tryptophan catabolism that can be over-expressed by tumours [13].  IDO 
is capable of blocking the activation and expansion of T cells, which are 
dependent on tryptophan for cell cycle progression [14].  Additionally, 
tumour infiltrating macrophages (TIMs) can secrete immunosuppressive 
cytokines such as interleukin10 (IL-10) and transforming growth factor β 
(TGF-β).  IL-10 down regulates antigen presentation and T cell expansion 
[15] and TGF-β can directly inhibit T cell activation and proliferation [16].  
 
As an alternative to the model of active immunosuppression, it has been 
suggested that immunogenic tumours do not escape from tumour 
recognition but instead induce a state of immune tolerance by the 
expansion of non-functional T cells [17].  One particular study has shown 
that tumour-specific T cells still have immunogenic potential, however the 
tumour microenvironment induces a state of T cell tolerance [18]. 
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1.3   Antigen processing and presentation 
1.3.1  Introduction 
The immune system is centred on two major types of lymphoid tissues; 
primary lymphoid organs such as the thymus provide the population of T 
cells from precursors, and secondary lymphoid organs such as the spleen, 
lymph nodes and Peyer’s patches represent the sites of immune induction.  
The activation of naïve T cells by their cognate ligand occurs within the 
secondary lymphoid organs.  Each of these organs is responsible for 
surveying different components of the body.  The spleen monitors antigens 
which are derived from the blood, while the lymph nodes screen their local 
regions.  Activated T cells (effector cells) are then able to exit the 
secondary lymphoid organs to the peripheral tissues where they can then 
target the source of immune activation [2].   
 
1.3.2  Role of antigen presenting cells 
 
1.3.2.1  Overview 
To elicit a humoral or cell-mediated immune response to an antigen, T cells 
must recognise and interact with antigen that has been degraded into 
peptides and then processed and presented within the cleft of an MHC 
molecule on the cell membrane.   
 
The majority of cells express MHC class I molecules on their surface, 
therefore are able to present peptide to T cells.  Cells which express 
peptides associated with MHC class I molecules to CD8+ T cells, which 
generally function as cytotoxic T cells (CTLs), are referred to as target 
cells.  A subset of cells, namely antigen presenting cells, in addition to 
expressing MHC class I molecules, also express MHC class II molecules 
on their surface and can present peptides associated with the MHC class II 
molecules to CD4+ T cells, which are typically referred to as T helper (TH) 
cells.  Peptides which are derived from endogenous antigens and processed 
within the cytoplasm; such as self antigens, tumour-associated antigens, 
viral or bacterial antigens are presented with MHC Class I molecules.   
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Exogenous antigens which are internalised by either phagocytosis or 
endocytosis are displayed with MHC Class II molecules.   
 
1.3.2.2  Professional antigen presenting cells 
All professional antigen presenting cells are able to take up antigen and 
present it to CD4+ T cells via MHC class II molecules, causing their 
proliferation and differentiation into effector T cells.  Some antigen 
presenting cells, specifically dendritic cells, are also able to present 
exogenous antigens via MHC class I molecules to CTLs, a process known 
as cross presentation, discussed in section 1.3.5. 
 
Dendritic cells are heterogeneous and can be divided into two subsets; 
plasmacytoid and conventional.  Upon encounter with toll-like receptor 
ligands such as CpG, plasmacytoid DCs produce high levels of type-I 
interferon, they promote activation of other DCs and can block viral 
replication.  They characteristically express CD45RA and only express low 
levels of the integrin CD11c.  Conventional DCs are sub-divided further 
into two groups; blood-derived DCs and tissue-derived DCs.  Blood-
derived DCs are found in the spleen and lymph nodes, whereas tissue-
derived DCs (langerhan’s cells and dermal or ‘interstitial’ DCs) migrate 
only to the lymph nodes. [19].    
 
Macrophages are only able to express MHC class II molecules and the B7 
costimulatory membrane molecules once they have phagocytosed material, 
either of self or non-self origin.  B cells constitutively express MHC class 
II molecules however must undergo activation before they express B7 [2]. 
 
 
1.3.2.3  Non-professional antigen presenting cells 
Fibroblasts, glial cells, pancreatic beta cells, endothelial cells and epithelial 
cells can all be induced to express MHC class II.  In these cases however 
the period of peptide-MHC class II presentation is limited to serve for the 
duration of an inflammatory response [2]. 
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1.3.3  Presentation of endogenous antigens : The cytosolic pathway 
Viruses which infect and then replicate within a cell provide a source of 
endogenous antigens.  Similarly altered self cells such as tumour cells, 
aging body cells or allogeneic cells from a graft also provide a source of 
intracellular antigen for presentation to CD8+ T cells.    
 
1.3.3.1  The Ubiquitin-proteosome system 
The degradation of approximately 80% of both normal and abnormal 
cytosolic proteins is mediated through their ubiquitination and subsequent 
degradation by the 26S proteosome; a 700kD multi-subunit proteolytic 
complex. 
 
Ubiquitin is a 76 residue protein which selectively attaches to proteins; 
causing their remodelling in a manner which affects their stability, activity, 
interactions with other proteins, and their sub-cellular localisation.   
Proteins that have been ubiquitinated are then targeted for proteolysis 
through their recognition by the proteosome.  The proteosome removes 
denatured, misfolded, damaged and improperly translated proteins.   
Additionally, it also regulates the levels of proteins such as cyclins and 
transcription factors.  It is made up of a core protease – barrel shaped 20S 
complex (referred to as the 20S proteosome) which is responsible for the 
proteolytic activity of the proteosome.  It consists of four stacked rings; 
two outer α-rings and two inner β-rings.  Each ring is comprised of 7 
subunits, one stacked on top of the next.  In addition to the 20S 
proteosome, the 26S proteosome also consists of two 19S regulatory 
particles which cap the ends of the 20S proteosome.  These subunits 
control the recognition of the ubiquitinated proteins, the ATP-dependent 
unfolding and the opening of the channel in the 20S proteosome that allows 
entry into the proteolytic chamber. 
 
1.3.3.2  Immunoproteosome 
The degradation of endogenous proteins into peptides for presentation by 
MHC class I molecules also utilises this proteosomal pathway, however, 
the activation of the 20S proteosome is not regulated by the 19S regulatory 
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particles but through the binding of PA28.  PA28 is a ring-shaped, 11S 
multimeric complex consisting of two homologous subunits, α and β, and 
the Ki antigen.  PA28, the expression of which is inducible by IFN-γ, binds 
to 20S along with a 19S regulatory particle to form the 
immunoproteosome.  The immunoproteosome is capable of generating 
MHC class I-binding peptides due to its ability to dramatically enhance its 
capability to hydrolyse oligopeptides which leads to the generation of small 
oligopeptides suitable for MHC class I presentation  [20]. 
 
Peptides generated through this immunoproteosomal pathway are 
transported to the rough endoplasmic reticulum (RER) via a protein, TAP 
(transporter associated with antigen processing).  TAP belongs to the 
family of ATP-binding cassette proteins and is a membrane spanning 
heterodimer that consists of two subunits, TAP1 and TAP2.   
 
The α-chain and β2-microglobulin components of the class I molecule are 
synthesized on polysomes along the rough endoplasmic reticulum.  The 
MHC class I complex can only assemble and exit the RER when there is a 
peptide within the binding groove.  Calnexin is a resident membrane 
chaperone protein in the ER which associates with free class I α chains and 
promotes its folding.  When the β2-microglobulin chain binds to the α 
chain, calnexin is released and the class I molecule can then associate with 
the chaperone calreticulin and tapasin.  Tapasin (TAP-associated protein) 
facilitates the TAP transporter into proximity with the MHC class I 
molecule and allows it to acquire the antigenic peptide.  Once the MHC 
class I-peptide complex is generated, it confers increased stability allowing 
its release from the calreticulin and tapasin and its exit from the RER; after 
which it proceeds to the cell surface via the Golgi [2].      
 
1.3.4  Presentation of exogenous antigens : The endocytic pathway 
APCs are able to ingest material via either phagocytosis or endocytosis.  
Once the material has been internalised the antigens are degraded into 
peptides within increasingly acidic compartments of the endocytic 
pathway; early endosome (pH6 – 6.6) to the late endosome (pH5 – 6) to the 
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lysosome (pH 4.5-5).  In each compartment, the peptides encounter 
hydrolytic enzymes which promote their gradual degradation into 13-18 
amino acids in length, which is the optimal length for MHC class II 
binding.   
 
When the MHC class II molecules are generated in the RER, the molecule 
associates with another protein called the invariant (Ii) chain which 
prevents it from binding to the same peptides as MHC class I molecules.  
Three pairs of class II αβ chains associate with a preassembled invariant 
chain trimer.  This trimeric protein interacts with the peptide binding cleft 
of the class II molecules, preventing any endogenously derived peptides 
from binding to the cleft while the MHC class II molecule is within the 
RER. 
 
The MHC class II-invariant chain complex is then processed through the 
endocytic pathway used to degrade antigenic peptides.  This movement 
through increasingly acidic compartments causes gradual degradation of 
the invariant chain.  The only part of the chain which remains is called 
CLIP (class II-associated invariant chain peptide).  CLIP prevents 
premature binding of the peptide.  The protein HLA-DM then removes 
CLIP and subsequently loads the MHC class II molecules with antigenic 
peptides.  The MHC class II-peptide complex can then translocate to the 
plasma membrane where the pH is neutral, therefore conferring its stability 
[2].   
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Figure 1.2 Antigen processing and presentation.  Schematic representation of antigen 
processing via the MHC class I, MHC class II, and cross-presentation pathways. 
Exogenous antigen is internalised by antigen presenting cells and processed within the 
lysosomal compartments where it associates with MHC class II molecules before 
translocating to the cell surface as an MHC class II –peptide complex for presentation to 
CD4+ T cells.  Endogenous antigen is processed through the proteosome, passes into the 
endoplasmic reticulum through TAP where is associates with MHC class I molecules 
before translocating to the cell surface as an MHC class I – peptide complex for 
presentation to CD8+ T cells.    
 
1.3.5  Cross-presentation 
 
1.3.5.1  Overview 
The limitation of MHC class I- and MHC class II-peptide complexes to 
stimulate CD8+ and CD4+ T cells respectively is referred to as self-MHC 
restriction.  Self-MHC restriction is designed to ensure that only infected or 
self-altered cells are killed, meaning that bystander cells which have 
endocytosed infected debris cannot process these antigens and present them 
with MHC class I molecules and therefore become targets themselves.     
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Some cell types, in particular dendritic cells are able to use distinct 
endocytosis mechanisms to simultaneously introduce antigen into separate 
intracellular compartments dedicated to either presentation with MHC class 
I or MHC class II molecules [21].  The access of exogenous peptides into 
the MHC class I presentation pathway is referred to as cross-presentation 
(as shown in figure 1.2).  Cross-presentation of exogenous antigen is 
required for effective immunity against viruses that do not infect 
professional APCs directly or against tumour antigens that are not 
endogenously expressed by them [19].  As discussed previously, there are 
many DC subsets; only some of these are able to efficiently cross present 
exogenous antigen, some do this constitutively such as murine CD8α
+ 
DC’s [22] and others cross-present upon activation by stimuli such as 
immune complexes (discussed further in section 1.4), T cell help, and toll-
like receptor ligands.  Other cell types such as B cells, endothelial cells and 
macrophages have also been reported to be able to cross-present [23, 24].   
 
Recent evidence suggests that it is the manner in which exogenous antigen 
is taken up by APCs which controls their ability to cross present antigen to 
CD8+ T cells [21].  The mannose-receptor for example introduces 
exogenous antigen through endocytosis.  This method of uptake allows 
antigen to localise in early endosomes but is excluded from late endosomes 
or lysosomes, thus permitting access to the MHC class I presentation 
pathway.  The constitutive pinocytosis of antigen by APCs is however 
transported exclusively towards lysosomes where it can co-localise with 
MHC class II molecules.  This apparent receptor dependence for cross-
presentation may allow APCs to restrict their ability to cross-present 
antigen depending on their stages or maturation or to limit cross-
presentation of specific classes of antigen.  It is also plausible for it to be 
subsequently limited to particular APC subpopulations; such as the murine 
CD8α
+ DC subset which expresses the mannose receptor [25].   
 
The constitutive pinocytosis observed in all DC subsets ensures that DCs 
which cross-present are also able to acquire antigen for the induction of 
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cognate CD4+ T cell help; which requires that the same DC stimulates both 
specific CD4+ and CD8+ T cells (see section 1.3.5.2).   
 
The resulting T cell activation after presentation of exogenous antigen with 
class I molecules leads to two fundamentally different immune outcomes.  
The first is termed cross priming.  In this instance, T cells become 
stimulated and expand into peptide-specific CTLs after which they can 
then travel into the peripheral tissues and target cells expressing their 
cognate ligand [26].  Conversely, cross-presentation of antigen can also 
lead to cross-tolerance where by T cells which are specific for the peptide 
being presented are either deleted or rendered anergic; a process which is 
essential for the maintenance of peripheral tolerance and the prevention of 
autoimmunity [27].   
 
1.3.5.2  DC maturation state dictates immune outcome 
The ability of exogenous antigen to become internalised and transported to 
the cytosol for presentation within the MHC class I complex is restricted to 
the early immature state of dendritic cells [28].  In the peripheral tissues, 
DCs are immature and characteristically express low levels of MHC class I 
and class II molecules, CD86, CD40 and CD54.  They are however highly 
efficient at antigen capture either by taking up particles or microbes by 
phagocytosis, forming large pinocytic vesicles in which extracellular fluid 
is sampled (macropinocytosis) or by receptor mediated endocytosis in 
which they utilise numerous surface receptors including αvβ5 integrin, 
CD36 and Fcγ-receptors [29] (discussed further in section 1.5.3).  During 
the course of an infection, DCs will mature either as a result of a pathogen 
such as the binding of lipopolysaccharide (LPS) or whole bacteria to toll-
like receptors (TLRs) or indirectly through inflammatory stimuli such as 
interleukin-1 (IL-1), granulocyte-macrophage colony stimulating factor 
(GM-CSF), or tumour necrosis factor α (TNF-α).  In the first stages of DC 
maturation, TLRs enhance the ability of DCs to capture antigen through 
up-regulating macropinocytosis.  This results in their improved capability 
of antigen presentation on MHC class I and class II molecules [30].   
Further DC maturation leads to their eventual down-regulation of endocytic 
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ability followed by their subsequent migration to the draining lymph nodes 
where they can then terminally differentiate [29]. 
 
The two signal model of T cell activation is typically used to explain how 
cross-presentation of exogenous antigen can either lead to cross-priming or 
cross-tolerance.  The first signal of T cell activation is provided for by the 
expression of MHC-peptide complexes which permits T cell receptor 
signalling.  The second signal is provided for upon DC maturation when co 
stimulatory molecules are up-regulated.  Evidence suggests that only the 
two signals working simultaneously ensure efficient T cell activation.   
Signal 1 in the absence of signal 2 causes the T cell to become deleted or 
alternatively induces a state of antigen-specific T cell unresponsiveness or 
anergy, referred to typically as tolerance [31]. 
 
In the absence of inflammation, effective CTL immunity can also be 
generated by a process referred to as DC licensing [32].  DC licensing 
describes the interaction between CD154 on activated CD4+ T helper cells 
and CD40 on DCs which promotes DC maturation, enhancing their 
expression of the costimulatory molecules CD80, CD86, CD70, 4-1BB 
ligand, and OX40 ligand on their surface and subsequently allows them to 
become fully competent at stimulating naïve CD8+ T cells [33].  DC 
licensing can also be induced without CD4+ T cell help by substitution 
with artificial stimuli such as the addition of the CD40 ligand, IL-1β or IL-
12  [33].    
 
1.3.5.3  Apoptotic cells provide a source of antigen for cross-
presentation 
The engulfment of apoptotic cells by dendritic cells provides a source of 
antigen which can be cross-presented for the generation of both MHC class 
I and MHC class II complexes [34].  Cross-presentation refers to the ability 
of antigens to “cross” classically defined restrictions for MHC class I 
presentation [35] and accounts for both the cross-priming and cross-
tolerance of apoptotic cell associated antigens.  Both macrophages [36] and 
dendritic cells [37] are able to cross-present antigens from apoptotic cells 
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in vitro however it is the migration of dendritic cells to secondary 
lymphoid organs after antigen capture which gives them their unique 
ability of presenting cell-associated antigen to CD8+ T cells in vivo. 
 
One of the first reports showing that antigen derived from apoptotic cells 
could be cross-presented to T cells by antigen presenting cells was by 
Albert and colleagues in 1998.  They showed that uninfected dendritic cells 
but not macrophages could acquire antigen from Influenza A virus-infected 
monocytes and cause proliferation of virus-specific CTLs in vitro [38].  
Continuous studies thereafter have supported this evidence, showing that 
dendritic cells can process antigen from apoptotic cells that contain whole 
or partially processed protein.  In addition to this, studies have also been 
completed which highlight the ability of the apoptotic cell to process 
antigens before being taken up by the DC through utilising its own 
proteosome and transporter machinery; the process of which does not then 
have to rely on antigens having to access the endocytic pathway of the DC.  
Apoptotic cells are therefore likely to play an active role in antigen 
presentation through the delivery of processed antigen which would allow 
for efficient generation of MHC class I – peptide complexes by the DC 
[34].     
 
In the mouse, cross-presentation of cell-associated antigens is observed 
exclusively by a subset of dendritic cells which express high levels of 
CD11c, CD8α, DEC-205 and CD36.  Studies have shown that they are 
highly efficient at internalising apoptotic cells in contrast to other murine 
DC subsets [39].   
 
DCs are also able to ingest apoptotic tumour cells and present tumour 
associated antigens to immune cells [40].  The differences in tumour 
associated antigen processing and presentation by DCs depends on the 
source or form of the tumour-derived materials, the maturation stage of the 
DCs, and the responsiveness of the T cell populations available for 
stimulation by DCs [41].  Recent data has shown that initial priming of 
tumour specific T cells does not necessarily lead to long lasting protective 
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immunity against the tumour.  DCs pulsed with peptide and matured ex 
vivo are able to stimulate naïve tumour-specific T cells causing reduction in 
tumour size.  T cells which were however persisting within the tumour 
environment gradually lost their antigen reactivity and became tolerant.  To 
elicit an effective anti-tumour response, T cells must be efficiently primed 
but must also be protected from the suppressive mechanisms of the tumour 
microenvironment to avoid tolerance [42].   
 
1.3.5.4  Dendritic cells play a vital role in peripheral T cell tolerance 
To prevent autoimmunity, mature T cells do not respond to self-peptides 
that are presented to them.  The development of both the B and T cell 
repertoire involves the rearrangement of immunoglobulin and T cell 
receptor genes to produce clones of lymphocytes which display unique 
receptors.  This rearrangement is random and therefore clones which 
respond to self are also generated.   During T cell development, only those 
T cells that have no, or low affinity towards the peptide antigens which are 
present in the thymus are allowed to mature and enter the circulation.  Any 
T cells that react with self-peptides which are presented to them by MHC 
molecules on murine thymic epithelial cells or dendritic cells are deleted, a 
process referred to as central tolerance.  Not all self antigens are 
represented in the thymus and consequently further deletion or silencing of 
self-reactive T cells in the peripheral tissues is imperative for the 
prevention of an autoimmune response; a process which is referred to as 
peripheral tolerance [43].      
 
Under steady state conditions (i.e. in the absence of infectious or 
inflammatory stimuli), DCs ingest exogenous antigen and migrate from the 
peripheral tissues to the lymphoid tissues.  Dendritic cells which present 
self-antigens in these conditions will not have received any maturation 
stimuli.  Their remaining immature state means that they will express low 
levels of co stimulatory molecules and thus will tolerize both self reactive 
CD4+ and CD8+ T cells (cross-tolerance) [44].   
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To the most part, peripheral tolerance to self antigens prevents the onset of 
autoimmunity so must therefore be considered as advantageous to the host.  
There are, as would be expected, exceptions to this rule where by cross-
tolerance is detrimental to the elimination of persistent infections such as 
HIV-1 or tumour cells, where the antigenic load is continuously high, 
resulting in the deletion or silencing of HIV-1 or tumour-specific T cells.   
 
As an example, the induction of tumour-antigen specific T cell tolerance by 
B cell lymphomas in vivo is attributed to bone marrow derived antigen 
presenting cells.  These APCs take up antigens shed from tumours and then 
present processed antigenic peptides to antigen-specific T cells.  The T 
cells, upon failure of receiving co-stimulation, are then either deleted or 
rendered anergic [45].   
 
The manner in which tumour cells are cleared by dendritic cells greatly 
influences the efficiency in which the tumour antigen is processed and 
presented.  The targeting of antigen to Fcγ receptors expressed on the 
dendritic cell surface has proven to enhance cross-presentation [46], a 
strategy which is currently of great interest for the immunotherapy of 
tumours. 
 
1.3.6  Role of Fcγ receptors in controlling immune outcome 
1.3.6.1  Overview 
As part of the immune response to bacterial infection, antibodies are 
secreted by plasma cells. Upon their encounter with microbes, they 
opsonise their surface and stimulate their ingestion by phagocytes through 
the interaction of Fc receptors, expressed constitutively on the phagocyte 
surface.  There are five classes of antibody – IgG, IgA, IgM, IgD and IgE 
all of which have a basic unit of two light chains and two heavy chains, the 
chains of which are folded into regions called domains.  Immunoglobulins 
are bifunctional in which one region of the molecule binds to its cognate 
antigen, while another region mediates their effector functions depending 
on the class of antibody.  Immunoglobulin G (IgG) is the most abundant 
class in serum, typically consisting of approximately 80% of the total 
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serum immunoglobulin.  The IgG molecule is made up of two γ heavy 
chains and two κ or two λ light chains.   
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Figure 1.3 General structure of the IgG molecule.   The N-terminal end of IgG is 
characterised by its variable region in both the heavy and light polypeptide chains, 
referred to as the VH and VL regions, respectively.   The constant region of the light chain 
is termed CL.  The constant region of the heavy chain is divided into three structurally 
discrete regions: CH1,  CH2, and CH3.  These domains are stabilised by intrachain 
disulphide bonds.  The hinge region allows flexibility permitting the two antigen-binding 
sites to operate independently.  Carbohydrate units are attached to the CH2 domains.   
 
The four subclasses of IgG in mammals are distinguishable by their 
differences in γ-chain sequences and in mice are numbered IgG1, IgG2a, 
IgG2b and IgG3 (see figure 1.3 for basic IgG structure) [2].  Each subclass 
has evolved to drive different effector immune responses such as 
cytotoxicity, phagocytosis, and the release of inflammatory mediators.   
Their expression is largely dictated by a number of factors, such as the 
cytokines released during the start of an immune response and also the type 
of stimulating antigen.  Among the different subclasses, IgG2a and IgG2b 
are considered the most potent for the activation of effector responses and 
dominate antiviral and autoimmune responses.  The different level of 
potencies observed by the different IgG subclasses is attributable to their 
differential binding to Fcγ receptors [47].     
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1.3.6.2  Fcγ receptors 
The interaction of Fc receptors for IgG provide a good example of how 
simultaneous triggering of activating and inhibitory signalling pathways set 
thresholds for cell activation and generate a well-balanced immune 
response.  The murine Fcγ receptor family includes the high affinity FcγRI, 
low affinity FcγRIIb and FcγRIII, and the intermediate affinity FcγRIV.   
 
1.3.6.3  Activating Fcγ receptors 
Activating Fcγ receptors (FcγRI, FcγRIII and FcγRIV) are expressed on all 
myeloid cells (neutrophils, monocytes, macrophages, and dendritic cells) 
and are not expressed on lymphoid cells. They associate with the gamma 
chain which transmits the activation signal. The intracellular region of the 
gamma chain contains an Immunoreceptor Tyrosine-based Activation 
Motif (ITAM) in their cytoplasmic tail that binds IgG either with relative 
high or low affinity.  Signalling through this ITAM occurs by cross-linking 
of the ligand binding extracellular domain. This then results in the 
phosphorylation of the tyrosine of the ITAM by members of the src kinase 
family, following subsequent recruitment of the SH2 containing signalling 
molecules.  The cellular phenotypes associated with activation through 
these Fcγ receptors include degranulation, phagocytosis, antibody-
dependent cellular cytotoxicity (ADCC), the transcription of cytokine 
genes, and the release of inflammatory mediators.  Mice which do not 
express these activation receptors are resistant to various autoimmune 
diseases such as collagen-induced arthritis (CIA) and glomerulonephritis 
[48, 49].   
 
1.3.6.4  Inhibitory Fcγ receptor IIB 
The activation responses observed by FcγRI, III and IV are modulated in 
the presence of the inhibitory Fcγ receptor IIB (FcγRIIB).  FcγRIIb is the 
most widely expressed FcR and is the only one expressed on B cells and 
the only inhibitory Fcγ receptor in the mouse. It is expressed on effector 
cells such as macrophages, dendritic cells, neutrophils, and mast cells, 
however is not expressed on T and NK cells.  FcγRIIb exists in a 
monomeric form that encodes an Immunoreceptor Tyrosine-based 
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Inhibition Motif (ITIM), the signalling of which promotes an inhibitory 
response, functioning to suppress B cell, mast cell and macrophage 
activation by cross-linking the B cell receptor (BCR) or FcRs [49].  It is 
subsequently able to suppress the development of autoimmune diseases 
such as CIA.  Macrophages from FcγRIIb 
-/- mice are hyper-responsive to 
stimulation with IgG immune complexes (antibody:antigen complexes) 
which leads to the augmented release of pro-inflammatory cytokines such 
as interleukin-1α (IL-1α); promoting the up-regulation of integrins and 
adhesion molecules [50].  Similarly on dendritic cells, the expression of 
FcγRIIb enforces peripheral tolerance by inhibiting effector T cell 
responses.  The coengagement of activating Fcγ receptors with the 
inhibitory receptor is able to suppress both human and mouse ITAM-
induced DC maturation [51].   
 
1.3.7  Fcγ receptor-mediated maturation and cross-priming potential 
of dendritic cells 
 
1.3.7.1  Overview 
In addition to mediating the internalisation of antigen-IgG complexes and 
promoting efficient MHC class II-restricted antigen processing and 
presentation, Fcγ receptors are also able to induce the maturation of 
dendritic cells upon antigen capture; and additionally sanction their 
processing of exogenous antigen into the MHC class I-restricted 
presentation pathway (cross-presentation) [52].  
 
1.3.7.2  IgG-complexed antigens are transported into specific 
compartments for cross-presentation 
Early studies observing the internalisation by phagocytes, such as 
macrophages, of IgG-opsonised particles through Fcγ receptors provided 
evidence that distinct cytoskeletal structures are involved in the 
phagocytosis compared to other receptors such as those mediated through 
complement [53].  This supports much more recent data in which IgG-
complexed antigens are transferred from the endocytic or lysosomal 
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compartments to the cytosol via the TAP transporter where they reach the 
conventional MHC class-I presentation pathway.    
 
FcγR-mediated internalisation of IgG-opsonised particles is only able to 
promote cross-presentation of antigen into the MHC class I pathway by 
dendritic cells.  FcγR internalisation by macrophages or transfected B 
lymphoma cells does not result in MHC class I presentation, even though 
both are efficient in mediating FcγR-mediated IC internalisation.   
 
1.3.7.3  FcγR-induced DC maturation and MHC class-restricted antigen 
presentation 
The engagement of Fcγ receptors induces dendritic cell maturation, as 
determined by their increased surface expression of MHC, CD40, CD80 
and CD86 upon internalisation of IgG-opsonised material as comparable to 
that observed with LPS or inflammatory cytokines.  FcγR-mediated cross-
priming of antigen is, as well as being specific to dendritic cells, only 
achievable by immature dendritic cells [52], suggesting that access to the 
cross-presentation pathway is limited to the time prior to their maturation.     
 
The ability of dendritic cells to capture antigen via Fcγ receptors and 
induce both MHC class I and MHC class II antigen presentation whilst 
undergoing maturation, permits not only the role of CD4+ T cells in 
providing cognate help for CD8+ T cells responses, but also allows the 
bypassing of cognate help and the priming of CD8+ T cells directly.  This 
role, specifically held by dendritic cells would implicate immune 
advantages in both anti-viral and anti-tumour immune responses.   
Conversely, it could also lead to the onset of a cytotoxic CD8+ T cell 
response against a self-antigen [52]. 
 
1.3.8  Inducing tumour immunity through engagement of activating 
Fcγ receptors on dendritic cells. 
 
The vaccination of patients with defined tumour-specific peptides restricts 
the T cell repertoire and does not allow for CD4+ T cell help.  The 
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advantage of using full length protein is that is has the potential to induce 
both CD8+ and CD4+ T cell responses against multiple epitopes.   
Numerous studies have shown that coating whole tumour cells with anti-
tumour monoclonal antibodies (mAbs) leads to enhanced cross-
presentation by dendritic cells to tumour-specific CD8+ T cells.  Moreover, 
research has shown that this is dependent of Fcγ receptor-mediated tumour 
cell clearance [54]. 
 
Studies to determine whether DCs loaded with tumour cells via Fcγ 
receptors could be effective in cancer therapies started by firstly 
determining which DC population is best for tumour antigen cross-
presentation, their required maturation state and also how or if they need to 
be activated prior to vaccination.  In one such study, primary human DCs 
were isolated directly from the blood (PBDCs) or generated in vitro from 
monocytes or from CD34+ progenitors.  Only CD1+ PBDCs and 
monocytes-derived DCs were capable of cross-presentation.  Plasmacytoid 
DCs as well as B cells, monocytes, and macrophages were unable to cross-
present tumour-associated antigen, irrespective or their maturation status.  
Targeting tumour antigen to Fcγ receptors however enhanced the cross-
presentation ability of plasmacytoid DCs [55].       
 
Human dendritic cells which are positively selected 4 h post culture with 
live mAb-treated tumour cells were shown to present tumour antigen more 
efficiently than DCs loaded with apoptotic tumour cells.  This was not, 
however attributable to the increased phagocytosis observed, as control 
mAbs did not cause this enhanced efficiency.  Additionally, treatment of 
the DCs with antibodies against FcγR is able to abrogate the increased 
cross-presentation by the DCs suggesting that this mechanism is clearly 
FcγR mediated [56].  This would suggest Fcγ receptor engagement 
increases the activation state of the dendritic cells rather than their 
phagocytic ability. 
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1.4   Apoptotic cell clearance 
1.4.1  Programmed cell death 
 
1.4.1.1  Apoptosis 
Apoptosis is commonly construed as a non-inflammatory form of 
programmed cell death where by cells are able to activate an intracellular 
pathway which orchestrates their demise [57].  Characterised by cell 
shrinkage, chromatin condensation, nuclear fragmentation, preservation of 
organelles and cell surface changes [58, 59], apoptotic cell clearance in 
vivo occurs rapidly and efficiently.  This prevents lysis and consequently 
affords the protection of surrounding tissues from the release of potentially 
noxious or immunogenic substances  [59, 60].  In some cell lineages, 
apoptosis is distinguished by blebbing of the plasma membrane which 
often leads to the detachment of membrane-bound bodies that can contain 
organelles or nuclear fragments.  (Reviewed in [61]).  
 
The treatment of cells with apoptotic stimuli such as ultraviolet radiation 
has been shown to promote the release of uric acid, an endogenous 
immunological danger signal which promotes dendritic cell maturation 
upon antigen capture in its presence.  The release of uric acid is thought to 
have an important role in immune surveillance by alerting the immune 
system to the presence of dying cells [62]. 
 
1.4.1.2  Necrosis 
 
Necrosis is traditionally referred to as a passive form of cell death in which 
cells die when subjected to high levels of stress caused by numerous toxins, 
hypoxia or extremes of temperature.  The resulting depletion in ATP 
prevents cell survival causing vacuolation of the cytoplasm and breakdown 
of the plasma membrane; the result of which is subsequent release of 
cellular contents such as heat shock proteins (HSPs) and high mobility 
group box protein 1 (HMGB1) into the local environment.  This in most 
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instances leads to inflammation and results in damage to neighbouring cells 
[59].   
 
Heat shock proteins (HSP) including gp96, calreticulin, hsp90 and hsp70 
are intracellular, soluble proteins that are conserved from bacteria to 
mammals.  Their release into the extracellular plasma induces macrophage 
stimulation and the subsequent release of cytokines such as tumour 
necrosis factor-α (TNF-α) [63].  Heat shock proteins bind to heat shock 
protein receptors on antigen presenting cells such as macrophages and 
dendritic cells, allowing the production of HSP-peptide complexes which 
are capable of inducing a partial maturation signal to dendritic cells [64].  
Studies have shown that only microgram quantities of HSP-peptide 
complexes are required to immunise rats or mice to elicit antigen-specific T 
cell responses [65].   
 
A key characteristic of cells which have undergone necrosis is their passive 
release of the ubiquitous nuclear protein, high mobility group box protein 1 
(HMGB1).  HMGB1 is secreted by endotoxin- or pro-inflammatory 
cytokine-activated macrophages and acts as a late mediator of 
endotoxaemia and sepsis [66].  Passive immunisation with neutralising 
antibodies is able to prevent organ damage and epithelial dysfunction in 
mice subjected to severe sepsis [67] Apoptotic cells in clear contrast retain 
HMGB1 bound to their chromatin.  The presence of HMGB1 in 
extracellular tissue can therefore be used as a necrotic marker [68].   
Extracellular HMGB1 acts as an endogenous adjuvant to promote DC 
maturation.  In tissue repair, HMGB1 acts as a chemoattractant for 
fibroblasts and induces the expression of surface molecules on endothelial 
cells involved in the recruitment of leukocytes [69]. 
 
If the load of apoptotic cells exceeds the local capacity for their phagocyte 
mediated clearance or there is a defect within in the clearance pathway, 
apoptotic cells which are not ingested will ultimately disintegrate and 
release their intracellular contents.  This form of cell death is referred to as 
secondary necrosis.  Secondary necrosis is physiologically identical to 
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primary necrosis and leads to the same inflammatory response caused by 
the release of immune stimulating material such as proteolytic enzymes, 
lytic enzymes, cationic proteins, oxidising molecules and self antigens 
[70]. 
  
1.4.1.3  Autophagy 
In recent years, it has become apparent that cells are able to undergo 
programmed cell death by a mechanism other than apoptosis.  Autophagy, 
literally meaning, ‘to eat oneself’, refers to an alternative form of cell 
death.  Autophagy can be initiated as a response to extracellular stimuli 
such as nutrient starvation, hypoxia, overcrowding, and high temperatures.  
It can also be caused by intracellular stimuli such as damaged or redundant 
organelles.  Autophagy provides an intracellular mechanism for degrading 
and recycling long-lived proteins and organelles and is recognised as 
playing a vital role in time of starvation, particularly in C.elegans.  
(Reviewed in [71]). 
 
The manner in which a cell undergoes its demise is able to determine the 
outcome of the inflammatory or immunological response.  As a prevention 
of auto-immunity and inflammation, apoptosis depicts the form of cell 
death utilised as part of embryogenesis, normal cell turnover and auto-
reactive lymphocyte deletion.  In addition, apoptosis is also important to 
induce peripheral tolerance and the killing of target cells by CTLs or 
natural killer (NK) cells [2].   
  
1.4.2  Caspase-dependent apoptosis 
The mechanisms that drive apoptosis are conserved as a feature of all 
eukaryotic cells from the worm, Caenorhabditis elegans to mammals.  This 
fact has enabled research across species to enhance our understanding of 
apoptosis in humans.   
 
The genes that drive apoptotic cell recognition and clearance were initially 
characterised by observing the consequences of genetic mutations during 
the development of the nematode, C.  elegans.  Studies have identified the 
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genes involved in the initiation of apoptosis, ced-3 and ced-4, genes that 
promote engulfment, ced-1,-2,-5,-6,-7,-8, and ced-10  and a gene, nuc-1, 
that encodes a nuclease that is required for the digestion of DNA in the 
apoptotic cell once it has been engulfed [72].  The use of C.elegans as a 
model organism to understand apoptotic cell clearance has aided the search 
for potential homologous genes within higher organisms.  Interleukin-1-
converting enzyme (ICE) was the first human gene to be identified that is 
homologous to a gene involved in nematode development, ced-3.  ICE is 
an intracellular protease that cleaves IL-1 (a signalling protein that induces 
inflammation).  The link between ICE and ced-3 provided one of the first 
indications that the programmed cell death pathway was dependent on 
proteolysis, to which the family of caspases were identified [73].   
 
Caspases are a unique class of cysteine proteases that control the majority 
of developmental cell death within nematodes, insects and mammals.   
Humans encode 13 caspases (caspase 12 is a pseudogene in all populations, 
with the exception of a small subset of individuals of African decent).  Of 
the identified caspases, 7 of them (caspases 2, 3, 6-10) contribute directly 
to apoptosis.  These can be divided further into two groups: initiator 
caspases, (caspases 2, 8, 9, and 10) and effector caspases (caspases 3, 6, 
and 7).   
 
Caspases are synthesized in an inactive form called procaspases and 
require activation either by proteolytic maturation or an allosteric activator.  
Some caspases, such as caspase 3, are also able to autoactivate [74].  There 
are two well defined pathways for caspase-dependent apoptosis; the 
extrinsic pathway and the intrinsic pathway.  The extrinsic pathway is 
activated upon ligation of death receptors such as CD95-Fas.  This 
promotes the generation of the death-inducing signalling complex (DISC) 
which causes proteolytic maturation of pro-caspase 8 followed by 
activation of the effector caspases.  The intrinsic pathway is activated in 
response to DNA damage, which can be caused by radiation and a number 
of anti-cancer drugs [75], and is initiated by the piddosome, a death 
domain-containing protein complex that catalyses the proteolytic 
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maturation of pro-caspase 2 (figure 1.1) [76].  Active caspase 2 leads to 
mitochondrial outer membrane permeabilisation (MOMP) causing the 
release of cytochrome c and subsequent generation of the apoptosome in 
which Apaf-1 mediated activation of caspase 9 occurs (figure 1.1) [77].   
 
One of the key enzymes required for DNA degradation (a classic hallmark 
of apoptosis) is caspase-activated DNAse 1.  Treatment with caspase 
inhibitors prevents this DNA degradation and subsequent nuclear 
condensation.  When the cell death program is prevented in this manner, 
there is a phenotypic shift in the morphological manifestation of cell death. 
As described previously, a number of caspases are involved in signal 
transduction and act as catabolic enzymes in apoptosis.  A small subset of 
caspases however, (caspases 1, 4, and 5 in humans and caspases 1 and 11 
in mice), are involved primarily in inflammatory cytokine production such 
as IL-1β and IL-18; neither or which are actively involved in apoptosis.  
Evidence suggests in mammalian models that activation of caspases does 
not necessarily initiate apoptosis.  The permeabilisation of the 
mitochondrial outer membrane causes the release of mitochondrial proteins 
that are in most instances toxic within the cytosol.  This leads to a rapid 
decrease in ATP levels and is considered as the ‘point of no return’ in 
apoptosis – caspase inhibition will no longer rescue the cell from 
undergoing programmed cell death thereafter.  In this instance, apoptosis is 
considered to be independent of caspases thereby promoting a death more 
comparable to that seen in necrosis or autophagy  [74].       
 
1.4.3  Apoptotic cell removal 
Apoptotic cells are highly proficient at being recognised by the innate 
immune system resulting in their rapid clearance by both ‘professional’ 
phagocytes such as macrophages, and ‘non-professional’ phagocytes such 
as fibroblasts, epithelial cells, muscle cells and immature dendritic cells.  
There is much evidence which shows that the persistence of apoptotic cells 
contributes to the pathogenesis of inflammatory and autoimmune diseases 
[78].   
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A number of mechanisms are therefore in place to ensure that this does not 
occur; cell surface changes on the apoptotic cell provide ‘eat me’ signals to 
the phagocytes, in addition they also secrete ‘find me’ signals into the 
plasma which are detected by receptors on the phagocyte surface.   
Additionally, ligands which are expressed on viable cells to prevent 
accidental removal are actively down regulated upon apoptosis.  The 
numerous receptor-ligand interactions which promote apoptotic cell 
clearance in a non-inflammatory setting again reinforce the importance of 
maintaining tissue homeostasis.    
 
1.4.4  Apoptotic cell surface changes 
 
1.4.4.1  Phosphatidylserine exposure 
The removal of apoptotic cells is dictated by a vast array of molecules that 
are either derived from the dying cell or the plasma and are collectively 
referred to as “eat me” signals [79].  The exposure of phosphatidylserine 
(PS) on the surface of cells which have become apoptotic is a fundamental 
‘eat me’ signal throughout cell types [80] with the only known exceptions 
being specific tumour cell lines such as PLB-985, a human acute myeloid 
leukaemic cell line [81, 82].  In resting cells, the plasma membrane consists 
of an asymmetric bilayer of phospholipids.  Phosphatidylserine and 
phosphatidyletholamine (PE) reside to the most part in the inner membrane 
and phosphatidylcholine (PC) and sphingomyelin are found abundantly in 
the outer membrane [83].  The distribution of lipids throughout the 
membrane in resting cells remains relatively stable, with only a small 
exchange of lipids between bilayers.  The stability of the plasma membrane 
is maintained by the activity of an enzyme called adenosine triphosphate 
(ATP)- aminophospholipid translocase, which becomes rapidly down-
regulated when cells become apoptotic [83, 84].  In contrast, a calcium-
dependent bidirectional movement of phospholipids across the membrane 
termed, ‘scrambling’, occurs which shows no preference for the location of 
PS throughout the membrane.  During apoptosis, the enzyme which 
controls this movement, phospholipid scramblase, becomes activated 
through phosphorylation by protein kinase C-δ, and as a consequence, is 
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able to enhance the exchange of PS from the inner to the outer membrane 
(Figure 1.4).   
 
Quite unexpectedly, plasma membrane lipid re-distribution is also required 
on the cell surface of the phagocyte initiated to engulf the apoptotic cell.  
The ATP transporter protein, ABC1 (ATP- binding cassette transporter 1), 
involved in the transport of substrates across membranes, is suggested to be 
involved in this process as it is expressed by macrophages in localised 
areas during developmental cell death.  Disruption of the ABC1 transporter 
protein greatly reduces the efficiency of phagocytosis  [60, 85]. 
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Figure 1.4 Intracellular signalling cascades which promote the exposure of PS on the 
apoptotic cell surface.  The exposure of apoptotic stimuli such as the binding of death 
domain receptors, UV or gamma radiation causes an intracellular signalling cascade which 
causes the eventual movement of phospholipids in the plasma membrane; namely that of 
the exposure of phosphatidylserine which serves to act as an ‘eat me’ signal to promote 
apoptotic cell uptake.  PS = Phosphatidylserine, PC = phosphatidylcholine, S = 
Sphingosine, PE = Phosphatidyletholamine [76, 80]. 
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1.4.4.2  Additional cell surface ‘eat me’ markers. 
In addition to the exposure of PS on the apoptotic cell surface, there are a 
number of other cell surface changes which act as ‘eat me’ signals to 
promote tethering to phagocytes.  These include changes to surface 
carbohydrates such as the loss of sialic-acid residues on complex sugars 
[86].  Apoptotic cells are also able to induce partial activation of both the 
classical and alternative complement pathways, which results in the 
formation of intermediates such as C1q, iC3b, mannose-binding lectin 
(MBL) and collectins such as surfactant binding protein A [87]. 
 
Further still, there are also molecules that promote apoptotic cell uptake 
that on viable cells function normally to promote adhesion and movement.  
Intercellular adhesion molecule 3 (ICAM-3) is expressed on both the 
surface of apoptotic and healthy leukocytes, but will only promote 
phagocytosis of the former.  Similarly, thrombospondin 1 (TSP-1), a 
calcium-binding protein which is secreted from apoptotic cells participates 
in cellular responses to growth factors, cytokines and injury and regulates 
cell proliferation, migration and apoptosis in a variety of physiological and 
pathological settings, including wound healing, inflammation, 
angiogenesis, and neoplasia [88].  The dual function of these molecules is 
only however possible due to further distinguishable features between 
viable and apoptotic cells.   
 
1.4.4.3  Viable cells actively protect themselves from accidental uptake 
The ability of macrophages to discriminate between viable and apoptotic 
cells is supported by studies that show the ability of viable cells to transmit 
detachment signals after ‘accidental’ ligation to macrophages.  CD31 (also 
known as platelet-endothelial cell adhesion molecule-1, (PECAM-1)) is a 
member of the immunoglobulin superfamily of transmembrane cell-surface 
adhesion and signalling molecules that is expressed on the surface of both 
leukocytes and macrophages.  The ligation of macrophages to CD31 on the 
viable cell surface promotes their active, temperature-dependent 
detachment.  When cells become apoptotic, CD31 on the apoptotic cell 
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surface becomes disabled, allowing tethering to phagocytes which can then 
engage with ‘eat me’ signals such as PS [89]. 
 
1.4.4.4  Apoptotic cells release soluble ‘find me’ markers 
Unlike in lower eukaryotes such as C.elegans, it is probable in higher 
organisms such as humans that when cells are rendered apoptotic, they are 
not within close proximity of a phagocyte.  Apoptotic cells are also able to 
secrete chemotactic factors that act as ‘find me’ markers for the phagocyte.  
The phospholipid, lysophosphatidylcholine (LPC) is one such marker.   
Studies have shown that upon apoptosis, caspase 3-mediated activation of 
phospholipase A2, leads to hydrolysis of the membrane lipid 
phosphatidylcholine into LPC which is then released into the plasma.   
Phagocytes which then express a receptor for LPC are then recruited to the 
site of apoptotic cell death to mediate their clearance  [90].   Further studies 
by Kim et al in 2002 have also suggested that in addition to LPC being 
secreted by apoptotic cells, it also becomes localised on the plasma 
membrane and is integrated as an additional ‘eat me’ signal [91]. 
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Figure 1.5 Diagram illustrating the receptors, ligands and bridging molecules 
required for phagocyte recognition of apoptotic cells.   Cells which are apoptotic up 
regulate a number of markers on their cell surface such as phosphatidylserine (PS), 
Intracellular adhesion molecule-3 (ICAM-3), sugars, and sites which bind components of 
complement such as C1q and iC3b.  The recognition of apoptotic cells is mediated by a 
plethora of receptors on the cell surface which include the αvβ3 integrin on macrophages, 
the class B scavenger receptor, CD36, T cell immunoglobulin and mucin domain 
containing molecule 4 (TIM-4), the LPS receptor, CD14 and complement receptors CR3 
and CR4.  A number of opsonizing molecules serve as a bridge between these markers; 
which include the milk fat globule-epidermal growth factor 8 (MFG-E8) and Gene arrest 
specific gene-6 (Gas-6) which provide a bridge between PS and αvβ3 integrin, CD36 
associates with the αvβ3 integrin via the bridging molecule thrombospondin (TSP) to PS as 
well as surface sugars.    
 
1.4.5  Phagocyte recognition of apoptotic cells. 
 
1.4.5.1  Phosphatidylserine recognition 
 
A myriad of receptors expressed on the surface of phagocytes exist which 
recognise apoptotic cell ‘eat me’ markers.  As discussed previously, the 
exposure of PS on the apoptotic cell surface is an integral part of apoptotic 
cell recognition.  It is therefore not unforeseen that there are numerous 
receptors which recognise and bind to it either directly or via bridging 
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molecules.  The search for a receptor which binds directly to PS on 
apoptotic cells has taken much longer than was first expected, owing to the 
original PS receptor being incorrectly identified in 2000 by Fadok et al.  
This group showed that the use of antibodies against this potential PS 
receptor greatly reduced the clearance of apoptotic cells [92].  A number of 
studies using mice as a model organism also showed that phagocytes that 
lack this molecule were also defective in removing apoptotic cells causing 
abnormal development and eventual neonatal lethality [93].  Initially Fadok 
et al suggested that the PSR bound directly to PS on apoptotic cells.   
Hoffman et al then demonstrated that this may not be the case and that the 
PSR binds via a bridging molecule, Annexin I.  Annexin I is expressed in 
the cytosol and upon apoptosis it becomes translocated to the outer cell 
membrane where it associates with phosphatidylserine plaques [94].   
Careful analysis of this PSR receptor by Bose et al [95] however indicated 
that PSR is not involved in the engulfment of apoptotic cells, and it is 
unlikely to work as a receptor for PS due to it not localising to the cell 
surface.  
 
The identity of a direct PS receptor was finally discovered in 2007 by 
Nagata’s group [96], who identified the T cell immunoglobulin- and mucin 
domain-containing protein, (TIM-4) as the phosphatidylserine receptor.   
Tim-4 is a member of the TIM gene family, some of which are 
differentially expressed by TH1 and TH2 cells. This is however the first 
TIM family member to be expressed in APC populations and not T cells 
[97].  Mouse Tim-4 is a type I membrane protein, consisting of a signal 
sequence and extracellular transmembrane and cytosolic regions.  Tim-4 
contains and RGD motif in its IgV domain, a motif also found in integrin 
binding adhesion molecules such as fibronectin, thrombospondin, and Milk 
fat globule – epidermal growth factor 8 (MFG-E8).  Tim-4 mediates the 
engulfment of apoptotic cells by recognising exposed PS.  It is expressed 
by resident peritoneal macrophages, and within tissues such as the spleen, 
lymph nodes, and fetal liver [96].  Additionally, Tim-1 has also shown to 
enhance the PS-dependent engulfment of apoptotic cells within the kidney 
tubule post ischaemia, suggesting that is may have a role in removing 
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apoptotic or injured cells during the restoration of the kidney.  As yet there 
are no publications providing functional evidence for this molecule such as 
mouse knock out models, so its physiological role is yet to be disclosed.  
The TIM family genes of human and mouse are however located on a 
genetic interval that is linked to a number of autoimmune diseases, such as 
asthma and allergy, making the role of Tim-1 and Tim-4 of key interest. 
 
In addition to TIM-4 binding directly to PS on apoptotic cells, there are 
also a number of bridging molecules and opsonising proteins which 
facilitate apoptotic cell removal by PS.  On macrophages, αvβ3 integrin 
binds via the bridging molecule MFG-E8 (Milk Fat Globule Epidermal 
Growth factor 8) to PS and mediates apoptotic cell clearance [98].   
Immature dendritic cells have also been shown to utilise MFG-E8 as a 
bridging molecule to PS via binding of the αvβ5 integrin receptor [37].  A 
more detailed role of MFG-E8 is described in more detail in section 1.6.  
Additionally the tyrosine kinase receptor, Mer on phagocytes, binds via its 
bridging molecule, Gas-6 (Growth Arrest Specific Gene-6) [99], and the 
β2-glycoprotein-1 receptor via β2-glycoprotein [100].  Savill et al have 
shown that the αvβ3 integrin also associates with the class B scavenger 
receptor, CD36, via thrombospondin, promoting apoptotic cell clearance 
[101].   
 
1.4.5.2  CD14 receptor mediated apoptotic cell uptake 
CD14 is a glycosylphosphatidylinositol-linked plasma membrane protein 
which is expressed on the surface of monocytes, macrophages and 
granulocytes as well as being found in soluble form (sCD14) in plasma.  
Until recently, the function of CD14 was thought to be related only to 
innate immune responses to bacterial and microbial structures such as LPS, 
muramyldipeptide and soluble peptidoglycan.   [102, 103].  It is now well 
established however that CD14 also plays a vital role in the tethering and 
clearance of apoptotic cells in a non-inflammatory  setting.  Antibody-
inhibition studies have shown that CD14 binding to apoptotic cells occurs 
through a domain identical to, or overlapping with the binding site for LPS 
[104].  It is most likely therefore that CD14 associates with apoptotic-cell 
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associated molecular patterns (ACAMPs); which are similar to but clearly 
distinct from pathogen-associated molecular patterns (PAMPs).  Studies 
have shown that CD14 binds to phospholipids [105], including, but not 
exclusively phosphatidylserine [106].  This would suggest that it is not a 
receptor for PS-mediated apoptotic cell recognition.  Additionally, CD14 
interacts with ICAM-3 which is expressed on the surface of leukocytes 
[103], however its ability to recognise apoptotic cells is not specific to 
leukocytes which again supports the theory that it also binds to another 
apoptotic cell marker, again the likelihood of which are apoptotic cell-
associated molecular patterns [104]. 
 
CD14
-/- macrophages in vivo are defective in clearing apoptotic cells, 
confirming its role in apoptotic cell removal.  Notably however, the 
resulting persistence of apoptotic cells does not cause inflammation or 
increased auto-antibody production.  A possible explanation for this is, 
while CD14
-/- macrophages are unable to promote apoptotic cell clearance, 
they retain the ability to generate anti-inflammatory signals in response to 
the apoptotic cells thus impeding maturation stimuli to dendritic cells and 
consequently rendering subsequently activated CD8+ T cells tolerant [106].   
 
1.4.6  Mechanisms of apoptotic cell uptake 
 
1.4.6.1  ‘Tether and tickle’ 
The exposure of phosphatidylserine on the cell surface does not only occur 
as a result of apoptosis.  When cells become activated, such as neutrophils 
which are exposed to the chemotactic factor, fMLP [107], phospholipid 
scramblase can become up-regulated causing PS movement to the outer 
membrane leaflet.  The first line of defence against accidental cell removal 
by PS exposure is provided by ATP-aminophospholipid translocase which 
remains unaffected during cell activation therefore is able to resolve any 
lost phospholipid asymmetry [81].  An additional protective measure is 
conferred by the classically defined two step process required for 
successful apoptotic cell clearance termed ‘tether’ and tickle’ [108] in 
which the ‘tether’ step refers to the interaction of apoptotic cells with 
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receptors such as CD36, integrins, and CD14 and the ‘tickle’ step that 
refers to the interaction of phosphatidylserine with its receptors or bridging 
molecules such as MFG-E8.  Without both mechanisms in tact, the removal 
of apoptotic cells through macrophage mediated phagocytosis is not 
achieved [109]. 
 
1.4.6.2  Two partially redundant pathways mediate engulfment of 
apoptotic cells  
The removal of apoptotic cells by phagocytosis is coordinated by ligands 
on apoptotic cells and receptors and other signalling proteins on the 
phagocyte.  Genetic screens in C.elegans have identified over a dozen 
genes that function in the apoptosis program, 7 of these of which are 
required for the efficient engulfment of apoptotic cells; ced-1, ced-2, ced-5, 
ced-6, ced-7, ced-10, and ced-12.  Using double mutant analyses of these 
genes, 6 of them have been placed into two partially redundant pathways; 
ced-1, ced-6 and ced-7 in one, and ced-2, ced-5 and ced-10 in the other 
[110].  Their mammalian homologues have since been identified.   
 
Within the first group, ced-1 encodes a transmembrane protein which 
shows homology to mammalian scavenger receptors, namely the class B 
scavenger receptor, CD36 [111].  ced-7 encodes an ATP binding cassette 
receptor which is homologous to the mammalian ABC1 transporter protein 
[85] and ced-6 encodes an adaptor protein [112].  In the second group of 
genes,  ced-2, ced-5 and ced-10 encode homologues of the mammalian 
CrkII, Dock180 and Rac1 GTPase proteins, respectively [113], all of which 
mediate reorganisation of the cytoskeleton during phagocytosis of 
apoptotic cells [114].  CrkII was originally identified as part of a viral 
oncogene however is now also implicated in a variety of cell shape and 
cytoskeletal changes.  DOCK180 binds to the first SH3 domain of CrkII.  
Genetic studies have shown that it functions upstream of Rac activation 
[115].  The activation of Rac GTPase leads to actin polymerisation at the 
edges of the cells, the formation of lamallipodia, cell motility and 
phagocytosis [116, 117].  ced-12 and its mammalian homologues elmo-1 
and  elmo-2 are also required for the engulfment process.  ELMO-1 
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functionally cooperates with CrkII and Dock180 to promote phagocytosis 
and cell surface changes.  It binds directly to Dock180 which then 
stimulates Rac1 activation [118].   
 
As discussed previously, integrin receptors are important in the 
phagocytosis of apoptotic cells.  Studies have shown that the activation of 
αvβ5 integrin receptor by the opsonising bridging molecule, MFG-E8 [119] 
mediates both the binding but also the internalisation of apoptotic cells.  
The internalisation is dependent upon signalling through the β5 cytoplasmic 
tail, resulting in recruitment of the p130cas-CrkII-Dock180 complex [120].  
Genetic and biochemical studies also show that the C.elegans homologue 
to the PS receptor, psr-1 directly binds to CED12 (ELMO) and CED-5 
(Dock180) to promote engulfment [121].  In 2007, a new type of 
engulfment receptor belonging to the adhesion-type G-protein coupled 
receptor (GPCR) family, BAI1 was identified. BAI1 (brain-specific 
angiogenesis inhibitor 1) – named because of an extra cellular fragment 
which inhibited neovascularisation in experimental angiogenesis binds to 
PS and forms a trimeric complex with ELMO and Dock180 [122].  The 
natural function of BAI1 in tissues is still unknown; however loss of BAI1 
from gliomas promotes the formation of more aggressive glioblastomas, 
implicating a potential role in its treatment. 
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1.5   Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) 
1.5.1  Structure and function 
Milk  Fat  Globule – Epidermal Growth Factor 8 (MFG-E8) was first 
identified a component of milk fat globules.  It is a secreted glycoprotein 
that was characterised in 1990 following the isolation of a 2.1 kb cDNA 
that encoded for a secreted protein from a murine mammary gland λgt11 
cDNA library.  MFG-E8 encodes 1389 bp and has a mass of 51.5kDa 
[123].  It consists of two epidermal growth factor (EGF)-like domains, E1 
and E2, at the N-terminus and two discoidin-like C domains, C1 and C2, at 
the C-terminus which show homology to the human blood clotting factors 
VIII and V respectively.   
 
 
 
 
  1    69             201            333    444                                                 909                                             1389 bp
 
Figure 1.6 Schematic representation of the primary structure of the long variant of 
murine MFG-E8.  The murine MFG-E8 gene is encoded by 10 exons within 16kb of 
genomic DNA on chromosome 7.  Structural analysis of this protein found two functional 
domains.  E1 and E2 are two N-terminal cysteine-rich domains which have homology to 
the epidermal growth factor domains of Drosophila Notch-1 protein.  The EGF-domain 
binds to αvβ3 integrin expressed on professional phagocytes via an RGD (arginine-glycine-
aspartate) motif located in the E2 domain of the gene.  C1 and C2 domains are 54.4% 
homologous with the C-terminal domains of human clotting factors VIII and V.  The two 
carboxyl-terminal domains are able to bind to PS.  PT is a proline/threonine rich domain 
which is only found in the longer form of MFG-E8 [98, 124]. 
 
 
A monoclonal antibody raised against the protein lead to the discovery of 
two isoforms of MFG-E8 which originate from two spliced variants of the 
same pre-messenger RNA [124].  The longer variant of 57kDa (also known 
as MFG-E8-L) encodes an additional proline/threonine rich domain whilst 
the shorter variant at 53kDa (also known as MFG-E8-S) does not encode 
this additional domain.  MFG-E8-L is produced predominantly by the 
lactating mammary gland, whilst the shorter isoform, MFG-E8-S, is 
E1   E2                   C1               C2 PT
  RGD 
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expressed ubiquitously in other tissues including the brain, lung, heart, 
kidney, skin and germinal centres in the spleen [125].  Expression of MFG-
E8-S can also be induced by peritoneal macrophages through stimulation 
with thioglycollate [98].    
 
MFG-E8 is strongly expressed in the germinal centres of the spleen and 
lymph nodes by “tingible body” macrophages which express MFG-E8 and 
CD68 [126].  MFG-E8 binds via an Arg-Gly-Asp (RGD) sequence motif 
located in the EGF-like domain, E2, to integrins, αvβ3 and αvβ5, which are 
expressed on the surface of macrophages and dendritic cells, respectively 
[127].  The C-terminus of MFG-E8, specifically the C2 domain, enables 
binding of phospholipids, with high specificity to phosphatidylserine.   
MFG-E8 provides a bridge between apoptotic cells and phagocytes to 
facilitate their rapid and successful clearance both in vitro and in vivo [98].   
 
1.5.2  MFG-E8 protein mediates apoptotic cell clearance 
The observation that MFG-E8 serves as a bridging molecule between 
apoptotic cells and phagocytes to enhance their engulfment was originally 
determined using a model system that could detect apoptotic cell uptake by 
macrophages [98].   
 
The  in vitro system uses thymocytes from CAD (caspase-activated 
DNase)- deficient mice, (CAD-deficient thymocytes do not undergo DNA 
degradation when exposed to apoptotic stimuli [128]) which were induced 
into apoptosis by treatment with dexamethasone.  Their ingestion by 
macrophages and consequent DNA degradation in the phagosome could 
then be detected by TUNEL (TdT-mediated dUTP nick end labelling) 
staining.   
 
Hanayama et al (2004) [126] studied the role of MFG-E8 in macrophage 
mediated apoptotic cell clearance by generating MFG-E8
-/- mice through 
gene targeting.  When compared with MFG-E8
+/+ macrophages, MFG-E8
-/- 
macrophages were substantially defective in their ability to phagocytose 
apoptotic CAD
-/- thymocytes.  The phagocytic index (average number of 
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apoptotic cells engulfed per macrophage) obtained using MFG-E8
+/+ and 
MFG-E8
-/- macrophages was 1.20 and 0.31, respectively.  The phagocytic 
index could however be restored by the addition of recombinant MFG-E8 
protein, in a dose-dependent manner.   
 
MFG-E8
-/- mice are fertile, however they develop splenomegaly in an age-
dependent manner.  At the age of 40 weeks, the spleen is approximately 3 
times the weight of a wild type spleen.  Histological analysis revealed that 
the white pulp was greatly enlarged and carried numerous germinal centres.  
There were also 2-3 times more lymphocytes in the spleen when compared 
to wild type mice.  Further examination unveiled that the apoptotic cells 
had become localised to the tingible body macrophages, but they had intact 
membranes indicating that the apoptotic cells were located outside the 
macrophages.  The macrophages had however wrapped around the 
apoptotic cells without engulfing them.  This suggests that MFG-E8 serves 
to facilitate apoptotic cell uptake, but is not required for apoptotic cell 
tethering to macrophages [126]. 
 
As discussed in section 1.4.6.2, the αvβ5 integrin expressed on the surface 
of dendritic cells is able to recruit the CrkII/Dock180/Rac1 complex for the 
initiation of phagocytosis of apoptotic cells.  Further studies have now 
shown that MFG-E8 is functionally linked to this αvβ5 signalling pathway.  
Both MFG-E8 and Dock180 are expressed by immature dendritic cells and 
their expression is greatly down-modulated upon DC maturation indicating 
that MFG-E8 is able to potentiate αvβ5 integrin-mediated Rac activation, 
which is dependent on the maturation state of the DC [119].   
 
1.5.3  MFG-E8 plays an essential role in the prevention of 
autoimmunity 
 
1.5.3.1  MFG-E8 deficient mice develop autoimmune disease 
Previous studies have shown that repeated systemic injections of apoptotic 
cells leads to the production of autoantibodies [129].  MFG-E8
-/- mice 
spontaneously develop autoantibodies in an age-dependent manner where 
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at 40 weeks the concentration of double stranded DNA (dsDNA) 
antibodies and anti-nuclear antibodies (ANA) in the serum is significantly 
higher (by up to 1000 times in half the mice) when compared with wild 
type mice [126].   
 
In the germinal centres, B cells which have a low affinity for their antigen 
are rendered apoptotic.  Tingible body macrophages are responsible for the 
clearance of these cells [130].  Impairment of apoptotic B cell clearance in 
the germinal centres by MFG-E8
-/- macrophages would therefore suggest 
that their accumulation lead to the onset of autoimmunity; an observation 
made by Hanayama et al [126].  A recent study in 2008 supports this 
evidence however it has also revealed that although tingible-body 
macrophages removed the apoptotic B cells, the source of MFG-E8 which 
facilitates apoptotic cell clearance within the germinal centres and primary 
B cell follicles is follicular dendritic cells.  The discovery was made simply 
by chance, when a marker used to detect follicular dendritic cells in the 
mouse (FDC-M1), was in fact identical to murine MFG-E8 [131].     
 
As a consequence of circulating autoantibodies, immune complexes 
become deposited in the kidneys, which leads to glomerulonephritis; 
resulting in high concentrations of protein in the urine [132].   Human 
patients with system lupus erythamatosus (SLE) often show defects in 
apoptotic cell clearance by tingible body macrophages in germinal centres.  
The possibility of a defect in MFG-E8 would be a plausible explanation for 
such a phenotype [133].    
 
1.5.3.2  Masking phosphatidylserine induces autoantibody production in 
mice 
A dominant-negative recombinant MFG-E8 protein has also been used to 
examine the requirement for the protein in apoptotic cell clearance.  Site-
directed mutagenesis was used to make an amino acid change (D89E) in 
the RGD motif of the E2 domain which is required for the binding to the 
integrin receptor.  The recombinant protein was subsequently only able to 
bind to PS on apoptotic cells and no longer had the ability to act as a bridge 
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between apoptotic cells and phagocytes to facilitate their uptake [98].   
Administration of D89E intravenously into wild type mice led to inhibition 
of apoptotic cell clearance in certain organs by binding to exposed PS and 
blocking endogenous wild type receptors from binding and mediating their 
uptake; causing autoantibody production.  The level of autoantibodies in 
the serum could be further enhanced by injecting apoptotic cells [134]. 
 
Injected apoptotic cells are also phagocytosed by CD8+ DCs.  This 
normally leads to cross-tolerance in the absence of maturation signals [62].  
The administration of D89E intravenously into wild type mice inhibited the 
production of the anti-inflammatory cytokine, IL-10 in LPS-stimulated 
macrophages which had been co-incubated with apoptotic cells.  It is 
therefore feasible that inhibiting PS-mediated apoptotic cell clearances 
induces inflammation and consequently leads to the break down of self-
tolerance [134].   
 
1.5.4  Developmental endothelial locus-1 (Del-1) is structurally and 
functionally homologous to MFG-E8 
As discussed, MFG-E8 is secreted by only a limited subset of phagocytes.  
Apoptotic cell clearance is therefore dependent on other mechanisms and 
molecules, such as Mer for apoptotic cell removal in the thymus, for 
example [135].  Studies have also shown that developmental endothelial 
locus-1 (Del-1) also provides a bridge between PS on apoptotic cells and 
αvβ3 integrin on macrophages to facilitate uptake [136].   
 
Del-1 was originally identified as a matrix protein expressed in endothelial 
cells of mouse embryos is both structurally and functionally homologous to 
MFG-E8 [137].  Del-1 encodes two epidermal growth factor-like domains 
which bind αvβ3 integrin with the same affinity as MFG-E8, and two blood 
clotting factor VIII-like domains (C1 and C2) which bind to PS.  Studies 
have shown that Del-1 is expressed by a different subset of macrophages 
than MFG-E8, namely fetal liver and thymic macrophages [136].  This 
again supports the previous evidence that different tissues use different 
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subsets of macrophages, secreting different molecules to facilitate 
apoptotic cell removal.   
 
1.5.5  Homologues of MFG-E8 are expressed in various mammalian 
species 
Orthologous proteins to murine MFG-E8 have been identified in other 
mammalian species including bovine (bovine-associated mucoprotein 
(PAS-6/7)) [138], human (Lactadherin) [139] and rat (rAGS) [140].   
 
The human homologue, Lactadherin, was first identified from a human 
infant brain cDNA library after a database search [141] and is 68% 
identical to murine MFG-E8 at the protein level [142].  In human breast 
carcinoma’s, antibodies are naturally produced against surface components 
of breast epithelial cells.  After screening these antibodies against cDNA’s 
from a lambda gt11 expression library from lactating breast, a sequence of 
1270 base pairs, encoding 217 amino acids was identified.  The cDNA 
encoded the partial sequence of Lactadherin from nucleotide 514 to 1190 
and then extends an additional 600 bases into an un-translated region.  The 
sequence analysis of the 46kDa glycoprotein showed strong homology to 
serum factors VII and V, which are involved in phospholipid binding.   
When this cDNA was used as a probe, it was found that a 2.2kb RNA was 
specifically over expressed in two human breast tissue carcinoma cell lines 
and a human ovary carcinoma cell line.  As a result, the probe is now used 
for both breast cancer diagnosis [139]. 
 
1.5.6  MFG-E8 mediates apoptotic cell clearance in mammary gland 
involution 
Mammary glands are organs which develop during pregnancy to nurse 
offspring under the control of lactogenic hormones such as prolactin.  In 
each cycle of pregnancy mammary glands undergo lactation and then 
involution.  Initially mammalian epithelial cells proliferate and differentiate 
and then undergo apoptosis upon weaning, causing subsequent involution.  
Apoptotic epithelial cells are initially cleared by neighbouring epithelial 
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cells however macrophages soon migrate into the glands to facilitate 
further clearance [143].   
 
Studies have shown that MFG-E8 is secreted by both mammary epithelial 
cells and macrophages during involution and its involvement in apoptotic 
cell clearance is highlighted by observing MFG-E8 deficiency, in which 
there is a large accumulation of milk fat globules in the mammary ducts 
during involution [144].   
 
Milk fat is composed mainly of triglycerides and is secreted as droplet of 
variable sizes.  Approximately 99% of the total lipid is found as milk fat 
globules.  These are initially released from the endoplasmic reticulum into 
the cytosol as microlipid droplets coated by proteins and polar lipids.  The 
lipid droplets are then secreted from the mammary epithelial cells during 
lactation [145].  The biological functions of the major components of milk 
fat globule membrane such as MFG-E8, butyrophilin and CD36 have been 
assessed during the gestation and lactation periods.   
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Figure 1.7 MFG-E8 mediated elimination of apoptotic mammary epithelial cells 
during mammary gland involution.  During lactation, MFG-E8 is released in association 
with exosome-like vesicles and milk fat globules.  MFG-E8 then binds to apoptotic 
epithelial cells where they can then be ingested by either macrophages or neighbouring 
epithelial cells.  (Adapted from [146]). 
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MFG-E8 plays an important role in the removing apoptotic epithelial cells 
and the removal of milk fat globules during mammary gland involution.  
Impairment of this process causes periductal mastitis and inhibits re-
development of the glands [144].  The gene expression in the mouse 
mammary gland during involution indicated that MFG-E8 transcripts 
gradually increase to about 1.5 times.  MFG-E8 also increases markedly in 
mammary gland induction, detectable at both the mRNA and protein 
levels.  This suggests therefore that the presence of MFG-E8 in facilitating 
macrophage mediated clearance of apoptotic mammary epithelial cells 
during mammary gland involution is essential to prevent inflammation and 
autoimmune responses to intracellular antigens [146]. 
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1.6   Tumour Immunology 
1.6.1  Overview 
Despite the expression of cancer-specific antigens and the generation of 
lymphocytes that can recognise these antigens, tumours are nonetheless 
able to escape immune attack and successfully become established within 
the host.  This is largely owing to the fact that anti-tumour T cells which 
both migrate to and accumulate within the tumour become tolerized within 
the tumour microenvironment and therefore lose their effector functions 
[147, 148].  This theory is supported strongly by research showing that the 
tumour-specific T cells, although ineffective within the tumour, can have 
profound effector functions at other sites within the host [147].  The 
development of effective immunotherapies to cancer has focused strongly 
on converting the immune unresponsiveness of these tumour-specific T 
cells into pathogenic cells capable of destroying the tumour.  
 
1.6.2  Tumour-associated antigens 
One of the overwhelming challenges when trying to generate a tumour-
specific immune response is that the majority of tumour associated 
antigens (TAA’s) that have been described are self antigens that are either 
selectively or over expressed by the tumour [149].  As a result of thymic 
negative selection, T cells which have high affinity for their cognate 
antigen are deleted.  Only low affinity autoreactive T cells escape thymic 
selection, unarmed with the capacity to generate effector functions in the 
immunosuppressive microenvironment of the tumour. 
 
The molecular identification of tumour specific antigens, their 
immunodominant peptides and TCR that recognise them have been focused 
on heavily in the development of cancer immunotherapy.  Point mutations 
within tumour cells can generate peptides that bind to MHC molecules or 
can generate new peptide epitopes.  Alternatively, a gene can be expressed 
by a tumour cell that is silent in normal cells (reviewed in [150]).  Antigens 
unique to that tumour or tissue, such as the prostate, encode prostate 
specific antigen (PSA), prostatic acid phosphatase (PAP), prostate specific 
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membrane antigen (PSMA), and prostate stem cell antigen (PSCA), have 
all been used to generate cytotoxic T cells responses [151].  A family of 
antigens (MAGE) which is restricted to melanomas has also been identified 
using T cells derived from tumour infiltrating lymphocytes which were 
obtained from patients [149].  
 
1.6.3  The tumour microenvironment – what makes it so 
immunosuppressive? 
 
It is widely accepted that the tumour microenvironment can protect the 
tumour from immune attack through its production of soluble and cell-
associated factors such as TGFβ, IL-10, prostaglandin E2, CTLA-4 ligands 
and PD-L1.  Two dominant cell types infiltrate solid tumours and 
orchestrate immune suppression; FoxP3+ regulatory T cells (T regs) and 
tumour associated macrophages (TAMs).  Both FoxP3+ T regs and tumour 
associated macrophages are found in high numbers in a number of human 
tumours [152, 153] as well as the peripheral blood [154].  They have been 
shown to suppress anti-tumour CTL immunity in experimental mouse 
models [155] through either direct interaction or through secretion of IL-10 
and TGFβ [156].  The depletion of CD25+ T regs in mice has shown to 
significantly reduce growth of a B cell lymphoma and conferred increased 
survival, owing as a result of an increased infiltration of CD8+ T cells and 
higher serum antibody levels.  Additionally however, 40% of mice 
depleted of T regs developed clinically detectable signs of autoimmunity 
[157]. 
 
Sakaguchi et al [158] first coined the term ‘regulatory T cells’ through the 
identification of a population of CD4+,CD25+ T cells which prevented 
autoimmunity in a murine model.  Naturally occurring T regs represent 
approximately 5-6% of the overall CD4+ T cell population and are 
paramount in ensuring suppression to immune responses generated against 
self [159].  They phenotypically express CD4, CD25, FoxP3, 
glucocorticoid-induced TNFR family related gene (GITR) and Cytotoxic T 
lymphocyte antigen 4 (CTLA-4).  Although T regs are functionally 
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anergic, they have the ability to actively inhibit CD4+,CD25- T cells, B 
cells [160], NKT cells [161], dendritic cells [162]  and CD8+ T cells [155].   
 
Coinhibitory molecules such as CTLA-4 are essential in the prevention of 
autoimmunity, highlighted by CTLA-4-deficient mice developing lethal 
autoimmunity and lymphoproliferation.  In the tumour however, CTLA-4 
expression on T regs results in their binding to CD80 and CD86 on 
dendritic cells, thereby suppressing their ability to activate other T cells 
[163].  Additionally, the expression of PD-L1 by tumours strongly 
correlates with the survival of cancer patients (reviewed in [164]).   
Interaction of PD-L1 on T cells with PD-1 on dendritic cells again,   
induces tolerance [163].  The targeting of either CTLA-4 or PD-1 
interactions may therefore prove effective as a cancer therapy. 
 
1.6.4  Enhancing the immunogenicity of tumour cell death 
Most chemotherapy and radiation therapies used to treat cancer patients 
have immunosuppressive side effects and thus eliciting an anti-tumour 
response thereafter is the focus of much research.  Upon exposure to 
cytotoxic drugs or radiation, tumour cells will die by apoptosis; an 
immunologically silent or even tolerogenic process.  Some studies in mice 
have however shown that the type of apoptosis induced with a specific 
drug largely dictates the tumour cell’s immunogenicity.  The treatment 
with the anthracyclin, doxorubicin, enhances the immunogenicity of dying 
tumour cells in a colon carcinoma model and as a consequence is able to 
elicit a CD8+ specific T cell response against the tumour.  This type of 
immunogenic tumour cell death is dependent on caspases, and requires that 
the cell be intact upon uptake by DCs  [165].  Further work since has 
shown that the treatment of tumours with anthacyclins, as opposed to other 
treatments such as other DNA damaging agents such as etoposide or 
mitomycin C, confers enhanced immunogenic cell death due to the rapid 
upregulation of calreticulin on the cell surface.  Calreticulin (CRT) is an 
‘eat me’ signal exposed by pre-apoptotic cells. i.e. before the exposure of 
phosphatidylserine.  Unlike PS however, the exposure of CRT on the cell 
surface dictates an immunogenic tumour cell death.  The treatment of 
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soluble CRT is alone however, unable to confer enhanced tumour 
immunity.  It is therefore likely that the signalling events that occur as part 
of its exposure determines its immunogenic effect [166].      
 
As a bid to overcome the tolerizing effect of PS exposure of apoptotic 
tumour cells, the immunogenicity of apoptotic cells can be enhanced by the 
blockade of PS using a PS binding protein, annexin V.  Annexin V binds to 
PS on apoptotic cells with high affinity and is able to inhibit apoptotic cell 
clearance by macrophages.  Upon injection of apoptotic cells treated with 
annexin V, one particular study revealed that PS blockade alleviated the 
immunosuppression observed with the administration of apoptotic cells 
alone and enhanced secondary humoral immune responses. [167].  (This 
technique is explored further in chapter 5).  
 
1.6.5  Adoptive T cell immunotherapy 
The adoptive transfer of tumour antigen-specific T cells has re-confirmed 
the important role of T cell immunity in the control of cancer growth and 
metastasis.  The challenges when trying to achieve this particular therapy 
include the generation of large amounts of T cells for adoptive transfer 
which need to retain their proliferative state as well as have the ability to 
home to the site of the tumour and retain their effector functions.   
Additionally, they also need to be able to confer long-term memory within 
the host. 
 
In addition to dendritic cells being administered in isolation (discussed in 
section 1.6.6), studies using mouse models have also shown that peptide-
pulsed dendritic cells are able to boost the anti-tumour activity of 
adoptively transferred T cells in vivo.  Mice which had B16 melanomas 
expressing the gp100 tumour antigen were treated with T cells encoding a 
transgenic T cell receptor which recognises the gp100 peptide in 
association with MHC class I.  In addition to this, they were also treated 
with or without peptide-pulsed dendritic cells.  The results of this particular 
study revealed that the dendritic cells produced cytokines and permitted 
effective T cell proliferation and increased tumour infiltration of the 
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adoptively transferred T cells.  This combined therapy was shown to be 
more effective than either of the therapies given separately [168] ; another 
potential route of vaccination needed to be tested for effectiveness in 
patients.   
 
A clinical trial in 2005 showed that lymphopenic patient immunity could 
be restored by vaccination and adoptive T cell transfer after they had 
received high dose chemotherapy for myeloma.  After treatment of 
myeloma with high-dose chemotherapy, the immune system is significantly 
impaired, even after autologous stem cell transplant.  This is partly owing 
to the limited T cell receptor repertoire.  A single infusion of antigen-
primed  ex vivo costimulated autologous T cells however leads to 
accelerated immune reconstitution and enhanced antigen-specific CD4+ 
and CD8+ T cell functions in vivo [169].   
   
1.6.6  Dendritic cell vaccines 
To date, it has been difficult to generate tumour-specific immune responses 
that correlate to good clinical outcome.  Current vaccines require that 
antigen is administered with exogenous adjuvants so as to generate an 
effective immune response.  The use of dendritic cells tries to overcome the 
requirement of exogenous adjuvants, providing a potentially safer and 
more specific immune response to tumours. 
 
Inaba  et al were the first group to demonstrate that the injection of 
dendritic cells loaded ex vivo with antigen could sensitize normal mice to 
protein antigens [170].  The potential therapeutic benefit of dendritic cell 
based vaccines is currently one of the new vaccination methods being 
investigated.  A recent study has focused on a cancer testis antigen, NY-
ESO-1, a highly immunogenic antigen, capable of eliciting both a humoral 
and cell-mediated immune response in many patients.  Initial trials using 
this as a peptide vaccine alone showed a CD8+ T cell response, however it 
had no clinically beneficial output.  This was potentially due to the peptide-
specific CD8+ T cells being low affinity or did not recognise naturally 
processed NY-ESO-1 antigen.  To improve the immunogenicity of the 
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peptide, one study [171] pulsed monocytes-derived dendritic cells with the 
MHC class I-restricted NY-ES0-1 peptide (p157-165) sequence that had 
been fused to the gene encoding heat shock protein 70 (hsp70).  HSP70 is 
an intracellular protein which acts as a transporter to chaperone processed 
peptides for loading onto MHC class I molecules in the endoplasmic 
reticulum.  The aim of the study was to determine whether the hsp70-NY-
ESO-1 fusion-pulsed DCs were able to present endogenously processed 
peptide to NY-ESO-1-specific CD8+ T cells.  The receptor-mediated 
internalisation of HSP-peptide complexes via toll-like receptors or CD91 is 
hypothesised to generate efficient antigen delivery to APCs in vivo.  This 
study however did not demonstrate that DC maturation can be achieved by 
internalisation of HSP70, therefore could not induce effective cross-
presentation of NY-ESO-1 peptide to CTLs.   
 
Thus far, a number of groups have successfully loaded both human and 
mouse dendritic cells with synthetic peptides, viral vectors, apoptotic or 
necrotic tumour cells, or RNA.  No consensus has yet emerged as to the 
most effective mode of antigen delivery to use for immunisation.  More 
research is therefore needed into which type of dendritic cells to use, their 
ideal maturation stage at immunisation, the optimal maturation stimuli to 
use, and at what stage of metastatic disease should they be used to provide 
the best clinical outcome. 
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1.6.7  Current immunotherapy-based clinical trials 
Cancer 
Immunotherapy 
Agent  Target  Main Clinical 
Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monoclonal 
Antibodies 
Metelimumab (AP-
12009: antisense 
oligodeoxynucleotide) 
TGFβ  Suggested survival 
advantage in patients 
with glioma and non 
small cell lung cancer. 
Bevacizumab (blocking 
mAb) 
VEGF  Approved for 
treatment of cancer 
(plus chemotherapy).   
Ipilimumab (MDX-010) 
ticilimumab (CP-675) 
blocking mAb 
CTLA-4  Active against 
melanoma (tumour 
response rate: 14%), 
frequent autoimmunity 
(enterocolitis : 21%) 
MDX-1106 (mAb)  PD-1  Phase I clinical trial 
ongoing. 
Anti-CD40  CD40  Objective tumour 
regression and tumour-
specific immune 
responses. 
 
 
 
Fusion protein 
Denileukin diflitox 
(anti-CD25 fusion 
protein) 
CD25  Approved for CD25+ 
tumours.  Conflicting 
results with T reg 
depletion and anti 
cancer immune 
responses. 
 
 
 
 
 
 
 
Dendritic cell 
Blood DCs  Tumour-
specific 
idiotype 
B cell lymphoma 
Mo-DCs  Tumour-
lysate/peptide 
+ KLH 
Melanoma 
Mo-DCs  Tumour lysate  Solid tumours 
Blood DCs   Recom. mouse 
prostate Ag 
Prostate cancer 
Mature Mo-DCs  MHC class I/ 
II  peptides 
Melanoma 
 
Figure 1.8 Table showing examples of current immunotherapy-based cancer 
therapies. Examples are explained in further detail in reviews [6, 172-174]. 
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1.7   Aims of the project 
Manipulating the mechanisms which control the protective immune 
response against tumours is a prerequisite to the development of tumour-
specific vaccines and immunotherapies.  One of the fundamental reasons 
which explain how tumours evade recognition by the immune system is the 
manner in which tumour cells die by apoptosis and are cleared through the 
same mechanisms that facilitate the removal of cells rendered apoptotic as 
part of normal cell turnover.   
 
Hypothesis: Re-directing tumour cells rendered apoptotic by artificial 
stimuli via a pathway independent of phosphatidylserine will break 
tolerance to tumour-associated antigens and confer protection against 
subsequent tumour challenge.    
 
The specific aims of this study are to: 
•  Generate recombinant MFG-E8 proteins which bind to 
phosphatidylserine on apoptotic cells which can either a.) Steer 
apoptotic cell uptake via a pathway other than PS, or b.) 
Specifically block PS-mediated apoptotic cell clearance and re-
direct their uptake through activating Fcγ receptors on antigen 
presenting cells. 
•  Determine the ability of the recombinant MFG-E8 proteins to bind 
to apoptotic cells and subsequently examine their ability to 
manipulate their clearance by professional phagocytes. 
•  Establish a model to examine the effect of loading apoptotic cells 
via different receptors on the ability of antigen presenting cells to 
present antigen to cytotoxic CD8+ T cells. 
•  Investigate the effect of different apoptotic cell clearance 
mechanisms on the humoral immune response. 
•  Ascertain whether the manipulation of the apoptotic tumour cell 
clearance pathway is alone, able to confer enhanced tumour 
immunity. 
  
Chapter 2 
 
Materials and Methods 
 
2.1 Cell Culture 
 
2.1.1 Cells lines and culture 
A20  mouse B cell lymphoma cells were grown in RPMI 1640 medium 
supplemented with 10% foetal calf serum, 50µM 2-Mercaptoethanol, 2mM 
L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 100µg/ml 
streptomycin at 37
0C, in a humidified atmosphere containing 5% CO2.   
 
π-BCL.1 mouse B cell lymphoma cells were grown in RPMI 1640 medium 
supplemented with 10% foetal calf serum, 50µM 2-Mercaptoethanol, 2mM 
L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 100µg/ml 
streptomycin at 37
0C, in a humidified atmosphere containing 5% CO2.  
Cells were subcultured when the density reached approximately 2.0 x 10
7 
cells / 75cm
2.  Cells were re-suspended into medium using a cell scraper. 
 
CHO-K1 (Chinese Hamster Ovary-epithelial like) cells were grown in 
RPMI 1640 medium supplemented with 10% foetal calf serum, 2mM L-
glutamine, 1mM pyruvate, 100U/ml penicillin, and 100Ug/ml streptomycin, 
at 37
0C, in a humidified atmosphere containing 5% C02.  Cells were 
subcultured when the density reached approximately 2.5 x 10
6 cells / 75cm
2.  
Cells were re-suspended into medium by adding trypsin and incubating 
them for 5 min at 37
0C. 
 
CT26 (Murine colon carcinoma cell line) cells were grown in RPMI 1640 
medium supplemented with 10% foetal calf serum, 2mM L-glutamine, 1mM 
pyruvate, 100U/ml penicillin, and 100Ug/ml streptomycin, at 37
0C, in a 
humidified atmosphere containing 5% C02.  Cells were subcultured when 
the density reached approximately 2.5 x 10
6 cells / 75cm
2.  Cells were re-
suspended into medium by adding trypsin and incubating them for 5 min at 
37
0C. 
 
54  
E.G7 cells ((EL-4 cells (C57BL/6, H-2b, thymoma) transfected with OVA) 
were grown in RPMI 1640 supplemented with 10% foetal calf serum, 50µM 
2-Mercaptoethanol, 2mM L-glutamine, 1mM pyruvate, 100U/ml penicillin, 
100µg/ml streptomycin, and 400µg/ml geneticin at 37
0C, in a humidified 
atmosphere containing 5% CO2.    
 
Human Embryonic Kidney 293-F cells (supplied by Invitrogen) were 
grown in Freestyle 293 Expression medium and incubated in a 37
0C 
incubator that has a humidified atmosphere containing 8% CO2 on an orbital 
shaker platform rotating at 125rpm.  Cells were subcultured when the 
density was between 2-3 x 10
6 cells/ml. 
 
Jurkat leukemic T cells were grown in RPMI 1640 medium supplemented 
with 10% foetal calf serum, 2mM L-glutamine, 1mM pyruvate, 100U/ml 
penicillin, and 100µg/ml streptomycin at 37
0C, in a humidified atmosphere 
containing 5% CO2. 
 
J558L mouse BALB/c myeloma cells (supplied by European Collection of 
Cell Cultures) were grown in Dulbecco’s Modified Eagle Medium 
supplemented with 10% foetal calf serum, 50µM 2-Mercaptoethanol, 2mM 
L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 100µg/ml 
streptomycin at 37
0C, in a humidified atmosphere containing 5% CO2.   
 
J774A.1 mouse BALB/c monocyte macrophages (supplied by European 
Collection of Cell Cultures) were grown in Dulbecco’s Modified Eagle 
Medium supplement with 10% foetal calf serum, 2Mm L-glutamine, 1mM 
pyruvate, 1000U/ml penicillin, and 100µg/ml streptomycin at 37
0C, in a 
humidified atmosphere containing 5% CO2.   
 
P388D.1 mouse macrophages (supplied by European Collection of Cell 
Cultures) were grown in RPMI 1640 medium supplemented with 10% foetal 
calf serum, 2mM L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 
100µg/ml streptomycin at 37
0C, in a humidified atmosphere containing 5% 
CO2. 
55  
2.1.2  Primary cell culture 
 
Resident peritoneal macrophages were obtained from 8 – 10 week old 
BALB/c or C57BL/6 mice.  Initially, mice were sacrificed and 10 ml, sterile 
PBS at 4
0C was used to lavage the peritoneal cavity.  Cells obtained were 
centrifuged at 400 g for 5 min at 4
0C.  The percentage of macrophages was 
determined using APC labelled CD11b antibody (B Pharmingen).  Typically 
approximately 20% peritoneal cells were CD11b positive.  Cells were then 
centrifuged again at 400 g for 5 min at 4
0C and were re-suspended into 
Dulbecco’s Modified Eagle Medium supplemented with 10% foetal calf 
serum, 50µM 2-Mercaptoethanol, 2mM L-glutamine, 1mM pyruvate, 
100U/ml penicillin, and 100µg/ml streptomycin.  Cells were plated into 
either 24 or 48 well plates and were incubated at 37
0C, in a humidified 
atmosphere containing 5% CO2 for 1.5 h to allow macrophages to adhere.  
Non-adherent cells were then washed using fresh supplemented DMEM 
medium and macrophages were incubated for a further 1.5 h, after which 
they were ready for use in assays. 
 
Thymocytes were obtained from 4 – 8 week old BALB/c mice.  After 
removing the thymus, a single cell suspension was made using a nylon 
filter.  Thymocytes were then washed twice with sterile PBS and then 
counted.  Thymocytes were then incubated in RPMI medium supplemented 
with 10% foetal calf serum, 50µM 2-Mercaptoethanol, 2mM L-glutamine, 
1mM pyruvate, 100U/ml penicillin, and 100µg/ml streptomycin at 37
0C, in 
a humidified atmosphere containing 5% CO2.   
 
Bone marrow-derived dendritic cells (BMDCs) were obtained from the 
femurs and tibias from 12 week old male C57BL/6 mice which were 
removed and placed in RPMI-1640 medium (supplemented with PS) on ice 
until all bones were prepared.  The ends of the bones (epiphyses) were cut 
with scissors and the bone marrow was obtained by flushing out each of the 
shafts with a 27 gauge myjector syringe.  The marrow was passed through a 
nylon filter to make into a single cell suspension.  Cells were then 
centrifuged at 300 g for 10 min.  Cells were re-suspended in 5 ml red cell 
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lysis buffer and incubated at room temperature for 3 min.  Cells were then 
centrifuged at 300 g for 10 min.  Cells were washed once with RPMI-1640 
medium (supplemented with PS) and then re-suspended into RPMI-1640 
medium supplemented with 5% FBS, PS, GP and 20 ng/ml GM-CSF at 1 x 
10
6 cells / ml.  Cells were then plated into 24 well tissue culture plates.  On 
day 2 and 4, non-adherent cells were removed by washing twice with 
RPMI-1640 medium (supplemented with PS) and fully supplemented 
medium was replaced.  On day 6, bone marrow-derived dendritic cells were 
collected (which included both non-adherent and slightly adherent cells).  
Staining cells with anti-CD11c antibody determined that the cells were 
approximately 90% CD11c+. 
 
2.1.3  Cell storage 
Cell lines were stored in freeze media (90% FCS and 10% 
dimethylsulphoxide) at -80° C or -196° C (liquid nitrogen).  After storage, 
cells were washed and re-suspended in media as required. 
 
2.1.4  Cell quantitation 
Cell concentrations were determined using a Coulter Industrial D cell 
counter (Coulter Electronics), or by counting manually using a 
haemocytometer (Improved Neubauer).  Cell viability was measured on the 
haemocytometer by diluting 1:1 with trypan blue (Sigma), and observing 
dye exclusion from viable cells. 
 
2.1.4 CFSE cell labelling 
5 x 10
7 cells were washed twice with sterile PBS and then re-suspended into 
1 ml PBS / 0.1% BSA containing 10µM CFSE (in DMSO).  The cells were 
then incubated at 37
0C for 10 min.  Cells were then washed twice with 10 
ml of complete growth medium.   
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2.2 Molecular  Biology 
 
2.2.1  Generation of recombinant mCD4-DN-MFG-E8 fusion protein. 
 
2.2.1.1 Cloning the full-length cDNA of murine MFG-E8. 
The full length murine MFG-E8 cDNA was isolated from a mouse 
macrophage cell line, P388D.1.  1 x 10
7 cells were isolated from cell culture 
and total RNA was made by following the protocol described using an 
RNeasy kit, (Qiagen).  The sample was eluted in 50µl dH2O.  5µg total 
RNA was then used for 1
st strand cDNA synthesis using the d(T18) primer 
and M-MuLV reverse transcriptase (Qiagen).   The MFG-E8 cDNA was 
then isolated by PCR using the 1
st strand cDNA template using primers 
based on its published sequence [124] (PubMed accession number: 
AB021130) and Pfu polymerase.   
 
 
2.2.1.2 Sub-cloning the PT, C1 and C2 domains of murine MFG-E8. 
The PT, C1, and C2 domains of full length murine MFG-E8 were amplified 
using PCR (Pfu polymerase) using the following primers; primer 1: 
5’- 
CGAATTCCGAAA CCGAGACCAACTACTAC-
3’ which encodes an 
EcoR1 restriction site upstream from the PT domain.  Primer 2: 
5’- 
CAGATCTTTAACAGCC CAGCAGCTC-
3’ which encodes a BglII 
restriction site downstream of the C2 domain, (PCR product = 1086 base 
pairs).  In a total volume of 20 μl,  1 ng full length murine MFG-E8 was 
used as a template and added to 0.5 µM primer 1, 0.5 µM primer 2, 0.2 mM 
dNTP’s, 1 x Pfu Buffer and 1.25 µl Pfu polymerase.  The PCR reaction was 
as follows: Step 1 = 95
0C for 6 min, step 2 = 95
0C for 1 min, step 3 = 62
0C 
for 1 min, step 4 = 72
0C for 3 min, step 5 = go to step 2, 24 more times, step 
6 = 72
0C for 20 min, step 7 = 4
0C.  The PCR product was visualised by 
running 10µl of the reaction on a 1% Agarose gel stained with Ethidium 
Bromide.  0.5 ng of the PCR product was then cloned into a pCR-BluntII-
TOPO vector (supplied by Invitrogen) by following the manufacturer’s 
protocol.  In brief, 0.5 ng PCR product was incubated with sodium chloride 
and magnesium chloride (200 mM NaCl, 10 mM MgCl2) and 1 µl TOPO 
vector to a final volume of 6 µl at room temperature for 5 min.  2µl of the 
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TOPO cloning reaction was then added to 50 µl competent TOP10 cells and 
then incubated on ice for 15 min.  The cells were then heated shocked for 45 
sec at 42
0C and then immediately returned to ice.  250 µl S.O.C. (Super 
Optimal Broth (with Catabolite repression)) medium (Invitrogen) was then 
added and the cells were incubated at 37
0C at 200 g for 1 h.  100 µl of cells 
were then plated onto a agar plate supplemented with 50 µg/ml Kanamycin 
and incubated over night at 37
0C.  Colonies were selected at random from 
the plate and 100 µl dH2O was added per colony.  1 µl of sample was then 
used per PCR reaction with M13 primers (supplied by Invitrogen) to 
confirm successful cloning into the TOPO vector.  10µl of the PCR product 
was then visualised on a 1% Agarose gel stained with Ethidium Bromide.  
The dominant-negative MFG-E8 (DN-MFG-E8) was then sequenced by 
following the protocol described in section 2.2.3.7. 
ha ccdB
pUC ori
PT-C1-C2
HI
E
Xba
Ec 1500
3000
 
EcoR1
BglII 
Figure 2.1 Plasmid map showing PT, C1 and C2 domains ligated into the blunt II-TOPO 
vector. (diagram generated using Lasergene 6 – Seqbuilder). 
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2.2.2 Generation of recombinant DN-MFG-E8-IgG2A-Fc fusion 
protein. 
 
2.2.2.1 Sub-cloning of the PT, C1, and C2 domains of murine MFG-E8 into 
a murine IgG2A Fc vector. 
The PT, C1 and C2 domains were amplified by PCR (using Pfu polymerase) 
from the pFLAG-PT-C1-C2  DNA template using the following primers; 
Primer 1 – 
5’ – CGAATTCCGAAACCGAGACCAACTACTAC – 
3’ – 
which encodes an EcoR1 restriction site upstream from the PT domain.   
Primer 2 – 
5’- CACATCTACATCC TCCTCCGCCACAGCCCAGCAGC 
TGCTCCAG-
3’ – encodes a (Gly)4Ser linker and then a Bgl II restriction 
site downstream from the C2 domain.  (PCR product = 1098 base pairs).  
1ng DNA template was added to 5µM Primer 1, 5µM Primer 2, 0.2Mm 
dNTP’s, 1 x Pfu polymerase buffer and 1.25µl Pfu polymerase in a total 
volume of 50µl with dH2O.  PCR reaction was as follows: Step 1 = 95
0C for 
6 min.  Step 2 = 95
0C for 1 min.  Step 3 = 61
0C for 1 min.  Step 4 = 72
0C for 
3 min.  Step 5 = Go to step 2, 24 more times.  Step 6 = 72
0C for 20 min.  
Step 7 = 4
0C.  The PCR product was visualised by running 10µl of the 
reaction on a 1% Agarose gel stained with Ethidium Bromide.  0.5ng of the 
PCR product was then cloned into a pCR-BluntII-TOPO vector (supplied by 
Invitrogen) by following the manufacturer’s protocol.  In brief, 1ng PCR 
product was incubated with sodium chloride and magnesium chloride 
(200mM NaCl, 10mM MgCl2) and 1µl TOPO vector to a final volume of 
6µl at room temperature for 5 min.  2µl of the TOPO cloning reaction was 
then added to 50µl competent TOP10 cells and then incubated on ice for 15 
min.  The cells were then heated shocked for 45 sec at 42
0C and then 
immediately returned to ice.  250µl S.O.C.  medium was then added and the 
cells were incubated at 37
0C, rotating at 200 g for 1 h.  100µl of cells were 
then plated onto a agar plate supplemented with 50µg/ml Kanamycin and 
incubated over night at 37
0C.  Colonies were selected at random from the 
plate and 100µl dH2O was added per colony.  1µl of sample was then used 
per PCR reaction with M13 primers (supplied by Invitrogen) to confirm 
successful cloning.  10µl of the PCR product was then visualised on a 1% 
Agarose gel stained with Ethidium Bromide.  The DN-MFG-E8-(Gly)4Ser 
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construct was then sequenced by following the protocol described in section 
2.2.3.7.  The construct was then excised using EcoR1 and Bgl II restriction 
enzymes and cloned into pFUSE-mFc2 (IL2ss) shown in figure 2.2. 
    
 
                          
 
Figure 2.2 pFUSE-mFc2 (IL2ss) – mouse IgG2A plasmid designed for the construction 
of Fc-Fusion proteins.  (supplied by Invivogen) 
 
 
 
2.2.3 Molecular Biology techniques 
 
2.2.3.1.  Mini and Maxi preparation of DNA 
Miniprep: A single colony of E.coli was picked from a freshly streaked 
selective plate which was then used to inoculate a culture of 5 ml Luria-
Bertani (LB) medium containing the relevant antibiotic at 100µg/ml.  This 
was then incubated over night at 37
0C on a rotating platform, rotating at 150 
rev / min.  The bacteria were harvested by centrifuging at 1500 g for 5 min 
at room temperature.  The following steps were then taken as instructed by 
the Qiagen miniprep handbook.  In brief: The pelleted bacterial cells were 
re-suspended in 250µl buffer containing RNase A.  Cells were then lysed 
with the addition of 250µl lysis buffer containing NaOH / SDS.  To 
neutralise the reaction, 350µl of high salt buffer was added which causes 
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precipitation of the denatured proteins, chromosomal DNA, cellular debris, 
and SDS, whilst the smaller plasmid DNA re-natures and remains in 
solution.  The precipitated material is then collected by centrifugation for 10 
min at 30,000 g in a table-top centrifuge.  The supernatant was then 
collected and placed onto a spin column provided in the Qiagen kit and 
centrifuged for 1 min at 30,000 g.  The flow-through was discarded.  The 
column was then washed with 0.5 ml PB buffer and again centrifuged for 1 
min at 30,000 g.  The flow-through is discarded.  The column was then 
washed with 0.75ml buffer PE containing ethanol and then centrifuged at 
30,000 g.  The flow-through was discarded and the column is centrifuged 
again.  The Qiaprep column was then placed in a clean 1.5 ml 
microcentrifuge tube.  The DNA was then eluted with 50µl 10Mm Tris.Cl, 
pH8.5.  The column was left to stand at room temperature for 1 min before 
being centrifuged at 13,000 g for 1 min.  The concentration of DNA was 
then determined by measuring the absorbance at 260nm.      
 
Maxiprep: To produce larger quantities of plasmid DNA for use in transient 
and stable cell transfections, the protocol for HiSpeed Plasmid Maxi 
purification provided by Qiagen was followed.  In brief: A single colony of 
E.coli was picked from a freshly streaked selective plate which was then 
used to inoculate a culture of 5 ml Luria-Bertani (LB) medium containing 
the relevant antibiotic at 100µg/ml.  This was then incubated for 7 h at 37
0C 
on a rotating platform, rotating at 150 rev / min.  2 ml of this growth 
medium was then added to 150 ml LB medium containing the relevant 
antibiotic at 100µg/ml and was then incubated over night at 37
0C on a 
rotating platform, rotating at 150 rev / min.  The bacteria were harvested by 
centrifuging at 1500 g for 15 min at 4
0C and the protocol in the handbook 
was followed to the point at which the DNA is eluted from the column.  To 
precipitate the DNA, 10.8 ml isopropanol was added to the eluate and then 
centrifuged at 8,000 g for 30 min at 4
0C.  The supernatant was then removed 
and the pelleted DNA was washed with 5 ml 70% Ethanol.  The sample was 
then centrifuged at 8,000 g for 10 min at 4
0C.  The supernatant was removed 
and the DNA pellet was allowed to dry at room temperature for 90 min.  
The pellet was then dissolved in 400µl of 10mM Tris, 0.1M EDTA.  The 
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concentration of DNA was then determined by measuring the absorbance at 
260nm.      
 
2.2.3.2 Restriction Enzyme Digests 
To determine the successful cloning and amplification of DNA, known 
restriction sites were cleaved with specific restriction enzymes and 
visualised by agarose gel / ethidium bromide electrophoresis.  Protocol: 
300ng DNA were added to 5-7 units of restriction enzyme per µg DNA, 1 x 
Enzyme buffer, then made up to a final volume of 20µl with dH2O.  (n.b.  
Glycerol content should not exceed more than 10% of total reaction 
volume.) Digest reactions were incubated at 37
0C for 1.5 h.   
 
2.2.3.3. Agarose Gel Electrophoresis 
DNA fragments were analysed on 1.0 % agarose gels made in TBE buffer 
(89 mM tris, 89 mM boric acid, 2mM EDTA, 0.5 μg/ml ethidium bromide), 
and compared to standard 1kB markers (Gene-ruler, MBI-Fermentas, UK) 
to allow estimation of fragment size.   DNA was visualised under UV light 
and a photograph record taken.  DNA samples were mixed 10:1 with 10 x 
loading buffer (20 % (w/v) Ficoll 400, 0.1 M EDTA, 0.25 % (w/v) 
bromophenol blue) before loading.  Gels were run in TBE buffer at 70 mA 
in a BioRad electrophoresis system for the appropriate time and visualised 
on a UV illuminator. 
 
2.2.3.4 Polymerase Chain Reaction 
DNA amplification was performed using either Taq polymerase (Promega, 
Southampton) or Pfu polymerase (Stratagene).  Each reaction contained 
approximately 100 ng of cDNA, 0.5 μM forward and reverse 
oligonucleotide primers, 0.2 mM dNTPs (Promega), 1x appropriate reaction 
buffer (Promega/Statagene) and 2.5 U Taq or Pfu polymerase made up with 
sterile deionised water.  Amplification was performed in a thermocycler 
(PTC-100, MJ Research Inc.).  DNA was denatured at 95
oC for 5 minutes, 
followed by 25 cycles of denaturing at 95
oC for 30 seconds, annealing at 
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oC for one minute, and elongation for two minutes at 72
oC.   A final 
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elongation reaction of 10 minutes was performed to ensure formation of 
full-length transcripts.   
 
2.2.3.5  DNA ligation 
The required vector and insert DNA fragments from restriction digests were 
isolated using agarose gel electrophoresis and purified from the gel using a 
QIAquick gel extraction kit (Qiagen) according to the manufacturer’s 
instructions.  Vector and insert were ligated at 1:1 or 1:3 ratios with a total 
of 100 ng DNA in the presence of 1.5 U T4 DNA ligase (Promega) and 1 x 
T4 ligase buffer (Promega) for 4 h at room temperature. 
 
2.2.3.6  Bacterial transformation and amplification 
Ligated DNA was transformed into chemically competent E.coli cells 
(Promega).  Approximately 100 ng of DNA was mixed with 50 μl of E.coli 
cells (Promega) and incubated on ice for 30 minutes, before heat shocking at 
42 °C for 45 seconds.  Cells were then returned to ice for 2 minutes before 
addition of 250 μl SOC media (Promega) and incubation at 37 °C in an 
orbital incubator for 1 hour.  Cultures were spread on agar plates (1.5 % 
(w/v) Bacto-Agar (Difco), 10 % (w/v) tryptone (Sigma), 5 % yeast extract 
(Sigma), 5 % NaCl) containing the appropriate selection antibiotic 
(ampicillin 100 μg/ml or kanamycin 50 μg/ml) and incubated at 37 °C 
overnight.  Individual colonies were selected and grown up by overnight 
culture in 10 mls LB-Broth (10 % (w/v) tryptone (Sigma), 5 % yeast extract 
(Sigma), 5 % NaCl, plus selection antibiotic), before DNA preparation. 
 
2.2.3.7  DNA sequencing  
Sequencing reactions were set up containing 500 ng of the DNA of interest, 
4  μl of BigDye terminator ready reaction mix (ABI-PRISM BigDye 
Terminator Cycle Sequencing Kit, PE Applied Biosystems) and 1.6 pmoles 
of T7 or SP6 oligonucleotide primer, made up to 10 μl final volume with 
sterile deionised water in 0.2 ml thin-walled PCR tubes (PE Applied 
Biosystems).  Reactions were run on a thermocycler (GeneAmp 9700) for 
25 cycles of: 96 °C for 10 seconds, 50 °C for 5 seconds, 60 °C for 2 min.  
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DNA was precipitated on ice for 10 minutes by addition of 10 % (v/v) 3 M 
sodium acetate and 3 volumes of cold 100% ethanol and pelleted in a 
microfuge at 11500g for 30 minutes.  The DNA was rinsed with 70 % (v/v) 
cold ethanol, re-pelleted briefly and air-dried.  DNA was resuspended in 1.5 
μl loading buffer (20 % (v/v) dextran blue loading buffer (PE Applied 
Biosystems), 80 % (v/v) formamide) and denatured at 95 °C for 2 minutes.  
Samples were run on a 5.25 % denaturing polyacrylamide gel on an ABI-
PRISM 3000 sequencer (PE Applied Biosystems) by Gavin Baggage 
(Tenovus Research Laboratory, Southampton) and analysed using DNAstar 
software. 
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2.3 Protein expression; purification; and detection. 
 
2.3.1 Transient cell transfection  
 
2.3.1.1 Transient transfection of HEK 293 F cells 
One day prior to transfection, HEK 293 F cells (Invitrogen) were seeded at 
8.0 x 10
5 cells/ml.  On the day of transfection, cells were counted and 
diluted to a concentration of 1.0 x 10
6 cells/ml and made into a single cell 
suspension by vortexing.  The DNA-lipid complex was then prepared as 
follows; 100µg DNA (for a 100ml transfection) was added to 5ml OPTI-
MEM I reduced serum (supplied by Invitrogen) and incubated at room 
temperature for 5 min.  At the same time, 130µl 293fectin (supplied by 
invitrogen) was added to 5ml OPTI-MEM I reduced serum and incubated at 
room temperature for 5 min.  The two samples were then added together and 
incubated at room temperature for a further 30 min.  The DNA-lipid 
complex was then added to the 293 F cells and then incubated at 37
0C in a 
humidified atmosphere containing 8% CO2 in air on an orbital shaker 
platform rotating at 125 rpm for 72 hours.  The cells were then centrifuged 
for 5 min at 400 g and the supernatant was collected.  The supernatant was 
again centrifuged for 5 min at 400 g.  The supernatant was then ready for 
purification. 
 
2.3.2 Stable cell transfection 
 
2.3.2.1 Stable transfection of CHO-K1 cells with DN-MFG-E8 or DN-MFG-
E8-Fc DNA constructs. 
One day prior to transfection, CHO-K1 cells were seeded at 8.0 x 10
5 cells / 
75cm
2 in GMEM-supplemented medium containing 10% foetal calf serum, 
2mM L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 100U/ml 
streptomycin.  The CaC12-DNA precipitate was prepared as follows; sample 
1: 186µl 1M CaCl2, 15µg DNA, made up to a total volume of 750µl with 
dH2O.  Sample 2: 750µl 2 x HBS, 5.2µl 1M HCl.  Sample 1 was then added 
over a period of 1 min to sample 2, whilst vortexing.  The solution was then 
incubated for 20 min at room temperature to allow a precipitate to develop.  
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The precipitated solution was then added to the CHO-K1 cells and 
incubated for 5 h at 37
0C, in a humidified atmosphere containing 5% CO2. 
    
The supernatant was then removed and the cells were washed twice with 
15ml GMEM-supplemented medium.  The cells were coated with 2 ml 15% 
w/v glycerol / 1 x HEPES-buffered saline (HBS) and incubated at 37
0C for 
2 min.  They were then washed twice with 15 ml GMEM-supplemented 
medium.  The cells were then incubated with 15ml GMEM-supplemented 
medium containing 10% dialysed foetal calf serum, 100U/ml penicillin, and 
100U/ml streptomycin over night at 37
0C, in a humidified atmosphere 
containing 5% CO2.   The following day, the medium was removed and 5 ml 
Trypsin-EDTA was added for 4 min at 37
0C.  The cells were re-suspended 
with GMEM-supplemented medium containing 10% dialysed foetal calf 
serum, 100U/ml penicillin, and 100U/ml streptomycin and 25µM MSX at a 
concentration of 5.0 x 10
4 cells/ml.  The cells were then plated into 96 well 
flat bottomed micro titre plates at 1.0 x 10
4 cells/well and incubated at 37
0C, 
in a humidified atmosphere containing 5% CO2.  After two weeks, colonies 
appeared in approximately 10% of wells per plate.  When the wells were 
fully confluent, the supernatant was analysed by ELISA and the cells were 
placed into increasingly larger flasks.  The clone that produced the highest 
concentration of secreted protein was then placed into a 3 layer flask and the 
supernatant was collected and purified by immunoaffinity column 
chromatography.   
 
2.3.3 Protein  purification 
 
2.3.3.1 Anti-murine CD4 Immunoaffinity Column Chromatography 
Rat anti-mouse CD4 YTA3.1.2 antibody was concentrated to 2mg/ml.   
30mg of antibody were injected into a 12ml dialysis cassette and then 
dialysed with 5 litre 0.2M citrate buffer (0.2M citric acid, 0.58M NaOH, 
pH6.5), over a period of 48 h at 4
0C.The antibody was then diluted to a final 
concentration of 2mg/ml.  200ml, 10mM HCl were added to 1.2g CNBr 
activated sepharose 4B beads (supplied by Amersham Biosciences) and left 
at room temperature for 20 min.  The beads were then poured over a 
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sintered glass filter and washed with 500ml 10mM HCl followed by 500ml 
0.2M citrate buffer.  The beads were placed into a universal tube and 26 mg 
anti-mouse CD4 (YTA3.1.2) antibody was added.  The coupling reaction 
was incubated, rotating for 4 h at room temperature.  The beads were then 
poured onto a sintered filter and were then washed with 20 ml, 1M 
Ethanolamine.HCl, pH9.5.  The beads were rotated for 1 h at room 
temperature.  The beads were again poured onto the sintered filter and were 
washed with 1 litre 0.1M Tris, 0.5M NaCl, 5mM Na2EDTA followed by 
ammonium thiocyanate, followed again by 1 litre 0.1M Tris, 0.5M NaCl, 
5mM Na2EDTA. 
 
To make the column, a small amount of glass wool was added to the bottom 
of a 10 ml syringe.  5 ml of beads were added to the column and the column 
was washed with 0.03M Tris, 0.14M NaCl, 1.43mM Na2EDTA, and 0.7M 
HCl.  The column was then washed with 0.1M Glycine.HCl, pH2.5 and then 
then neutralised with 5 column volumes of 0.1M Tris, 0.5M NaCl, 5mM 
Na2EDTA and 5mM HCl followed by 5 column volumes of 0.03M Tris, 
0.14M NaCl, 1.43mM Na2EDTA, and 0.7M HCl.  The recombinant DN-
MFG-E8 protein was then purified from the transfected supernatant by 
being passed through the column at a rate of approximately 1 ml / min at 
4
0C.  The column was then washed with 5 column volumes of 0.03M Tris, 
0.14M NaCl, 1.43mM Na2EDTA, and 0.7M HCl followed by 5 column 
volumes of 0.1M Tris, 0.5M NaCl, 5mM Na2EDTA and 5mM HCl, 
followed again by a further 5 column volumes of 0.03M Tris, 0.14M NaCl, 
1.43mM Na2EDTA, and 0.7M HCl.  The protein was then eluted from the 
column using 0.1M Glycine.HCl, pH 2.5 and the eluate was collected in 1 
ml fractions containing 100µl, 2M Tris, pH 8.5.  The absorbance of each 
fraction was measured at 280nm and all fractions containing protein were 
pooled and concentrated to between 0.5 – 1mg/ml and stored at -20
0C.   
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2.3.4  Enzyme-linked Immunosorbent Assay (ELISA) 
 
2.3.4.1 Inhibition ELISA 
Capture reagent (CD30-CD4) was diluted to 5 µg/ml in coating buffer (15 
mM Na2C03, 28.5 mM NaHC03, pH 9.6) and 100 µl was added to 96-well 
ELISA plates (Nunc Immunoplate;
 Invitrogen) which were incubated for 1 
hour at 37
oC and then overnight at 4
oC.   Coating solution was removed and 
100 μl/well blocking solution (1 % (w/v) BSA in PBS) added and incubated 
for 1 hour at 37
oC.  The inhibition reaction was also incubated during this 
time for 1 h at 37
0C which was set up according to the following protocol: 
Standard curve: 0.02µg/ml anti mCD4 antibody (YTA 3.1.2) was added to a 
titration of mCD4-DN-MFG-E8 protein or mCD4-CD30 protein at 
concentrations of 0, 0.1, 0.2, 0.3, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 μg/ml which 
were diluted with 0.25%BSA/PBS.  To determine the level of mCD4-DN-
MFG-E8 protein present in the supernatant, 0.02µg/ml anti mCD4 antibody 
was added to fold dilutions of the supernatant; again this was diluted with 
0.25% BSA/PBS.  The microtitre plate was then washed 3 times with 200µl 
PBS/0.1% Tween and 100µl of the samples were added to each well then 
incubated for 1 h at room temperature.  Again the wells were washed 3 
times with 200µl PBS/0.1% Tween and 100µl of rabbit anti rat HRP 
labelled antibody (1 in 40,000 dilution) was added to each well and 
incubated for 1 h at room temperature.  The wells were washed 3 times with 
200µl PBS/0.1% Tween and then 100µl substrate (1 tablet of 0-
Phenylenediamine, 25ml Citrate (19.5g/l citric acid), 25ml Phosphate (28.4g 
Na2HPO4/l), 20µl H202, and 49.98µl dH2O) was added to each well and 
incubated at room temperature in the dark for 15-20 min.  To neutralise the 
reaction, 50µl H2SO4 was added.  The absorbance490nm of each well was 
determined using a Dynatech MR4000 plate reader (Dynatech laboratories). 
 
2.3.4.2 Sandwich ELISA 
Capture reagent (polyclonal rabbit anti-mouse IgG) was diluted to 25 µg/ml 
in coating buffer (15 mM Na2C03, 28.5 mM NaHC03, pH 9.6) and 100 µl 
was added to 96-well ELISA plates (Nunc Immunoplate;
 Invitrogen) which 
were incubated for 1 h at 37
oC and then overnight at 4
oC.   Coating solution 
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was removed and 100 μl/well blocking solution (1 % (w/v) BSA in PBS) 
added and incubated for 1 h at 37
oC.  The plate was then washed three times 
with wash solution (PBS + 0.05 % Tween-20) and the test supernatants and 
standards added to the wells.  Following incubation for 60 minutes at 37
oC, 
the plate was washed again (x 5 in wash solution).  Horse-radish peroxidase 
(HRP)-conjugated detection reagent (diluted 1:2000 to 1: 10000) was added 
to the plate (100 μl/well) for 60 minutes.  Following washing (x 5 in wash 
solution), 100 µl of HRP substrate (0.375 M citric acid, 0.8 M Na2HPO4, 0.2 
M o-phenylenediamine, 0.006% (v/v) H2O2) was added and incubated in the 
dark at room temperature for 15-20 min.  The reaction was terminated by 
the addition of 50 μl/well 2.5 M H2S04 and the subsequent colour change 
quantified by measurement of absorbance at 495 nm on a micro plate 
photometer (Dynatec MR4000, Dynatec).  Colour change was proportional 
to protein concentration and unknowns were determined using standard 
calibration curves of known concentration. 
 
2.3.4.3 ELISA to determine saturation concentration of DN-MFG-E8-Fc 
onto tissue culture plate 
A titration of DN-MFG-E8-Fc protein (0 – 150 μg/ml) was coated onto a 24 
well tissue culture plate in 250μl PBS per well for 2 h at room temperature, 
followed by incubation at 4
0C over night.  Each well was then blocked with 
2 ml PBS/1% BSA for 1 h at 37
0C.  Well were then washed 3 times with 3 
ml PBS / 0.05% tween.  Anti-mouse IgG-HRP was then diluted 1 in 40,000 
with PBS / 0.05% BSA and 500 μl was added per well for 1 h at room 
temperature.  Wells were again washed 3 x with 3 ml PBS / 0.05% tween. 
500 μl HRP substrate buffer was added and incubated in the dark at room 
temperature for 15-20 min.  The reaction was terminated by the addition of 
50 μl/well 2.5 M H2S04 and the subsequent colour change quantified by 
measurement of absorbance at 495 nm on a micro plate photometer 
(Dynatec MR4000, Dynatec).  Colour change was proportional to protein 
concentration and unknowns were determined using standard calibration 
curves of known concentration. 
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2.4 Induction of apoptosis 
2.4.1 γ-irradiation 
All cell lines (E.G7, J558L, A20, πBCL.1 and thymocytes) were re-
suspended into 1 x 10
7cells / 10ml medium (specific to individual cell line) 
without foetal bovine serum and placed into a universal tube.  Cells were 
then exposed to 25 Gray of caesium radiation from a closed source.   
Irradiated cells were then plated back into sterile flasks and incubated for 24 
h at 37
0C in a humidified atmosphere containing 5% CO2.  The percentage 
of apoptotic cells was determined either by trypan or using Annexin V-FITC 
staining.   
 
2.4.2 UVC-irradiation 
E.G7, J558L, A20, πBCL.1 cell lines and thymocytes were centrifuged at 
300 g for 5 min.  Cells were then washed twice with sterile PBS and were 
resuspened into 2 x 10
6 cells/ml in PBS.  5 ml (1 x 10
7 cells) were then 
placed into a sterile petri dish (without the lid) and were exposed to either 
30 J/m
2 (Thymocytes) or 50 J/m
2 (all other cell lines) UVC radiation   
(Stratalinker).  Cells were then placed back into a universal tube and were 
centrifuged at 300 g for 5 min.  They were then placed into culture medium 
(without feotal bovine serum).  Cells were then incubated over night at 37
0C 
in a humidified atmosphere containing 5% CO2.    
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2.5 Phagocytosis Assay 
2.5.1 Evaluation of tumour cell uptake by resident peritoneal 
macrophages in vitro. 
5 x 10
7 E.G7 cells were labelled with CFSE as described in section 2.1.4 
and were washed with sterile PBS.  They were then placed in a petri dish 
and exposed to 50 J/m
2 UVC radiation.  The cells were then placed in RPMI 
medium supplemented with 10% foetal calf serum, 50 µM 2-
Mercaptoethanol, 2 mM L-glutamine, 1 mM pyruvate, 100 U/ml penicillin, 
and 100 µg/ml streptomycin) for 48 h at 37
0C in a humidified atmosphere 
containing 5% CO2 after which time they were 100% apoptotic as 
determined by Annexin V staining.  Resident peritoneal macrophages from 
8 week old C57BL/6 mice were prepared as described previously.  3.0 x 10
5 
CD11b positive macrophages were plated per well in a 48 well plate and 
incubated in DMEM medium supplemented with 10% foetal calf serum, 
2mM L-glutamine, 1mM pyruvate, 100U/ml penicillin, and 100µg/ml 
streptomycin) at 37
0C in a humidified atmosphere containing 5% CO2 for 
1.5 h.  All non-adherent cells were then washed off and macrophages were 
incubated for a further 1.5 h.  1 x 10
6  CFSE labelled
 apoptotic E.G7’s in 
100µl Annexin V buffer were added to each well.  Control cells were left 
untreated and added directly to macrophages.  Blocking phosphatidylserine 
with CD4-DN-MFG-E8 on apoptotic E.G7’s : 1 h prior to adding E.G7’s to 
the macrophages, cells were washed once with 1 x Annexin V Binding 
Buffer and were treated with a titration of CD4-DN-MFG-E8 protein 
(0.75µg/ml – 60µg/ml), for 1 h at room temperature.  Control : E.G7’s were 
washed once with 1 x Annexin V Binding Buffer (0.01M HEPES/NaOH, 
pH 7.4, 0.14M NaCl, 2.5Mm CaCl2) and incubated for 1 h at room 
temperature prior to being added to the macrophages.  Positive control : 30 
min prior to adding control E.G7’s to adhered macrophages, 10 mM Sodium 
Azide was added to the medium. 
 
E.G7’s were incubated with the adhered resident peritoneal macrophages for 
75 min at 37
0C in a humidified atmosphere containing 5% CO2.  The wells 
were then washed with DMEM medium without supplements and cells were 
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then treated with Trypsin-EDTA for 10 min at 37
0C in a humidified 
atmosphere containing 5% CO2.  Cells were then scraped from each well 
and placed into FACs tubes.  Cells were resuspended in 100 µl PBS / 0.2% 
BSA and were treated with 1 µl CD11b-APC (BD Pharmingen) and 
incubated at 4
0C for 20 min.  Cells were then washed once with PBS / 0.2% 
BSA.  FACs analysis was then used to determine the percentage of double 
positive (CFSE + CD11b) cells. 
 
2.5.2 Evaluation of apoptotic cell uptake by resident peritoneal 
marophages in vitro using confocal microscopy. 
Thymocytes from a 4 week old BALB/c mouse were prepared as described 
previously (section 2.1.1), labelled with 1 µM CarboxyFluorescein 
Succinimidyl Ester (CFSE), (section 2.1.4), and exposed to 2500 RAD 
caesium  γ-radiation.  They were then incubated with RPMI medium 
(supplemented with 1 mM pyruvate, 100 U/ml penicillin, and 100 µg/ml 
streptomycin) over night at 37
0C in a humidified atmosphere containing 5% 
CO2.  Resident peritoneal macrophages from 8 week old BALB/c mice were 
prepared as described previously (section 2.1.1).  2.5 x 10
5 CD11b positive 
macrophages were plated onto cover slips coated with Poly-L-Lysine (PLL) 
that were placed into the bottom of wells in a 24 well plate and were then 
incubated in DMEM medium supplemented with 10% foetal calf serum, 2 
mM L-glutamine, 1 mM pyruvate, 100 U/ml penicillin, and 100 µg/ml 
streptomycin) at 37
0C in a humidified atmosphere containing 5% CO2 for 
1.5 h.  All non-adherent cells were then washed off and macrophages were 
incubated for a further 1.5 h.  1 x 10
6  CFSE labelled
  apoptotic thymocytes 
in 100 µl Annexin V buffer were added to each well.  Control cells were left 
untreated and added directly to macrophages.  Blocking phosphatidylserine 
with recombinant CD4-DN-MFG-E8 protein on apoptotic thymocytes : 1 h 
prior to adding thymocytes to the macrophages, cells were washed once 
with 1 x Annexin V Binding Buffer and were treated with a titration of 
CD4-DN-MFG-E8 protein (30 μg/ml and 60 μg/ml), for 1 h at room 
temperature.  Control : Thymocytes were washed once with 1 x Annexin V 
Binding Buffer and incubated for 1 h at room temperature prior to being 
added to the macrophages.  Positive control : 30 min prior to adding control 
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thymocytes to adhered macrophages, 10 mM Sodium Azide was added to 
the medium.  Non-phagocytosed thymocytes were then removed by washing 
the cover slips with PBS / 0.2% BSA followed by 200 µl Trypsin-EDTA 
followed by PBS / 0.2% BSA.  Each sample was then treated with 10 µg/ml 
biotinylated F4/80 (BD Pharmingen) in 1 ml PBS / 0.2% BSA for 30 min at 
4
0C.  Cells were then washed with PBS / 0.2% BSA.  Cells were then 
treated with 10 µg/ml streptavidin – Alexa546 (Invitrogen) in 1 ml PBS / 
0.2% BSA for 30 min at 4
0C.  Cells were again washed with PSB / 0.2% 
BSA.  Cells were fixed with 2 ml 4% Paraformaldehyde / PBS for 20 min at 
4
0C.  Cells were washed with PBS.  Cells were washed with 2 ml 20 mM 
Glycine / PBS.  Cells were washed with PBS.  Cells were visualised using a 
Leica SP2 confocal laser scanning microscope using an Argon (488) and 
GreNe (543) laser and a pinhole equivalent to 1 Airy Disc.    
 
2.5.3 Evaluation of apoptotic cell uptake by resident peritoneal 
marophages in vivo 
Thymocytes were prepared as described in section 2.1.1 and labelled with 1 
µM CFSE as described in section 2.1.4.  They were then exposed to 2500 
RAD caesium γ-radiation and incubated with RPMI medium (supplemented 
with 1 mM pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin) 
over night at 37
0C in a humidified atmosphere containing 5% CO2.   
Thymocytes were washed with PBS and then incubated for 45 min at room 
temperature with or without 100 µg/ml recombinant CD4-DN-MFG-E8.  1 
x 10
7 thymocytes were then injected (200 µl) into the peritoneal cavity of 8 
week old BALB/c mice.  30 min later, mice were sacrificed and the 
peritoneal cavity was lavaged with 10 ml cold PBS.  Cells were centrifuged 
at 300g for 5 min at 4
0C.  Cells washed in 2 ml PBS / 0.2% BSA and then 
treated with 10 µg/ml biotinylated F4/80 (BD Pharmingen) in PBS / 0.2% 
BSA for 30 min at 4
0C.  Cells were then washed with PBS / 0.2% BSA and 
were then treated with 5 µg/ml streptavidin – APC (BD Pharmingen) for 30 
min at 4
0C.  Cells were washed again with PBS / 0.2% BSA and were then 
analysed by FACs. 
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2.5.4  OVA-loading apoptotic bm1 splenocytes 
Splenocytes from mice which are unable to bind the OVA peptide, 
SIINFEKL, to their MHC class I (b haplotype mutation 1 -H2-K
bm1) were 
obtained from 8-10 week old mice.  After red blood cell lysis, splenocytes 
were re-suspended in PBS and exposed to 50 J/m
2 UVC radiation to induce 
apoptosis.  5 x 10
7 UVC-radiated splenocytes / ml were re-suspended in 
PBS containing 10 mg/ml soluble OVA.  Cells were incubated for 10 min at 
37
0C. They were then added to 9ml RPMI 1640 medium without washing 
the cells (concentration of OVA was then 1 mg/ml). Cells were then 
cultured over night at 37
0C, in a humidified atmosphere containing 5% CO2.  
Prior to use, splenocytes were harvested and washed to remove non-
internalised OVA.  They were then used for subsequent phagocytosis 
assays.   
  
2.5.5  Generation and loading of BMDC with apoptotic cells 
 
 
Bone marrow derived DCs were prepared as described previously.  On day 
6 of DC culture, non-adherent and loosely adherent cells were harvested by 
gentle pipetting and replated at 2.5 x 10
5 CD11c+ cells/ml in RPMI 
supplemented with PS and 20ng/ml GM-CSF (supplied by Peprotech) in a 
48 well tissue culture plate.  Thymocytes or splenocytes were prepared for 
DC co-culture by CFSE labelling as described previously and then either 
treating with 25Gy caesium gamma radiation or 50J/m
2 UVC radiation, 
respectively, then incubating over night at 37
0C to promote apoptosis.  The 
apoptotic cells were then incubated for 1 hour at 37
0C with recombinant 
CD4-DN-MFG-E8 protein, DN-MFG-E8-Fc protein, or without protein.   
DCs were harvested over a time course (1 h, 2 h, 3 h, and over night), 
washed and determined for apoptotic cell uptake.  See below. 
 
2.5.6 Evaluation of apoptotic cell uptake by DC 
 
Cells were labelled with 10µM CFSE before radiation and treatment with 
recombinant proteins.  DCs were harvested after assay and labelled with 
10µg/ml biotinylated anti-CD11c antibody (supplied by BD Pharmingen) 
for 20 min at 4
0C, washed with PBS/0.2%BSA and then stained with 
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10µg/ml Streptavidin – APC (supplied by BD Pharmingen) for 20 min at 
4
0C.  Cells were then washed again with PBS/0.2%BSA.  Samples were 
analysed using a FACScaliber flow cytometer and CELLQuest pro 
software.  DCs phagocytosing apoptotic cells were visualised as double 
positive cells. 
 
2.6 T  cell  proliferation  assays 
 
2.6.1 Thymidine  incorporation  in vitro proliferation assay 
Transgenic OVA-specific CD4+ or CD8+ T cells (OT-I and OT-II 
respectively) were obtained from isolating the spleen and lymph nodes from 
8-10 week old transgenic mice.  Cells were treated with 5 ml red blood cell 
lysis buffer for 2 min and then centrifuged for 5 min at 300g.  Cells were 
then washed in PBS and then re-suspended at 2 x 10
5 cells / 100 μl in RPMI 
1640 medium supplemented with 10% foetal calf serum, 50µM 2-
Mercaptoethanol, 2mM L-glutamine, 1mM pyruvate, 100 U/ml penicillin, 
and 100µg/ml streptomycin.  100 μl cells were then added per well to a 96 
well U-shaped tissue culture plate.  OVA-positive cells or soluble OVA 
protein, OT-I peptide or OT-II peptide were then added to the cells.  After 
48 h, 1 μCi 
3H thymidine was then added per well.  Thymidine 
incorporation was then determined 18 h later by washing the cells 
extensively using a cell harvester and plating them onto a 96 well unifilter 
plate (PerkinElmer).  The plate was then dried at 37
0C for 2 h and the level 
of thymidine (cpm) per well was detected using a Topcount -5.00.     
                                                                                               
Chapter 3 - Results 
 
Expression and characterisation of recombinant MFG-E8 
proteins 
 
3.1 Introduction 
MFG-E8 is a murine glycoprotein secreted by macrophages and immature 
dendritic cells that provides a bridge between apoptotic cells and 
phagocytes to facilitate their uptake.  The two carboxyl-terminal domains, 
C1 and C2, bind to phosphatidylserine upon its exposure on the apoptotic 
cell surface;  and the N-terminal epidermal growth factor-like domains, E1 
and E2, bind via an amino acid RGD motif in domain E2 to αvβ3 integrin 
and αvβ5 integrin expressed on the surface of macrophages and dendritic 
cells, respectively.  There are two isoforms of MFG-E8 generated by 
spliced variants from the same mRNA. MFG-E8 L and MFG-E8 S differ 
only by an additional proline/threonine (PT) rich domain encoded by the 
longer variant, shown to increase the affinity for PS in vitro by up to 8 fold 
when compared to MFG-E8 S [98].   
 
To elucidate the potential use of MFG-E8 in enhancing the 
immunogenicity of apoptotic tumour cells; either by blocking PS or 
additionally, through re-directing their uptake though Fcγ receptors, the 
recombinant proteins were first expressed and their functions characterised.   
 
Previous studies have shown that mutating the RGD motif required for 
integrin recognition generates a dominant-negative MFG-E8 protein which 
no longer has the ability to bind to integrins on phagocytes, and thus 
inhibits apoptotic cell clearance by up to 40% [98].  In this study, a 
dominant negative form of the protein has been produced which encodes 
only the domains required for PS binding (PT, C1 and C2) and no longer 
encodes the N-terminal domains necessary for integrin recognition (E1 and 
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E2).  The first aim was to investigate the ability of DN-MFG-E8 protein to 
bind to an array of apoptotic tumour cells and to ensure that the binding 
was specific to PS. 
 
In addition to blocking PS-mediated apoptotic cell clearance, the effect of 
re-directing the apoptotic cells through Fcγ receptors was also examined.  
Previous studies have shown that material opsonised with IgG is 
phagocytosed through Fc gamma receptors expressed on the surface of 
dendritic cells, promoting effective cross-priming to cytotoxic T cells [52].  
Evidence to support this hypothesis is provided in studies showing that  Fc-
mediated phagocytosis of apoptotic tumour cells induces tumour immunity 
by promoting DC maturation in a manner that allows cross-presentation of 
tumour associate antigens to CD8+ T cells [46].  To utilise this pathway, a 
second recombinant dominant-negative protein (DN-MFG-E8) was 
generated which was ligated to the Fc region of mouse IgG2a comprising 
the CH2 and CH3 domains of the IgG heavy chain and the hinge region.  
Again, this recombinant protein expression and function has been 
characterised. 
  
This chapter describes the manner in which both recombinant MFG-E8 
proteins were expressed in mammalian cells; their biochemical 
characterisation; and their ability to bind specifically to apoptotic cells. 
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3.2 Generation of a dominant-negative MFG-E8 protein. 
 
3.2.1  Cloning and expression of recombinant DN-MFG-E8 protein 
Total RNA was extracted from 10 x 10
6 P338D.1 mouse macrophage cells.  
5 µg of RNA was then used to generate 1
st strand cDNA using a d(T18) 
primer and M-MuLV reverse transcriptase.  1/20 of the cDNA produced 
was used to amplify MFG-E8 cDNA by PCR using specific primers (see 
section 2.2.1.2) and Pfu polymerase.  The PCR product was then cloned 
into a TOPO Blunt II plasmid, after which the plasmid was sequenced 
using M13 primers.  The PT, C1, and C2 domains were then ligated to a rat 
CD4 leader and murine CD4 sequence (domains 3 and 4 only) so that the 
protein could be detected and purified by anti-CD4 mAb.  Figure 3.1 shows 
a schematic representation of the primary structure of the fusion protein 
which was cloned into two separate mammalian expression vectors; 
pEF1/V5-His A and pEE14, for use in both transient and stable cell 
transfections, respectively. 
 
 
 
 
 
 
Figure 3.1 Schematic representation of the primary structure of DN-MFG-E8.   
Rat CD4 leader and murine CD4 (domains 3 and 4) were isolated and ligated into a 
pEF1/V5-His A vector at restriction sites, Spe1/Xba1 and EcoR1.  The PT, C1 and C2 
domains of MFG-E8 were then isolated and cloned downstream of the CD4 (3 and 4) 
domain at restriction sites, EcoR1 and Xba1.   
 
Initially, the recombinant protein was expressed transiently in 293F cells 
following the protocol described in section 2.3.1.1.  The secreted protein 
resolved on SDS-PAGE at approximately 70kDa (Figure 3.2) which could 
be determined after purifying the protein from the cell culture supernatant 
using anti-CD4 immunoaffinity column chromatography, where a single 
band was observed (Figure 3.3).  Both reduced and non-reduced protein 
resolved at the same molecular weight which suggests that there are no 
inter-protein disulphide bonds (Figure 3.4). A schematic representation of 
the predicted folded protein structure is shown in figure 3.5.    
PT C1 C1 rL mCD4 (3+4) 
0 119 669 1755 bp
Bgl II EcoR1 Xba1/Spe1
PT C1 C1 rL mCD4 (3+4) 
0 119 669 1755 bp
Bgl II EcoR1 Xba1/Spe1
C2 
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Figure 3.2 T ransiently expressed recombinant DN-MFG-E8 protein. 8.5% SDS-
PAGE gel.  Lane 1, 25µl concentrated (50-fold) supernatant from HEK 293 F cells 
transfected 72 hours previously with 100µg pEF-1/V5-His A-CD4-DN-MFG-E8.  Lane 2, 
25µl 200 fold concentrated supernatant from HEK 293 F cells transfected 72 hours 
previously with 100µg PigPlus-mCD4-CD30 (control).   
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Figure 3.3 Purified transiently expressed recombinant DN-MFG-E8 protein.  8.5% 
SDS-PAGE gel.  Lane 1, 25µl concentrated (50 fold) supernatant from HEK 293 F cells 
transfected 72 hours previously with 100µg pEF-1/V5-His A-CD4-DN-MFG-E8.  Lane 2, 
6.5µg DN-MFG-E8 protein eluate from 100ml supernatant from HEK 293 F cells 
transfected 72 hours previously with 100µg pEF-1/V5-His A-CD4-DN-MFG-E8 and then 
purified using anti-mCD4 YTA3.1.2 immunoaffinity column chromatography. 
 
 
 
 
80  
                                                                                               
 
 
 
 
 
                                                                 Lane 1         Lane 2      
                                                  
kDa
175
83 
62 
47.5
37.5 
 
Figure 3.4 Reduced and non-reduced purified recombinant DN-MFG-E8 protein.  
8.5% SDS-PAGE gel.  Lane 1, 6.5µg DN-MFG-E8 protein reduced with 40µM DTT.  
Lane 2, 6.5µg non-reduced DN-MFG-E8 protein.   
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Figure 3.5 Schematic representation of the predicted protein structure of DN-MFG-
E8 protein. Domains 3 and 4 of murine CD4 are encoded upstream of the PT,C1 and C2 
domains of murine MFG-E8.  Domains C1 and C2 show homology to human clotting 
factors VIII and V, respectively; the PS binding domain of which has been identified as a 
site within the C2 domain [175]. 
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3.2.2  Stable transfection of mammalian cells to constitutively secrete 
DN-MFG-E8 protein. 
To produce larger amounts of recombinant DN-MFG-E8 protein, the CD4-
PT-C1-C2 construct was cloned into a pEE14 vector and was used to stably 
transfect CHO-K1 cells using the transfection protocol described in section 
2.3.2.1.  After transfecting CHO-K1 cells with pEE14-CD4-DN-MFG-E8, 
they were then grown in selection GMEM-S medium, containing 25µM 
MSX.  All colonies were then screened by an inhibition ELISA to detect 
secreted DN-MFG-E8 protein (Figure 3.6).  The most viable and highest 
secreting clone was then selected for expansion.  At each stage of 
expansion, the supernatant was again tested for protein expressed by 
inhibition ELISA.  The supernatant was collected after the cells were 
established.   
 
The protein was purified from the supernatant using anti-CD4 
immunoaffinity column chromatography (described in section 2.3.3.1) and 
then dialysed with PBS for use in functional assays.  The size of the protein 
was confirmed using SDS-PAGE and resolved at the same molecular 
weight (approximately 70kDa) as the transiently transfected construct.   
 
To determine the structure of the protein when it was in solution, 100µg of 
protein from both a stable and transient transfection was analysed by size-
exclusion chromatography using a Superdex 200 column.  As figure 3.6 
shows, the protein produced transiently resolved as two peaks, 
corresponding to molecular masses of approximately 50kDa and over 
900kDa.  The large molecular mass is likely to be protein which has 
formed as multimers.  All of the protein produced by stably transfected 
CHO-K1 cells appeared to also have formed multimers.  Section 3.2.4 
(figure 3.10), would suggest however that this does not affect the ability of 
it to bind to PS on apoptotic cells. 
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Figure 3.6 Inhibition ELISA to determine secretion levels of DN-MFG-E8 protein 
produced by stably transfected CHO-K1 cell clones.  A: DN-MFG-E8 standard curve.  
B: Dilution curve; Supernatant was removed from each clone that had been stably 
transfected with pEE14-CD4-DN-MFG-E8 and then had successfully grown in selection 
medium (+ 25µM MSX).  Graph B alone determines the cell lines which are expressing 
the DN-MFG-E8 protein, whilst graph A can be used to then calculate the final 
concentration of protein in the supernatant.   
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Figure 3.7 High Performance Liquid Chromatography (HPLC) to determine the 
molecular weight of recombinant DN-MFG-E8.  A: Molecular weight markers at 
1mg/ml (total of 133µg) were loaded onto a Superdex column and eluted in a total of 
24ml.  900 = 900 kDa Human IgM, 150 = 150 kDa Human IgG, 100 = 100 kDa OKT3 
F(ab)2, 50 = 50 kDa Human Fc.  B: 100µg DN-MFG-E8 protein from 293 F transiently 
transfected cells was loaded on a Superdex column and eluted in 24 ml.  C: 100µg DN-
MFG-E8 protein from CHO-K1 stable transfected cells was loaded onto a Superdex 
column and eluted in 24 ml. 
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3.2.3  Determining an effective method for the induction of apoptosis. 
Following isolation and purification of recombinant DN-MFG-E8 protein, 
it was necessary to first confirm that it was fully functional.  Initially this 
was determined by ensuring that the protein bound preferentially to 
apoptotic cells.   
 
To determine the most effective method of inducing apoptosis in 
lymphoma cells, a number of cell lines (A20, J558L, πBCL.1, and EG.7) 
and also primary cells (thymocytes), were exposed to either 25 Gy caesium 
γ-radiation or 50 J/m
2 UVC irradiation.  The percentage of cells that had 
become apoptotic and had consequently translocated PS to their surface 
was determined by treatment with 10 μg/ml fluorescently labelled annexin 
V and analysed using flow cytometry.  In all cell lines, apoptosis could be 
induced using both stimuli.  Overall however, the percentage of cells from 
tumour cell lines that had become apoptotic 24 h post treatment was 
slightly increased when the cells had been treated with UVC radiation 
(Figure 3.8).  This method of inducing apoptosis was therefore used in 
subsequent assays.  Thymocytes were however significantly more sensitive 
to gamma radiation when compared to UV radiation 24 h post treatment 
(Figure 3.8).  Gamma radiation was therefore used to render thymocytes 
apoptotic in any subsequent assays.  
 
A time course following treatment with both UV and gamma radiation was 
also carried out to determine the time required for cells to become 
apoptotic.  After 2, 4 and 8 hours there was no significant change in the 
percentage of cells that had become apoptotic.  48 h post treatment, the 
cells were no longer cellular, so could not be used in phagocytosis assays.  
24 h was therefore considered to be the optimal time to incubate all cells 
post treatment with radiation. 
 
 
 
 
85  
                                                                                               
 
UVC radiation γ-radiation 
 
 
 
 
 
 
 
 
 
 
 
 
                                  
                
 
 
 
 
         
 
 
                                      
 
 
 
 
 
Figure 3.8 FACs analysis comparing the effect of UVC or γ-irradiation to induce 
apoptosis in a range of tumour cell lines and thymocytes.  All cell lines were analysed 
24 h post treatment with either 50 J/m
2 UVC radiation or 25 Gy caesium radiation.  The 
percentage of cells apoptotic cells was measured by the level of Annexin V-FITC binding 
(FL-1).  Thymocytes were prepared from 4 week old BALB/c mice and were analysed 24 
h post treatment with either 50J/m
2 UVC radiation or 25 Gy caesium radiation.  The 
percentage of apoptotic cells was measured by the level of Annexin V-Biotin binding, 
which was detected using APC labelled Streptavidin as the secondary antibody (FL-4).  
Solid histograms indicate untreated cells.  Open histograms indicate irradiated cells.   
Numbers indicate % of Annexin V positive irradiated cells (top) and the mean 
fluorescence of the cells (bottom). 
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3.2.4  Recombinant DN-MFG-E8 binds specifically to apoptotic cells. 
To ensure that DN-MFG-E8 protein was able to bind specifically to 
apoptotic cells, a number of tumour cell lines (πBCL.1, A20 and J558L) 
and primary cells were either left untreated or rendered apoptotic using 
50J/m
2 UVC or 25Gy gamma irradiation, respectively.  In all cases, DN-
MFG-E8 protein was able to bind specifically to apoptotic cells to levels 
comparable to that seen with annexin V (figure 3.9). All cells bound both 
DN-MFG-E8 protein and annexin V to different degrees, suggesting that 
the level of PS exposure either varies between cell types or that different 
cells expose PS on their surface at different time points after exposure to 
apoptotic stimuli.  Both transiently and stably produced proteins bound to 
apoptotic cells to the same degree (figure 3.10).  
 
3.2.5  The binding of DN-MFG-E8 to PS is not dependent on extra-
cellular calcium. 
Previous studies have shown that the ability of Annexin V protein to bind 
to PS on the surface of apoptotic cells is dependent on the presence of extra 
cellular calcium [176].  To determine whether the same is also true for DN-
MFG-E8, the binding of recombinant DN-MFG-E8 to apoptotic Jurkat and 
EG.7 cells with or without buffer containing 2.5mM CaCl2,  was 
determined.   
 
Jurkat cells were either left untreated or treated with 500ng/ml CH-11 (IgM 
anti Fas) and incubated over night at 37
0C rendering them 70% apoptotic 
(as determined by Annexin V-FITC staining).  10µg/ml DN-MFG-E8 was 
added per sample (5 x 10
5 cells) for 1 h at room temperature either in 
buffer containing calcium (0.01M Hepes, pH7.4; 0.14M NaCl; 2.5mM 
CaCl2) or without calcium (0.01M Hepes, pH7.4; 0.14M NaCl).  Binding 
of DN-MFG-E8 was then determined by staining with 5µg/ml rat anti-CD4 
FITC (YTA.3.1.2).  EG.7’s were treated as described in section 3.2.4; 
however, the binding was also determined using buffer that did not have 
additional calcium.  The results shown in figure 3.11 illustrate that 
additional extra-cellular is not required for binding of DN-MFG-E8 to 
apoptotic cells.    
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Figure 3.9 Recombinant DN-MFG-E8 protein binds to an array of apoptotic cells.  A: 
πBCL.1 cells were either untreated (solid histogram) or exposed to 50J/m
2 UVC radiation 
(open histrgram) and incubated at 37
0C for 24 h.  Cells were then washed with calcium 
buffer and 1 x 10
6 cells were used per sample.  Positive control - 1µl Annexin V-FITC 
was added to 1 x 10
6 cells/100µl for 5 min.  Negative control – CD30-CD4 protein was 
added to 1 x 10
6/100µl at concentrations ranging from 0.5µg/ml to 62.5µg/ml.  Cells were 
incubated for 1 h at room temperature and were then treated with 2µg/ml anti-CD4 
antibody (YTA 3.1.2) for 30 min at room temperature before being analysed by FACS.  
DN-MFG-E8 protein was added to 1 x 10
6 cells/100µl at concentrations ranging from 
0.5µg/ml to 62.5µg/ml.  Cells were incubated for 1 h at room temperature and were then 
treated with 2µg/ml anti-CD4 antibody (YTA 3.1.2) for 30 min at room temperature 
before being analysed by FACS.  Top number on histogram indicates % of treated cells 
which bind to Annexin V, CD30-CD4 or DN-MFG-E8.  Bottom number indicates the 
mean fluorescent intensity of binding.  B: Assay to determine binding of DN-MFG-E8 to 
live versus apoptotic A20 cells.  The assay was performed as described in figure 3.8A. 
 
 
88  
                                                                                               
 
 
 
 
 
 
 
 
 
 
 
C 
DN-MFG-E8 
CD30-CD4 
 
D   
 
                          Annexin V-biotin                DN-MFG-E8-biotin 
                               
93.0%
659.9
94.3%
690.2
 
 
Figure 3.9 cont… C: Assay to determine binding of DN-MFG-E8 to live versus apoptotic 
J558L cells.  The assay was performed as described in figure 3.8A. D:  Thymocytes 
obtained from an 8 week old BALB/c mouse were either untreated (solid histogram) or 
treated with 25 Gy caesium radiation (open histogram) and incubated at 37
0C for 24 h.  
Cells were then washed with calcium buffer and 1 x 10
6 cells were used per sample.  Cells 
with either treated with 10µg/ml Annexin V-biotin or 10µg/ml CD4-DN-MFG-E8-biotin 
for 30 min at room temperature.  Cells were then washed and then treated with 10µg/ml 
APC labelled Streptavidin (FL-4).  Top number on histogram indicates % of treated cells 
which bind to Annexin V or CD4-MFG-E8.  Bottom number indicates the mean 
fluorescent intensity of binding. 
 
 
 
 
 
 
 
 
 
 
 
89  
                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 DN-MFG-E8 proteins produced either transiently or by stable cell 
transfection bind specifically to apoptotic cells.  
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Additional extra-cellular calcium is not required for DN-MFG-E8 to 
bind to apoptotic cells in vitro.  A: Comparing the ability of recombinant CD4-DN-
MFG-E8 to bind to live (solid graph) versus apoptotic (open graph) Jurkat cells.  B: 
EG.7’s were used instead of Jurkat cells. 
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3.2.6  DN-MFG-E8 competes with recombinant Annexin V for 
binding to PS. 
To examine whether the binding of DN-MFG-E8 to apoptotic cells was 
specific to phosphatidylserine, UVC induced apoptotic EG.7 cells were 
treated with various concentrations of DN-MFG-E8 protein either in the 
absence or presence of excess recombinant annexin V protein (50µg/ml).  
The ability of DN-MFG-E8 to bind to PS in the presence of Annexin V 
was then determined using YTA3.1.2-FITC anti-CD4 antibody.  As figure 
3.12 shows, the ability of DN-MFG-E8 to bind to phosphatidylserine on 
apoptotic cells was significantly reduced in the presence of excess Annexin 
V.  These results demonstrate that recombinant DN-MFG-E8 protein binds 
specifically to PS. 
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Figure 3.12 DN-MFG-E8 competes with recombinant Annexin V for binding to PS.  
0.5 x 10
6 live or UVC induced apoptotic EG7’s were treated with either Annexin V-FITC 
or a titration of recombinant CD4-DN-MFG-E8 protein (3µg/ml, 1.5µg/ml and 0.75µg/ml) 
with or without 50µg/ml recombinant Annexin V protein.  Binding of CD4-DN-MFG-E8 
to cells was determined using 2µg/ml YTA3.1.2-FITC anti-CD4 antibody.  A:  FACs 
analysis.  Purple: live cells; Green: Apoptotic cells with a titration of CD4-DN-MFG-E8; 
Pink: Apoptotic cells with a titration of CD4-DN-MFG-E8 + 50µg/ml recombinant 
Annexin V.  B: Graph representing data from FACs data.    
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3.3 DN-MFG-E8-Fc protein.  DN-MFG-E8-Fc protein. 
 
3.3.1  Cloning 
 
3.3.1  Cloning and expression of recombinant DN-MFG-E8-Fc 
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The DNA generated previously from the full length MFG-E8 L was used to 
PCR the PT,C1 and C2 domains and to include an EcoR1 site at the N-
terminus, a (Gly)4Ser flexible linker, and then a Bgl II site at the C-
terminus.  This was then fused via the (Gly)4Ser linker to a mouse IgG2a 
Fc region comprising of the CH2 and CH3 domains of the IgG heavy chain 
and the hinge region followed by its cloning into a PEE14 expression 
vector so that it could be used to generate stable cell
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Figure 3.13 Schematic representation of the primary structure of recombinant DN-
MFG-E8-Fc fusion protein.  The PT, C1 and C2 domains were isolated from the TOPO 
Blunt II vector using EcoR1 and Bgl II restriction enzymes and were then cloned in
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3.3.2 Generation of stable cell lines secreting DN-MFG-E8-Fc protein. 
The pEE14-MFG-E8-Fc construct was used to stably transfect CHO-K1 
cells following the protocol described in section 2.3.3.1. 10 days after 
transfection, clones which were resistant to treatment with 25µM MSX 
were expanded and the secretion of MFG-E8-Fc protein was determined by 
anti-mouse IgG sandwich ELISA (Figure 3.14).  The highest secreting and 
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most viable clone was then expanded. The protein was purified by Protein 
A column chromatography as described in section 3.2.2. As figure 3.15 
shows, the non-reduced protein resolved at greater than 175kDa and the 
reduced protein resolved at approximately 70kDa, suggesting that Fc 
region of the protein had formed a dimer.  A schematic representation of 
the predicted protein structure is shown in figure 3.17. 
3.3.3  N-MFG-E8-Fc protein binds specifically to 
comparable to that with annexin 
 and recombinant DN-MFG-E8 protein. 
 
Recombinant D
apoptotic cells. 
To determine the ability of the recombinant DN-MFG-E8-Fc protein to 
bind specifically to apoptotic cells, J558L plasmacytoma cells were 
rendered apoptotic by treatment with 50J/m
2 UVC radiation followed by 
incubation overnight in serum free medium. A titration of DN-MFG-E8-Fc 
protein was then added to either live or apoptotic J558L cells and its 
binding ability was determined by treating the cells with a fluorescently 
labelled (FITC) anti-IgG antibody.  DN-MFG-E8-Fc protein was able to 
bind specifically to apoptotic cells, which was concentration dependent, as 
shown in figure 3.16A.  In addition to this, the ability of the protein to bind 
specifically to apoptotic thymocytes when compared to annexin V and 
recombinant DN-MFG-E8 protein was also examined. As figure 3.16B 
shows, DN-MFG-E8-Fc protein was able to bind specifically to apoptotic 
thymocytes and the binding observed was 
V
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Figure 3.14 Sandwich ELISA to determine secretion levels of DN-MFG-E8-Fc 
protein produced by stably transfected CHO-K1 cell clones.  A: Standard curve using 
mouse anti-human CD3 mAb; IgG2a.  (OKT3) B:  Dilution curve; Supernatant was 
removed from each clone that had been stably transfected with pEE14-DN-MFG-E8-Fc 
and then had successfully grown in selection medium (+ 25µM MSX).  Graph B alone 
determines the cell lines which are expressing the protein, whilst graph A can be used to 
en calculate the approximate final concentration of protein in the supernatant.  Each line 
presents a separate clone.   
th
re
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Figure 3.15 Non-reduced and reduced purified DN-MFG-E8-Fc protein.  10% SDS-
PAGE gel. Lane 1, 10μg purified DN-MFG-E
175
83
62
47.5
kDa
8-Fc protein. Lane 2, 10μg purified DN-
FG-E8-Fc protein reduced with 40μM DTT.  M
 
 
 
 
 
 
 
 
 
 
 
 
32.5
175
83
62
47.5
32.5
175
83
62
47.5
kDa
32.5
96  
                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
0 10 20 30
0
100
200
300
contol IgG2a
DN-MFG-E8-Fc
Protein concentration ( μg/ml)
B
i
n
d
i
n
g
 
t
o
 
a
p
o
p
t
o
t
i
c
 
c
e
l
l
s
 
(
M
F
I
)
 
 
100 101 102 103 104
FL1-H
100 101 102 103 104
FL1-H
100 101 102 103 104
FL1-H
100 101 102 103 104
FL1-H
 
 
 
 
 
Figure 3.16 DN-MFG-E8-Fc protein binds specifically to apoptotic cells. A: J558L 
plasmacytoma cells were either live or rendered apoptotic with 50J/m
2 UVC radiation. 1 x 
10
6 cells were then treated with a titration of either control protein (anti-CD20 IgG2a) or 
recombinant DN-MFG-E8-Fc protein. After washing non-bound protein from the cells, 
bound protein was detected by staining the cells with a fluorescently labelled (FL-1) anti-
IgG antibody. Binding to live (solid histogram) or apoptotic (open histogram) was then 
determined by flow cytometry.  Graph below represents data from histograms. B: 
Thymocytes were either untreated or rendered apoptotic by treatment with 25 Gy γ-
radiation. 1 x 10
6 cells were then treated with either FITC-labelled annexin V, 60 μg/ml 
DN-MFG-E8 protein or 60 μg/ml DN-MFG-E8-Fc protein. Binding of the DN-MFG-E8 
protein was determined by staining the cells with FITC-labelled anti-CD4 antibody. 
Binding of the DN-MFG-E8-Fc protein was determined by staining the cells with FITC-
labelled anti-IgG antibody. Top number indicated % of cells which have bound protein. 
ottom number indicates mean fluorescence intensity (MFI) of open histogram peak.  B
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Figure 3.17 Schematic representation of the predicted protein structure of DN-MFG-
E8-Fc protein.  The PT,C1 and C2 domains of murine MFG-E8 are encoded upstream of 
the CH2 and CH3 domains of mouse IgG2a. The IgG domains form a dimer in solution 
s determined in figure 3.15). 
3.3.4  vels in DN-MFG-E8 and DN-MFG-E8-Fc 
 both measured <5.00 Eu/ml, which is accepted as 
ndotoxin low.  
(a
 
 
 
 
Endotoxin le
preparations. 
To ensure the immunological effect of both the DN-MFG-E8 and DN-
MFG-E8-Fc proteins was not caused as a result of the presence of LPS, 
both proteins were passed through an Endotrap Red endotoxin removal 
system (Lonza). After which 25 μl of each sample was tested using an 
endosafe-PTS gram detection assay (Charles River Laboratories). Both 
protein endotoxin levels before purification were 60 Eu/ml, however after 
purification they
e
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3.4 Discussion 
A fundamental characteristic of cells which become apoptotic is their 
ability to expose phosphatidylserine on their cell surface for recognition by 
a plethora of phagocyte receptors [177].  This study aimed to exploit this 
feature by using it as a means to specifically target apoptotic tumour cells 
and re-direct their uptake via a PS-independent pathway; so as to enhance 
their immunogenicity in a manner that would not require a specific target 
r each tumour. 
 immune response against tumour cells 
hich have undergone apoptosis. 
munogenic or 
lerogenic response is initiated after antigen presentation.   
fo
 
The clearance of apoptotic cells via PS has been studied extensively and it 
is widely accepted that this pathway is associated with a resulting immune 
tolerance against cell-associated antigens [27, 178].  In addition to 
examining the immunological effect of blocking this pathway, it was also 
of interest to determine whether an alternative phagocytic pathway would 
be more suitable in generating an
w
 
The binding of the Fc regions of IgG antibodies to their receptors on 
antigen presenting cells has long been known to augment immune 
responses including phagocytosis, NK cell antibody-dependent cellular 
cytotoxicity, activation of neutrophils, and the inhibition of B cell 
activation by IgG immune complexes (as reviewed in [49]).  The targeting 
of Fcγ receptors on dendritic cells is therefore a plausible target for 
therapies due to their ability to regulate whether an im
to
 
In mice, there are 4 subclasses of IgG (IgG1, IgG2a, IgG2b and IgG3) 
which bind with differential affinities for both activating and inhibitory Fcγ 
receptors [179].  Although FcγRIA is the highest affinity receptor for IgG 
molecules in both mice and humans, it does not make a suitable target for 
therapy due to the fact that it is always saturated with its ligand in vivo (the 
cell does however become activated through this receptor until the 
antibody is cross-linked with antigen).  All other FcγRs have 100-1000 fold 
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100 
for 
inding to Fcγ receptors on dendritic cells, owing to its preferential binding 
n of bi-
pecific antibodies and allows the movement of both arms of the secreted 
CHO-K1 cells.  This high molecular fraction may represent 
e formation of protein multimers, the nature of which was not fully 
ng this.  This multimer formation did not 
however appear to affect the binding sites of the protein to PS on apoptotic 
cells (figures 3.8 and 3.15).   
lower affinity for their antibody which prevents monomeric antibodies in 
the serum from binding. IgG2a and IgG2b are the most proinflammatory 
IgG molecules, showing greatest activity in the mouse than either IgG1 or 
IgG3 [47].  The preferential binding of IgG2a to FcγRIV [180] has been 
shown to be an effective target in mediating antibody-dependent cellular 
cytotoxicity (ADCC) in a metastatic melanoma model [47].  With this in 
mind, it was decided that IgG2a was the most suitable IgG subclass 
b
to FcγRIV and its ability to generate high immunostimulatory response. 
 
In addition to generating a dominant-negative MFG-E8 protein for 
blockade of apoptotic cell clearance via PS, the domains of both the DN-
MFG-E8 and the Fc region of IgG2a were linked together using an amino 
acid linker, Gly4Ser.  This is a widely used linker for the productio
s
protein to move and retain their separate functional integrity [181]. 
 
As described in this chapter, both DN-MFG-E8 and DN-MFG-E8-Fc DNA 
constructs were successfully used to transfect cell lines so that the protein 
was expressed and secreted at detectable levels by SDS-PAGE (figure 3.3 
and 3.14).  Size exclusion chromatography used to analyse both proteins 
showed that both DN-MFG-E8 and DN-MFG-E8-Fc had a higher 
molecular mass.  This was more apparent in the proteins which were 
produced by 
th
addressed.   
 
Other CD4-fusion proteins made in house did not form aggregates under 
the same conditions, which suggested that it was the structure of the MFG-
E8 region which was causi 
                                                                                               
 
Additionally, the binding of the PT, C1 and C2 domains to apoptotic cells 
was specific to PS, as the binding could be inhibited in the presence of 
recombinant annexin V protein (Figure 3.11). 
 
The next stage in this study was to then determine what effect both 
recombinant MFG-E8 proteins would have on apoptotic cell clearance, 
both in vitro and in vivo.  
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Chapter 4 – Results 
 
Manipulating the phagocytosis of apoptotic cells by professional 
phagocytes 
 
4.1 Introduction 
One of the fundamental problems in achieving immunity against tumours is 
due, in part, to the fact that most tumour cells die when treated with 
radiotherapy or chemotherapeutic drugs by apoptosis.  It is widely accepted 
that the clearance of apoptotic cells promotes tolerance against cell-
associated antigens, including those associated with tumours, rather than 
immunity [44].  When cells become apoptotic, they expose a number of 
receptors on their surface, commonly referred to as “eat me” signals, which 
are then recognised by professional phagocytes.  The classical route for 
apoptotic cell uptake is via phosphatidylserine exposed on the cell surface 
at early stages of apoptosis.  PS is recognised by a myriad of receptors and 
opsonising bridging molecules to ensure that apoptotic cells are cleared 
rapidly and efficiently so as to prevent their break down by secondary 
necrosis [182]. 
 
Inhibiting apoptotic cell clearance in vivo can lead to the development of 
autoimmune diseases such as system lupus erythematosus (SLE) [126, 
183].   Necrotic cells promote the maturation of dendritic cells and in turn 
convert the tolerogenic response associated with the presentation of self-
antigens, to the cross-priming pathway which promotes expansion of naïve 
self-antigen specific CD8+ T cells [184, 185].  If an immune response to 
self-antigens can be established in this manner, it is conceivable that an 
immune response to tumour-associated antigens could be generated 
through the same means by manipulating the clearance pathway of 
apoptotic tumour cells.   
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The ability to prime tumour-specific CTLs in vivo by ex vivo matured 
peptide-pulsed dendritic cells has already been shown to generate 
immunity against tumours.  This effect was however short lived and did not 
permit long lasting protection against subsequent tumour challenge [42].  
As discussed in chapter 1 (section 1.6.3) the tumour microenvironment is 
highly immunosuppressive.  This prevents the maturation of DCs and thus 
elicits a tolerogenic effect upon tumour-associated antigen uptake and 
presentation to tumour-specific CTLs [186-188]. 
 
Before the generation of a CD8+ T cell response against a tumour antigen 
can be examined, the first step towards this goal was to control the manner 
in which apoptotic tumour cells are cleared by phagocytes.  This chapter 
describes the way in which this was achieved.  Firstly, the effect of DN-
MFG-E8 on apoptotic cell uptake by both macrophages and dendritic cells 
was studied.  Additionally, re-directing apoptotic tumour cell clearance 
through Fcγ receptors using the DN-MFG-E8-Fc protein was also 
examined.   
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4.2 Recombinant MFG-E8 proteins can manipulate the 
clearance of apoptotic cells by macrophages. 
4.2.1  DN-MFG-E8 protein inhibits phagocytosis of apoptotic cells by 
macrophages 
 
4.2.1.1 DN-MFG-E8 binds to PS on apoptotic EG.7 cells and inhibits 
their clearance by resident peritoneal macrophages. 
 
In 2002, Nagata and colleagues [98] showed that MFG-E8 carrying a point 
mutation in the RGD motif, required for binding to integrins, behaved as a 
dominant-negative protein and inhibited the phagocytosis of apoptotic cells 
by peritoneal macrophages in vitro and in vivo.  The initial step therefore, 
was to first determine whether this was also true for the recombinant DN-
MFG-E8 protein generated in this study.  In the first instance, the ability of 
DN-MFG-E8 to block uptake of UVC-induced apoptotic EG.7 cells by 
resident peritoneal macrophages in vitro was determined.  CFSE-labelled 
apoptotic cells which had either been treated with a titration of recombinant 
DN-MFG-E8 protein or left untreated, were added to resident peritoneal 
macrophages at a ratio of 1 macrophage to 4 apoptotic EG.7 cells.  Using 
light microscopy it was possible to observe the uptake of apoptotic cells 
into the macrophage cytoplasm after 1 h 15 min at 37
0C.  The level of 
phagocytosis was then determined using FACs analysis by staining 
macrophages with fluorescently labelled (APC) anti-CD11b antibody and 
determining the percentage of cells that were positive for both CFSE and 
APC fluorescence.       
 
DN-MFG-E8 protein inhibited PS-mediated phagocytosis of apoptotic cells 
by resident peritoneal macrophages in a dose-dependent manner as seen in 
figure 4.1.  This resulted in up to 40% inhibition of apoptotic cell clearance 
by resident peritoneal macrophages when compared to untreated apoptotic 
cells. 
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Figure 4.1 Recombinant DN-MFG-E8 inhibits phagocytosis of apoptotic cells by 
macrophages in vitro in a dose-dependent manner.  A: FACs analysis.  X-axis indicates 
CD11b +ve macrophages.  Y-axis indicated CFSE labelled thymocytes.  Double positive 
cells indicate that macrophages have phagocytosed apoptotic thymocytes.  A total of 
10,000 events were collected per sample.  B: Graph representing data from FACs analysis, 
showing the percentage of phagocytosis seen either from a positive control, negative 
control (10mM Sodium Azide), or with a titration of DN-MFG-E8 protein (0.75 – 
6µg/ml).  Errors bars indicate the results from 3 separate experiments. 
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4.2.1.2 Inhibition of apoptotic cell clearance by macrophages in the 
presence of DN-MFG-E8 protein is confirmed using confocal 
microscopy. 
 
In addition to determining the ability of recombinant DN-MFG-E8 protein 
to inhibit the percentage of PS mediated apoptotic cell phagocytosis by 
peritoneal macrophages, the effect of the recombinant protein on the 
phagocytic index (where the phagocytic index refers to the average number 
of apoptotic cells phagocytosed per macrophage) was also determined in 
vitro.   
 
Although in the previous phagocytosis assay EG.7 cells were used as a 
source of apoptotic cell, for this assay cells of smaller size were used so 
that the number of cells internalised per macrophage could be calculated 
accurately.  For this purpose, thymocytes were used as a source of 
apoptotic cell.  CFSE-labelled apoptotic thymocytes were treated with or 
without a titration of recombinant DN-MFG-E8 protein and were added to 
resident peritoneal macrophages, prepared as described in section 2.1.1; 
which instead of being allowed to adhere to the bottom of a 48 well plate, 
were placed on Poly-L-Lysine (PLL) cover slips.  After 75 min, non-
phagocytosed apoptotic thymocytes were washed off and the peritoneal 
macrophage membrane was stained with 10 µg/ml biotinylated F4/80 
antibody followed by a fluorescently labelled Streptavidin Alexa 546.  The 
number of apoptotic thymocytes which had been phagocytosed was then 
determined using Confocal laser scanning microscopy (CLSM) as 
described in section 2.5.2.   
 
Consistent with the previous experiment, the blocking of PS on the 
apoptotic cell surface by DN-MFG-E8 protein was able to cause a 53% 
reduction in phagocytosis (figure 4.2a).  The effect of DN-MFG-E8 
inhibition was again proven to be dose dependent (figure 4.2b).   
Additionally, using confocal imaging, the number of thymocytes 
internalised per macrophage was also calculated.  The phagocytic index 
was significantly reduced in the presence of the DN-MFG-E8 protein.  At a 
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concentration of 6 µg/ml, recombinant DN-MFG-E8 was able to reduce the 
phagocytic index from 1.21 to 0.48 (figure 4.2c).   
 
From these images alone it was not possible to determine whether the 
apoptotic cells were adhered to the macrophage cell surface or had been 
internalised.  Successful phagocytosis was confirmed when images were 
taken from different focal points throughout the cells so that 1-dimensional 
images taken at different planes cell could be transformed into a 3-
dimensional image (known as Z stacks).   
 
Noticeably, the level of blocking in both in vitro assays could not be 
abrogated entirely by treatment with 10 mM Sodium Azide.  Studies by 
Hanayama’s group have also shown that phagocytosis cannot be 
completely inhibited and have shown that treatment with 2 µg/ml of D89E 
recombinant DN-MFG-E8 protein reduced phagocytosis of apoptotic 
thymocytes by NIH3T3 cells by up to 60% [98].  This suggests that either 
other competing PS receptors operate during PS-mediated clearance of 
apoptotic cells or that there is a partial redundancy in the clearance 
pathway.  In any case, Nagata and colleagues have shown in their work that 
total phagocytic blockade is not necessary in order to observe an altered 
immune response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107  
                                                                                               
         
           Control            3 µg/ml DN-MFG-E8  6µg/ml DN-MFG-E8   10 mM Sodium Azide      
A  
 
 
 
 
 
 
 
 
 
 
0
25
50
75
Control 3ug/ml
dnMFG-E8
6ug/ml
dnMFG-E8
10mM Sodium
Azide
P
h
a
g
o
c
y
t
o
s
i
s
 
(
%
)
0.0
0.5
1.0
1.5
Control 3ug/ml
dnMFG-E8
6ug/ml
dnMFG-E8
10mM Sodium
Azide
P
h
a
g
o
c
y
t
i
c
 
I
n
d
e
x
 
B  C 
 
D 
Number of Phagocytosis  Phagocytic
macrophages (%) 0 1 2 3 ≥4I n d e x
Control 175 57.88 76 40 27 14 18 1.21
3μg/ml DN-MFG-E8 123 31.81 85 17 14 4 3 0.58
6μg/ml DN-MFG-E8 121 27.63 89 18 7 5 2 0.48
10mM Sodium Azide 109 20.33 86 17 5 1 0 0.26
Number of thymocytes per macrophage
 
 
Figure 4.2 Confocal microscopy showing that recombinant DN-MFG-E8 is able to 
inhibit the phagocytosis of apoptotic thymocytes in vitro.  Resident peritoneal 
macrophages from 8 week old BALB/c mice were co-cultured with γ-irradiated apoptotic, 
CFSE labelled thymocytes treated with or without DN-MFG-E8 protein.  The macrophage 
membranes were stained with biotinylated F4/80 antibody and then treated with 
fluorescent Streptavidin Alexa546.  A: Pictures obtained from Confocal microscopy 
showing the number of apoptotic thymocytes (Green) taken up by each macrophage (Red) 
B: Graph showing the percentage of cells that had phagocytosed apoptotic cells after each 
treatment.  C:  Phagocytic index = the average number of engulfed apoptotic thymocytes 
per macrophage.  D: Table showing data used to plot graphs.   
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4.2.1.3 Inhibition of phagocytosis with DN-MFG-E8 protein is also 
observed in vivo. 
 
To examine the effect of recombinant DN-MFG-E8 protein on apoptotic 
cell clearance in vivo, 1 x 10
7 CFSE-labelled γ-irradiated apoptotic 
thymocytes that had been untreated or pre-treated with either a titration of 
recombinant DN-MFG-E8 protein (100 µg/ml or 25µg/ml) or 100µg/ml a 
control CD4-CD30 protein were injected into the peritoneum of 8 week old 
BALB/c mice.  30 min post injection, mice were sacrificed and the 
peritoneal macrophages were harvested.  To determine the percentage of 
peritoneal macrophages that had phagocytosed the apoptotic thymocytes, 
macrophages were labelled with 10 µg/ml biotinylated F4/80, followed by 
10 µg/ml APC-labelled Streptavidin.  The cells were then examined using 
flow cytometry to determine the percentage of double-positive (CFSE + 
APC) cells and thus the level of phagocytosis.   
 
As shown in figure 4.3, 100µg/ml of recombinant DN-MFG-E8 
consistently reduced the level of apoptotic cell uptake by resident 
peritoneal macrophages by approximately 44% when compared to both the 
untreated control and the negative control.  In contrast, at 25µg/ml the 
ability of DN-MFG-E8 to inhibit macrophage uptake in vivo was variable. 
Interestingly, after 60 min all apoptotic cells had been cleared from the 
peritoneal cavity regardless of their treatment with either the control or 
DN-MFG-E8 protein.  This suggested that either the protein did not remain 
bound to PS or that there was direct competition for PS with other PS 
binding proteins within the peritoneum.  
 
 
 
 
 
 
 
 
109  
                                                                                               
                Control                          100µg/ml                      25µg/ml                        100µg/ml 
                                                    DN-MFG-E8                DN-MFG-E8              CD4-CD30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data.003 Data.003
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.004 Data.004
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.003 Data.003
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.005 Data.005
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.001 Data.001
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.001 Data.001
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.002 Data.002
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.003 Data.003
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
Data.003 Data.003
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4 81.8% 48.5%
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
85.0% 64.7% 86.7%
79.7% 30.0% 17.7% 82.0%
C
F
S
E
F4/80 + APC
A 
B 
Control
g/ml DN-MFG-E8
μ
100 
g/ml DN-MFG-E8
μ
25 
CD30-CD4
0
25
50
75
100
%
 
p
h
a
g
o
c
y
t
o
s
i
s
Figure 4.3 FACs analysis demonstrating the ability of DN-MFG-E8 protein to inhibit 
macrophage mediated apoptotic cell clearance in vivo.  A: 3 mice were injected per 
group with either 1 x 10
7 CFSE (y-axis) labelled apoptotic thymocytes (control), 1 x 10
7
 
CFSE labelled apoptotic thymocytes treated with 100 µg/ml DN-MFG-E8 protein, 1 x 10
7
 
CFSE labelled apoptotic thymocytes treated with 25 µg/ml DN-MFG-E8 protein, or 1 x 
10
7 CFSE labelled apoptotic thymocytes treated with 100µg/ml CD30-CD4.  Macrophages 
were pooled together in each group and labelled with 10 µg/ml biotinylated F4/80 
antibody; followed by 5 µg/ml Streptavidin labelled APC antibody (x-axis).  Double 
positive (CFSE + APC) were considered as macrophages that had engulfed apoptotic 
thymocytes.  Number indicates percentage of macrophages that had engulfed apoptotic 
thymocytes. Each graph is representative of one mouse B: Graph representing data from 
A. This experiment was performed once. 
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4.2.3  DN-MFG-E8-Fc protein can inhibit phagocytosis through 
PS receptors and facilitate clearance through Fcγ 
receptors. 
 
4.2.3.1  DN-MFG-E8-Fc increases the  uptake of apoptotic cells by 
macrophages in vitro. 
 
DN-MFG-E8 protein successfully reduced PS-mediated clearance of 
apoptotic cells by macrophages both in vitro and in vivo.  To examine what 
effect this protein would have once linked to an Fc domain, DN-MFG-E8-
Fc protein was used to treat CFSE-labelled apoptotic thymocytes which 
were then cultured with resident peritoneal macrophages at a ratio of 4:1.  
After 75 min, the percentage of phagocytosis was determined by labelling 
the macrophages with fluorescently labelled (APC) anti-CD11b antibody.  
The percentage of phagocytosis was then determined by enumerating cells 
that displayed double staining. 
 
In contrast with the effects of DN-MFG-E8, DN-MFG-E8-Fc protein 
enhanced the clearance of apoptotic cells by macrophages in vitro in a 
dose-dependent manner.  (figure 4.4).  To determine whether this enhanced 
phagocytosis was sustainable, uptake was determined over a time period of 
3 hours.  As shown in figure 4.5, the presence of DN-MFG-E8-Fc was able 
to enhance uptake of apoptotic cells consistently over a period of 3 hours 
when compared to non-treated apoptotic cells.  The inhibitory effect of 
DN-MFG-E8 was again clearly apparent in this experiment and was 
comparable to the inhibition seen with sodium azide. 
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Figure 4.4 DN-MFG-E8-Fc increases phagocytosis by macrophages in a dose-
dependent manner in vitro.  A: FACs analysis showing the effect of DN-MFG-E8-Fc 
protein on resident peritoneal macrophage-mediated clearance of CFSE-labelled apoptotic 
thymocytes in vitro.  Apoptotic thymocytes were either untreated or treated with a titration 
of recombinant DN-MFG-E8-Fc protein (100 μgml – 0.49 μg/ml) and then added to 
macrophages at a ratio of 4:1 for 75 min at 37
0C.  Percentage of phagocytosis was 
determined by cells staining double positive for CFSE and APC-labelled CD11b.  B:  
Graph representing data from FACs anaylsis. n = 3.  
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Figure 4.5 DN-MFG-E8-Fc enhances phagocytosis of apoptotic cells.  A: CFSE-
labelled apoptotic thymocytes were added to resident peritoneal macrophages at a ratio of 
4:1 over a time course of 1 to 3 h.  The percentage of phagocytosis was determined by 
labelling the macrophages with APC-conjugated CD11b antibody and then analysing the 
cells by flow cytometry.  Number indicates percentage of double-positive cells shown in 
gated region of plot.  B: Graph representing data from triplicate samples. 
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4.2.3.2 The effect of DN-MFG-E8-Fc protein on the uptake of 
apoptotic cells by peritoneal macrophages in vivo. 
 
To investigate the functional role of DN-MFG-E8-Fc protein in vivo, 
CFSE-labelled apoptotic thymocytes were either left untreated or treated 
with 100 μg/ml DN-MFG-E8, DN-MFG-E8-Fc or annexin V protein prior 
to being injected into the peritoneal cavity of BALB/c mice.  20 min post 
injection, the resident peritoneal macrophages were harvested and the 
percentage of macrophages which had phagocytosed apoptotic cells was 
determined by staining the macrophages with a fluorescently labelled 
(APC) anti-CD11b antibody.   
 
DN-MFG-8E-Fc was unable to significantly increase the percentage of 
apoptotic cell clearance by resident peritoneal macrophages in vivo (figure 
4.6) when compared to the control where an increase of only 8% was 
observed.  It is noteworthy, however, that uptake of apoptotic cells in the 
control group was particularly efficient reaching 70%, even in the 
relatively short time that the apoptotic cells were present in the peritoneal 
cavity (20 min).  It is plausible that an upper limit of phagocytic clearance 
of apoptotic cells had already been reached in this model which can not be 
enhanced by re-directing uptake to Fcγ receptors.   
 
Interestingly, whereas DN-MFG-E8 inhibited uptake by approximately 
22.5% in this experiment, recombinant annexin V protein failed to block 
uptake of apoptotic cells by peritoneal macrophages.  Overall, the evidence 
would suggest that the peritoneal cavity is a highly phagocytic environment 
that is capable of efficiently removing of apoptotic cells. 
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Figure 4.6 DN-MFG-E8-Fc protein is unable to increase phagocytosis of apoptotic 
cells  in vivo.  Graph representing data from FACs analysis where by CFSE-labelled 
apoptotic thymocytes were either untreated or treated with 100 μg/ml annexin V protein,  
DN-MFG-E8 protein, or DN-MFG-E8-Fc protein prior to being injected into the 
peritoneum of BALB/c mice.  20 min post injection, resident peritoneal macrophages were 
harvested and the percentage of phagocytosis was determined by labelling the 
macrophages with APC-labelled anti CD11b antibody and calculating the percentage of 
CFSE and APC double-positive cells.  There were 3 mice per group. 
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4.3  Investigating the effect of recombinant DN-MFG-E8 
proteins on apoptotic cell uptake by dendritic cells. 
4.3.1  Blocking PS on apoptotic cells does not inhibit 
phagocytosis by bone marrow-derived dendritic cells. 
 
Dendritic cells are considered the dominant cell type in vivo for cross-
presentation of antigen owing to their unique ability to capture antigen and 
then migrate to secondary lymphoid organs, where they present the antigen 
to CD8+ T cells [29].  In the case of cell-associated antigen, the cross-
presentation by dendritic cells of antigen derived from apoptotic cells 
typically renders antigen-specific T cells tolerant [44] (examined further in 
chapter 5). 
 
Bone marrow from C57Bl/6 mice was grown in GM-CSF-supplemented 
culture medium for 6 days.  Dendritic cells were then harvested and re-
suspended into serum free X-vivo medium, supplemented with GM-CSF.  
This was to ensure that any manipulation of apoptotic cell clearance would 
not be as a consequence of other clearance mechanisms such as 
complement-mediated phagocytosis [87].  After the percentage of CD11c+ 
cells had been determined by labelling the cells with fluorescently labelled 
anti-CD11c antibody and analysed by flow cytometry, BMDCs were 
seeded at 2.5 x 10
5 CD11c+ cells / ml in a 48 well culture plate.  CFSE-
labelled thymocytes were then treated with or without 100 μg/ml DN-
MFG-E8 or DN-MFG-E8-Fc proteins in 100 μl of serum free medium for 1 
h at 37
0C prior to being cultured with the BMDCs. The final concentration 
of the recombinant proteins in the culture medium was 10 μg/ml.  As a 
negative control 10 mM sodium azide was added to BMDCs 1 h prior to 
the addition of apoptotic thymocytes.  BMDCs were harvested at different 
time points and the percentage of BMDCs which had phagocytosed 
apoptotic thymocytes was determined by flow cytometry.   
 
In contrast to macrophages, the blockade of PS on apoptotic cells using 
DN-MFG-E8 protein was unable to inhibit their phagocytosis by CD11c+ 
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BMDCs.  As shown in figure 4.7, the percentage of phagocytosis observed 
was modestly increased when PS was blocked when compared to the 
control.  This suggested that an alternative clearance pathway by an as yet 
unknown receptor on the dendritic cells is more efficient at mediating 
apoptotic cell clearance, or that PS-blockade forced the DC to use a 
different clearance pathway.  Similar work using annexin V as a blockade 
for PS-mediated apoptotic cell clearance by splenic CD11c+ dendritic cells 
also showed enhanced that this enhanced phagocytosis.; the explanation of 
which was not confirmed [189]. 
4.3.2  DN-MFG-E8-Fc enhances phagocytosis of apoptotic cells 
by bone marrow-derived dendritic cells. 
 
DN-MFG-E8-Fc protein efficiently binds to PS on apoptotic cells and is 
able to significantly increase the percentage of phagocytosis by 
macrophages  in vitro in a dose-dependent manner (figure 4.5).  This 
enhancement was also observed when apoptotic thymocytes were treated 
with DN-MFG-E8-Fc protein and added in vitro to bone marrow-derived 
dendritic cells from C57BL/6 mice.  Phagocytosis was higher by 43% after 
2 h when compared to control non-treated apoptotic thymocytes and also 
when apoptotic thymocytes were treated with an isotype control (IgG2a 
mouse anti-human CD20).  After 18 h however, the percentage of double 
positive cells after treatment with DN-MFG-E8-Fc protein had slightly 
decreased, most likely as a result of apoptotic cell degradation within the 
phagosome.   
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Figure 4.7 Recombinant MFG-E8 protein can be used to manipulate phagocytosis of 
apoptotic cells by BMDCs.  A: CFSE-labelled apoptotic thymocytes were either 
untreated or treated with 100 μg/ml DN-MFG-E8 or DN-MFG-E8-Fc protein prior to 
being added to BMDCs over a time period of 1-3 h at 37
0C.  BMDCs were harvested and 
the percentage of phagocytosis was determined by labelling the BMDCs with a 
fluorescently (APC) labelled anti-CD11c antibody.  The cells were then analysed by flow 
cytometry.  Number on density plots indicates percentage of double positive cells.   B: 
Graph representing data from triplicate samples. 
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4.3.3 Inflammatory stimuli do not increase the capacity of 
phagocytosis by BMDCs 
 
In an inflammatory environment, the phagocytic activity of macrophages is 
markedly increased to resolve the inflammation as quickly as possible [63].  
To determine whether this also holds true for dendritic cells in vitro, the 
assay as shown in figure 4.7 was repeated, however the assay was 
performed in the presence or absence of 25 ng/ml LPS.  As shown in figure 
4.8, the presence of a toll-like receptor agonist did not increase the 
phagocytic capability of CD11c+ BMDCs in vitro.  Again, DN-MFG-E8-
Fc protein increased the phagocytosis of apoptotic thymocytes by BMDCs 
over a time period of 18 h when compared to control.  Blockade of PS with 
DN-MFG-E8 protein again demonstrated that BMDCs are able to 
phagocytose through PS-independent mechanisms.  
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Figure 4.8 Inflammatory stimuli do not affect the phagocytic capability of BMDCs in 
vitro.  Graphs representing flow cytometry analysis where CFSE-labelled apoptotic 
thymocytes were either untreated or treated with 100 μg/ml DN-MFG-E8 or DN-MFG-
E8-Fc protein prior to being added to BMDCs (apoptotic thymocytes: BMDC ratio 4:1) 
over 1,2,3 and 18 h.  After incubation at 37
0C, percentage phagocytosis was determined 
by cell which stained double positive for CFSE and CD11c.  n=3 
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4.3.4  DN-MFG-E8-Fc protein enhances phagocytosis of 
apoptotic cells by FcγR
-/- BMDCs due to the presence of 
the inhibitory FcγRIIb. 
 
The treatment of apoptotic cells with DN-MFG-E8-Fc protein clearly 
enhances their uptake by BMDCs in vitro.   To address the role of Fcγ 
receptors in this assay, BMDCs from Fcγ receptor knock out mice were 
cultured for 6 days as described previously.  BMDCs were harvested and 
the assay as described from 4.3.1 was repeated with either wild type or Fcγ 
receptor
-/- BMDCs.  As figure 4.9 shows, DN-MFG-E8 protein failed to 
inhibit the uptake of apoptotic cells.  More surprisingly however, apoptotic 
cells treated with DN-MFG-E8-Fc protein were still cleared more 
efficiently by BMDCs generated from FcγR-deficient mice compared to 
that seen with BMDCs generated from wild-type mice.    
 
Of the three groups of Fcγ receptors in mice, (FcγRI, II and III), the 
activating Fcγ receptors I and III require co-expression of the common γ-
chain for their assembly and signalling functions.  The inhibitory receptor, 
FcγRII is, in contrast, a single chain receptor which does not require the γ-
chain [190].  The result obtained here may therefore be as a result of 
apoptotic cell clearance through the inhibitory Fcγ receptor IIb, the 
immunological outcome of which is examined further in chapter 5. 
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Figure 4.9 DN-MFG-E8-Fc can still increase phagocytosis of apoptotic cells in γ-
chain knock out BMDCs.  Graph representing flow cytometry analysis where CFSE-
labelled apoptotic thymocytes were either untreated or treated with 100 μg/ml DN-MFG-
E8, DN-MFG-E8-Fc protein or an isotype control (anti-human CD20 IgG2a) prior to 
being added to BMDCs (apoptotic thymocytes: BMDC ratio 4:1) for 2 h at 37
0C.  
Percentage phagocytosis was determined by cells which stained double positive for CFSE 
and CD11c.  P values are generated from students T test where p<0.05 is statistically 
significant.  Results are shown in triplicate where the error bars represent the standard 
deviation of the mean.  
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4.3.5  FcγRIIb-deficient dendritic cells have enhanced phagocytic 
properties compared to wild-type dendritic cells. 
 
To elucidate the potential role of the inhibitory Fcγ receptor, FcγRIIb 
(CD32b), in mediating apoptotic cell clearance by dendritic cells in the 
presence of the DN-MFG-E8-Fc protein, BMDCs from FcγRIIb-deficient 
mice were grown in culture as described previously.  CFSE-labelled 
apoptotic thymocytes were treated in the absence or presence of DN-MFG-
E8, DN-MFG-E8-Fc, or an isotype control IgG2a protein, anti-CD20 
IgG2a (at 100 μg/ml) prior to being added at a ratio of 4 apoptotic cells: 1 
CD11c+ BMDC in vitro for up to 3 h.  As shown in figure 4.10, DN-MFG-
E8-Fc protein was able to enhance the uptake of apoptotic cells over the 
period of 1-3 h when compared to all other treatments.   It was clear from 
this result and that observed in figure 4.9  that to obtain blockade of Fcγ 
receptor-mediated apoptotic cell clearance in the presence of DN-MFG-E8-
Fc protein, BMDCs which were deficient in both activation and inhibitory 
Fcγ receptors would have to be used; an option that was not available at the 
time of study. 
 
Additionally, the level of phagocytosis observed with all treatments was 
markedly higher than that observed in either wild type or FcγR-deficient 
BMDCs; suggesting a potential role of FcγRIIb in limiting the level of 
apoptotic cell clearance; in an attempt to limit autoreactivity to self-
antigens. 
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Figure 4.10 DN-MFG-E8-Fc protein enhances uptake of apoptotic cells by CD32b-
deficient BMDCs.  Graph representing flow cytometry analysis where CFSE-labelled 
apoptotic thymocytes were either untreated or treated with 100 μg/ml DN-MFG-E8, DN-
MFG-E8-Fc protein or an isotype control (anti-human CD20 IgG2a) prior to being added 
to CD32b-deficient BMDCs (apoptotic thymocytes: BMDC ratio 4:1) for 1-3 h at 37
0C.  
Percentage phagocytosis was determined by cells which stained double positive for CFSE 
and CD11c.  P values are generated from students T test where p<0.05 is statistically 
significant.  Data is representative of triplicate samples.   
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4.4 Discussion 
The engulfment of apoptotic cells has been shown to involve a two-step 
process. The first step involves the tethering of apoptotic cells to the 
macrophage by receptors such as CD14 and CD36 and the second step, 
referred to as the ‘tickle’ step, requires the exposure of PS on the apoptotic 
cell membrane [191].  The binding of PS via bridging molecules to 
integrins on phagocytes induces reorganisation of the actin-based 
cytoskeleton through activation of the CrkII-DOCK180-Rac1 complex 
allowing successful internalisation of apoptotic cells [120].  The ‘tickle’ 
step is, alone, not sufficient to mediate apoptotic cell clearance, highlighted 
by the accumulation of apoptotic cells in the spleen of MFG-E8-deficient 
mice, unable to be cleared effectively by tingible-body macrophages [126].  
 
In support of this well documented model, this study has also shown that 
the blockade of PS by recombinant DN-MFG-E8 is able to inhibit the 
uptake of apoptotic cells by macrophages in vitro in a dose-dependent 
manner by up to 40% (figure 4.1 and 4.2).  The use of Confocal laser 
scanning microscopy confirmed that the method used to determine 
phagocytosis in this assay showed that apoptotic cells were internalised and 
not simply bound to the macrophage cell surface.  Additionally, it was also 
possible to determine the number of thymocytes that had been engulfed per 
macrophage; referred to as the phagocytic index [98].  In this study, the 
percentage of phagocytosis was reduced from 57.9% to 27.6% when 
thymocytes were treated first with recombinant DN-MFG-E8 protein.  The 
phagocytic index was also reduced from an average of 1.21 thymocytes per 
macrophage down to 0.48 thymocytes per macrophage (Figure 4.2).  This 
effect was then also observed using an in vivo system (figure 4.3) where by 
DN-MFG-E8 protein was able to inhibit phagocyte mediated apoptotic cell 
clearance in vivo by approximately 42% using a saturating concentration of 
DN-MFG-E8 protein (100 μg/ml).  The ability for DN-MFG-E8 protein to 
inhibit phagocytosis at lower concentrations such as 25µg/ml was however 
highly variable, suggesting that only complete PS blockade is sufficient to 
inhibit apoptotic cell clearance mediated by all other PS receptors and 
bridging molecules found in the peritoneum.  Recent studies have shown 
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that resident peritoneal macrophages preferentially secrete the PS-receptor 
molecule, TIM-4, for mediating apoptotic cell clearance and that MFG-E8 
is only secreted when the macrophages have been stimulated with 
thioglycollate [96].  This would suggest that when DN-MFG-E8 protein is 
used at lower concentrations there is still PS exposed on the apoptotic cell 
membrane which can bind to TIM-4; facilitating their clearance.   
Additionally, the inhibition shown using 100 μg/ml DN-MFG-E8 protein 
could only be observed within the first 20 min of injecting treated apoptotic 
cells into the peritoneal cavity; after which time, all apoptotic cells were 
cleared regardless of their treatment.  This again would suggest that there is 
direct competition within the peritoneal cavity for the binding to PS, the 
most likely competitor being TIM-4.   
 
With that in mind, it is important to consider that only a single defect 
within the apoptotic cell clearance pathway is sufficient to promote the 
onset of autoimmunity and that complete inhibition is not an absolute 
requirement [134], it may therefore not be necessary to induce complete 
blockade of apoptotic cell clearance in order to observe an immune effect.  
As mentioned previously, MFG-E8
-/- mice develop autoimmune disease in 
an age-dependent manner [126].  Similarly, mice deficient in the 
complement receptor, C1q, develop excessive inflammation and SLE-like 
autoimmunity [87, 192]. Conversely, defects in other apoptotic cell 
clearance pathways, such as those mediated through CD36 or mannose-
binding lectin (MBL) show increased levels of apoptotic cell bodies in 
tissues, however their deficiency in mice does not lead to detectable 
autoimmunity [193, 194].  This indicates a possible redundancy within this 
system or that there is an incomplete characterisation of apoptotic cell 
receptors (explored further in the general discussion).   
 
Although the blockade of PS in some tumour models with annexin V has 
already been shown to enhance their immunogenicity [189], additional 
studies have shown that targeting of cells through activating Fcγ receptors 
expressed on dendritic cells induces effective tumour immunity [46].  The 
aim of this study was to determine whether tumour cells which die by 
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apoptosis can also be targeted to Fcγ receptors by taking advantage of the 
PS which becomes exposed on the cell membrane. 
 
Numerous studies have shown that the targeting of activating Fcγ receptors 
on dendritic cells promotes their maturation; as determined by their 
activation status, costimulatory molecule expression, and cytokine 
secretion [46, 52, 54, 56, 195].  This study was therefore aimed at targeting 
the activating Fcγ receptor clearance pathway with the intention of 
enhancing DC maturation and therefore immunity against cell-associated 
antigen upon apoptotic cell uptake.  
 
The treatment of apoptotic cells with DN-MFG-E8-Fc protein was able to 
bind to PS on apoptotic cells (as demonstrated in chapter 3) and increase 
the percentage of phagocytosis by macrophages in vitro in a dose-
dependent manner (figure 4.4). This enhanced uptake was also observed 
over a time period of 1-3 h where by apoptotic cells treated with DN-MFG-
E8-Fc were cleared by more than 2.5 fold more efficiently than untreated 
apoptotic cells under the same conditions (figure 4.5).  This would support 
that DN-MFG-E8-Fc protein is able to block PS on apoptotic cells and re-
direct their uptake through Fc receptors on macrophages.   
 
To then examine the effect of this protein on apoptotic cell uptake by 
dendritic cells, BMDCs were cultured in vitro with GM-CSF and their 
ability to phagocyte apoptotic cells in the presence or absence of either 
DN-MFG-E8 or DN-MFG-E8-Fc proteins was examined.  DN-MFG-E8-
Fc consistently enhanced the uptake of apoptotic cells by BMDCs in vitro 
(figure 4.7).  However, in contrast to the data obtained using resident 
peritoneal macrophages, the presence of DN-MFG-E8 protein was unable 
to reduce apoptotic cell uptake by BMDCs in vitro (figure 4.7).  In fact, the 
ability of BMDCs to phagocytose apoptotic cells was actually modestly 
enhanced in the presence of DN-MFG-E8, a similar finding that has been 
observed upon PS blockade on apoptotic cell with annexin V protein [189].  
This evidence is however in stark contrast to the finding by Miyasaka et al 
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[196] in which MFG-E8-/- BMDCs showed a clear reduction in their 
ability to phagocyte apoptotic cells.  
 
The presence of LPS in this assay did not affect the phagocytic ability of 
the BMDCs in either the presence or absence or DN-MFG-E8 or DN-
MFG-E8-Fc protein when compared to non-stimulated BMDCs (figure 
4.8).  This would suggest that BMDCs are able to internalise material when 
they are at the same time exposed to inflammatory stimuli.  Studies done 
by other groups have already shown however that if BMDCs are matured 
with inflammatory stimuli prior to their culture with apoptotic cells, their 
phagocytic capacity is significantly down-regulated [37].  However, in 
constrast, studies have also shown that within the first hour, the presence of 
LPS caused significantly enhanced endocytosis by dendritic cells, followed 
by its rapid decline [30].  This evidence, including that which is shown in 
this study, would suggested that the time of exposure, amount of stimulus, 
variants in culturing of the dendritic cells, all induce variable outcomes.   
 
One of the key aims in this study was to assess the effect of  re-directing  
apoptotic tumour cell uptake through activating Fcγ receptors on dendritic 
cells, with the goal of facilitating tumour-associated antigens into the cross-
presentation pathway for effective priming to CD8+ T cells (and to mature 
or activate DCs).  To determine whether DN-MFG-E8-Fc protein utilised 
the activating Fcγ receptor pathway, BMDCs from FcγR-deficient mice 
were used in an in vitro phagocytosis assay.  FcγR
-/- BMDCs still showed 
enhanced clearance of apoptotic cells when treated with DN-MFG-E8-Fc 
protein, comparable to that seen from wild type BMDCs (figure 4.10).   
Because FcγR
-/- mice still express the inhibitory FcγRIIb, it was therefore 
likely DN-MFG-8-Fc protein was re-directing their uptake through this 
receptor.  To determine whether this was the case, BMDCs from FcγRIIb-
deficient mice were used in an in vitro phagocytosis assay.  Again, DN-
MFG-E8-Fc protein was able to enhance the clearance of apoptotic cells 
when compared to untreated apoptotic cells.  To note, the total percentage 
of phagocytosis by FcγRIIB-deficient BMDCs was much greater that that 
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seen by wild type or FcγR
-/- BMDCs suggesting a potential role of the 
inhibitory receptor in controlling the capacity for phagocytic cell clearance.   
 
It was not possible from this data alone to determine the preferential 
receptor that would be utilised when apoptotic cells are re-targeted to Fcγ 
receptors using the DN-MFG-E8-Fc protein.  It was however clear that the 
protein is able to facilitate their clearance through both activating and 
inhibitory Fcγ receptors; a factor that may influence the immunological 
outcome upon subsequent cross-presentation of antigen to antigen-specific 
CD8+ T cells.  Previous studies have shown that the presence of the 
inhibitory Fcγ receptor on dendritic cells induces T cell tolerance to 
internalised antigen due to its ability to inhibit effective DC maturation 
upon its engagement [51].  It was therefore of key interest to assess the 
balance between activating and inhibiting Fcγ receptors on dendritic cells 
when apoptotic cells were treated with both DN-MFG-E8 and DN-MFG-
E8-Fc proteins. 
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Chapter 5 - Results 
 
Investigating the effect of re-directing apoptotic cell uptake via 
Fc receptors on their immunogenicity. 
                                                                                                                                             
5.1 Introduction 
Dendritic cells have the privileged ability of being able to initiate in vivo 
CD8+ T cell responses through either direct priming, or through cross-
presentation; involving the presentation of peptide-MHC class I complexes 
derived from exogenous proteins.   
  
The cross-presentation of exogenous antigen to CD8+ T cells has one of 
two outcomes; antigenic tolerance (cross-tolerance) or immunity (cross-
priming).  Research published in 1998 [38] provided the first evidence that 
antigens that are expressed by apoptotic cells can be presented by dendritic 
cells to CD8+ T cells via cross-presentation.  In mice, cross-presentation is 
exclusive to a subset of CD8α+, CD11c+ dendritic cells, which have the 
ability to internalise dying cells and cross-present the cell-associated 
antigen onto MHC class I complexes, whilst retaining the ability to form 
peptide-MHC class II complexes for presentation to CD4+ T cells [39].    
 
The evidence that apoptotic cells can provide a source of antigen to prime 
CD8+ T cells in vivo lead to subsequent research to determine whether 
apoptotic tumour cells could be used as a suitable cancer vaccine.  With 
this is mind, Ronchetti and colleagues examined the therapeutic outcome of 
immunising mice with apoptotic cancer cells.  They discovered however 
that this induced a decreased level of cytotoxic T cell response compared to 
the immunisation with live, growth arrested tumour cells [40].  In support 
of this knowledge, it is well established that apoptotic cells have 
immunosuppressive properties, owing to their rapid elimination by 
monocytes/macrophages which, in turn, show enhanced expression of anti-
inflammatory cytokines, such as IL-10 and TGFβ, while decreasing their 
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expression of pro-inflammatory cytokines, such as TNFα, IL-1 and IL-12 
[197].  It is therefore not surprising that the efficient presentation of 
apoptotic-derived antigens by dendritic cells is extremely limited when 
apoptotic cells are administered alone as a vaccine.   
 
The blockade of phosphatidylserine on apoptotic cells has been shown to at 
least partially enhance their immunogenicity.  The treatment of apoptotic 
tumour cells with Annexin V protein prior to their administration in vivo 
both reduced their phagocytosis by macrophages whilst maintaining their 
ability to be cleared by dendritic cells, leading to an increased level of 
protection against subsequent tumour challenge [189].  In further support 
of this, BALB/c mice which were immunised with xenogeneic apoptotic 
human T cells treated with Annexin A5 protein produced enhanced 
secondary antibody responses when compared to apoptotic cells alone.   
Although this study showed that PS blockade enhanced the 
immunogenicity of apoptotic cells upon secondary challenge, this effect 
was not observed in the primary response [198], highlighting the need for 
more investigation into this model. 
 
One of the determining factors dictating whether tolerance or immunity 
ensues after antigen capture is largely owing to the maturation state of the 
dendritic cell during DC-T cell interactions.  In the absence of acute 
inflammation and/or infection, most dendritic cells in vivo are functionally 
immature, giving them the ability to capture antigens in the form of whole 
cells or opsonised particles.  In the absence of either endogenous or 
exogenous stimuli, T cells which are engaged by the cross-presenting DC 
are rendered tolerant [44, 199].  Conversely, in the presence of stimuli such 
as inflammatory cytokines, CD40 ligand, and viral and microbial 
components such as d.s RNA and LPS, dendritic cells undergo a state of 
active maturation where by the expression of costimulatory molecules and 
cytokine secretion is induced.  The engagement of CD40 with its cognate 
ligand, expressed by CD4 T cells, leads to the enhanced expression of 
costimulatory molecules including CD86, CD80, CD70, 4-1BB ligand and 
OX40 ligand on the APC cell surface.  The upregulation of CD70 on APCs 
130  
                                                                                               
for example is required for effective CD40-mediated priming of CD8+ T 
cells in vivo [200].   
 
One of the aims in this study was to determine if re-directed uptake of 
apoptotic cells via FcγRs would lead to maturation of DCs.  Previous 
studies have shown that targeting of soluble antigen via immune complexes 
through activating Fcγ receptors, expressed on the DC cell surface, is able 
to alter the balance of DC-mediated peripheral T cell tolerance by 
provision of both antigen loading and DC maturation [201].  Targeting 
immune complexes through activating FcγRs has already been shown to 
induce both CD4+ and CD8+ T cell responses that can confer tumour 
immunity [46]. 
 
FcγR-mediated activation of DCs is also able to alter the tolerogenic 
outcome of cognate DC-T cell interactions by the induction of enhanced 
costimulatory molecules and cytokine production [202].  DCs which take 
up antigen through FcγRs permits rapid targeting of antigen to the 
endosomal/lysosomal compartment for cross-presentation [52], whilst 
engagement of activating Fcγ receptors induces DC maturation as assessed 
by increased surface expression of CD40 and CD86 as well as secretion of 
IL-12 [203]. 
 
This chapter describes the effect of targeting apoptotic cell-associated 
antigens to dendritic cells, either via PS-independent mechanisms using 
DN-MFG-E8 protein, or via activating Fcγ receptors on DCs using DN-
MFG-E8-Fc protein with the overall objective of developing an approach 
to enhance the immunogenicity of apoptotic tumour cells. 
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5.2  Observing the effect of different clearance mechanisms 
on apoptotic cell-associated antigen presentation to 
CD8+ T cells in vitro. 
  
5.2.1  Clearance of apoptotic cells in the presence of DN-MFG-E8-Fc 
enhances CD8+ T cell proliferation, in particular at sub-
optimal levels of stimulation. 
 
Chapter 4 described how the use of recombinant MFG-E8 proteins is able 
to re-direct the clearance of apoptotic cells by dendritic cells through 
alternative receptors other than the classical phosphatidylserine pathway.  
To elucidate the possible effects that these alternative clearance pathways 
may have on subsequent antigen presentation, the first experiment 
examined the ability of APCs to process cell-associated antigen from 
apoptotic cells treated with DN-MFG-E8-Fc protein and then present 
antigen to antigen-specific CD4+ and CD8+ T cells in vitro.  The model 
antigen used for this assay was Ovalbumin (OVA), which when processed 
by APCs is degraded into a peptide of 9 amino acids (SIINFEKL) which is 
presented with MHC class I to transgenic OVA-specific CD8+ T cells (OT-
I).  Similarly, the CD4 helper epitope for OVA (OVA323-339  – 
ISQAVHAAHAEINEAGR) is also processed by antigen presenting cells 
and is presented with MHC class II molecules to transgenic OVA-specific 
CD4+ T cells (OT-II). 
 
OVA-expressing EG.7 tumour cells were rendered apoptotic by treatment 
with UVC radiation and either left untreated or treated with 100 μg/ml DN-
MFG-E8-Fc protein.  A titration of apoptotic EG.7 cells were then added in 
vitro to lymph node and spleen cells from either OT-I or OT-II mice.  Two 
independent experiments, (Figure 5.1 and 5.2), suggested that apoptotic 
cells expressing the model antigen OVA induced better proliferation of 
OVA-specific CD8+ T cells in the presence of DN-MFG-E8-Fc.   
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This in vitro assay did not however exclude the possibility that EG.7 cells 
are themselves able to directly present the SIINFEKL peptide on MHC 
class I to the OT-I CD8+ T cells.  Additionally, when the protein was 
tested for endotoxin contamination, there were higher than background 
levels of endotoxin detectable (43 Eu/ml).  All subsequent antigen 
presentation and T cell proliferation studies were performed using 
apoptotic splenocytes from H2-K
bm1mice, which were then loaded with 
OVA (see section 2.5.4 for protocol).  APCs from bm1 mice, unlike those 
from C57BL/6 mice, are unable to present OVA peptides to OT-1 T cells 
[204].  The endotoxin in the protein preparation was also removed using an 
Endotrap column, thereby eliminating the possibility of non-specific T cell 
stimulation.  
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Figure 5.1 DN-MFG-E8-Fc protein enhances antigen presentation to OT-I T cells in 
vitro.  Graph representing the level 
3H Thymidine (CPM) incorporated into proliferating 
OT-1 and OT-II T cells, stimulated with apoptotic OVA-expressing EG.7 cells treated 
with or without 100 μg/ml DN-MFG-E8-Fc protein. n=3 for each bar. Error bars represent 
the standard error of the mean. 
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Figure 5.2 Effect of DN-MFG-E8-Fc protein on antigen presentation is limited to a 
range of apoptotic cell doses.  Graph representing the level 
3H Thymidine (CPM) 
incorporated into proliferating OT-I T cells, stimulated with apoptotic OVA-expressing 
EG.7 cells treated with or without 100 μg/ml DN-MFG-E8-Fc protein. n=3 for each bar.  
Error bars represent the standard error of the mean. 
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5.2.2  Cultured BMDCs are able to cross-present cell-associated 
antigen from apoptotic cells to CD8+ T cells in vitro. 
In addition to using bm1 splenocytes as a source of apoptotic cell to 
prevent direct MHC class I-OVA-peptide presentation, it was also 
important to ensure that the phagocytes which clear the apoptotic cells 
were professional dendritic cells, capable of cross-presentation.  For this 
purpose, dendritic cells were cultured from murine bone marrow (BMDCs) 
and used in future cross-presentation assays.   
 
To firstly assess the efficiency of BMDCs to cross-present antigen from 
syngeneic apoptotic cells in vitro, and then subsequently determine 
whether this can be manipulated in the presence of either DN-MFG-E8 or 
MFG-E8-Fc protein, BMDCs were cultured with OVA-loaded apoptotic 
bm1 splenocytes alone, or in the presence of 100 μg/ml DN-MFG-E8 or 
DN-MFG-E8-Fc protein.  The ability of CD11c+ apoptotic cell-loaded 
BMDCs to cross-present MHC class-I-OVA peptide complexes was then 
assessed by then culturing them in vitro with purified CFSE-labelled OT-I 
cells.  After 72 h, OT-I cell proliferation was determined by flow 
cytometry in which the dilution of CFSE fluorescence was measured.     
 
The data shown in figure 5.3 indicated that CD11c+ BMDCs were able to 
effectively cross-present apoptotic cell-associated OVA-peptide to antigen-
specific CD8+ T cells in vitro.  This did not however appear to be 
dependent on a particular apoptotic cell clearance pathway, where by 
apoptotic cells phagocytosed via both PS-independent pathways (as 
determined by their treatment with either DN-MFG-E8 or DN-MFG-E8-Fc 
proteins) did not promote, nor inhibit the ability of BMDCs to cross-
present antigen when compared to using apoptotic cells alone.  
 
The ratio of OT-I: DC appeared to be an important factor in this assay, as 
the highest ratio (1 OT-I: 4 DC) did not confer successful cross-
presentation, possibly due to a high cell concentration which could have 
reduced specific cell-cell contact interactions.  This ratio was therefore 
excluded in the following experiment.  
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Figure 5.3 Cross-presentation of OVA-peptide to purified CD11c+ BMDCs to 
transgenic OT-I cells in vitro.  BMDCs from C57BL/6 mice were loaded with OVA-
loaded apoptotic bm1 cells that had been either untreated or treated with 100 μg/ml DN-
MFG-E8 or DN-MFG-E8-Fc protein (at a ratio of 1 DC: 4 apoptotic cells) for 3 h at 37
0C.  
After BMDC purification (by CD11c MACs separation), they were added to CFSE-
labelled transgenic OT-I cells at different ratios.  The ratio of OT-I: DC used is shown 
above each graph.  OT-I proliferation was determined using flow cytometry where one 
CFSE dilution was equivalent to one round of cell proliferation.  Bottom-left graph shows 
the total percentage of OT-I cells which had undergone proliferation compared to non-
stimulated cells.  Each sample shown was performed in triplicate.  Error bars represent the 
standard error of the mean.     
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To further probe the role of Fcγ receptors on facilitating apoptotic cell 
clearance by dendritic cells in this model, BMDCs from γ-chain knock out 
mice were grown in culture and their ability to cross-present antigen 
derived from OVA-loaded apoptotic cells compared to wild type BMDCs 
was examined.  The use of BMDCs from γ-chain knock out mice was able 
to establish what the effect of targeting through the inhibitory Fcγ receptor 
in the absence of FcγRI and III, and IV would have on subsequent antigen 
cross-presentation to CD8+ T cells.  Previous studies have shown that 
expression of inhibitory FcγRIIb on dendritic cells enforces peripheral 
tolerance by inhibiting effector T cell responses, where by the 
coengagement of activating Fcγ receptors with the inhibitory receptor can 
suppress both human and mouse ITAM-induced DC maturation [51].   
 
As demonstrated in chapter 4, figure 4.9, γ-chain knock out BMDCs 
phagocytosed apoptotic cells more readily in the presence of the DN-MFG-
E8-Fc protein compared to their wild-type control.  As shown in figure 5.4, 
this did not however enhance nor inhibit their ability to cross-present 
antigen to antigen-specific CD8+ T cells in vitro.  Similarly, the blockade 
of PS by DN-MFG-E8 protein had no effect on antigen cross-presentation 
when compared to loading γ-chain KO BMDCs with apoptotic cells alone.   
 
An additional observation obtained from this assay, suggested that cross-
presentation by wild-type BMDCs was more effective at high OT-I: DCs 
ratios, whereas the converse was true for γ-chain KO BMDCs.  It was not 
however possible at this stage to ascertain a plausible reason for this 
finding.  It is possible that this BMDC/OT-I in vitro system is highly 
efficient in processing and presenting OVA to T cells.  This contrasts with 
using whole OT-I splenocytes which have fewer DCs and are likely to be 
less activated than BMDC and therefore in this setting the effects of Fc 
protein-targeting/activation can be observed.  BMDC are well known to 
have a partially activated phenotype.  Thus the effects of the Fc protein 
could be seen in the first but not second in vitro culture system.  
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Figure 5.4 Cross-presentation of OVA peptide by CD11c+ BMDCs to transgenic OT-
I cells in vitro.  BMDCs from C57BL/6 or γ-chain knock out mice were loaded with 
OVA-loaded apoptotic bm.1 cells that had been either untreated or treated with 100 μg/ml 
DN-MFG-E8, DN-MFG-E8-Fc, or an isotype control protein, 1F5 (anti-human CD20 
IgG2a) at a ratio of 1 DC: 4 apoptotic cells for 3 h at 37
0C.  After BMDC purification (by 
CD11c MACs separation), they were added to CFSE-labelled transgenic OT-I cells at 
different ratios for 72 h.  The ratio of OT-I: DC used is shown above each graph.  OT-I 
proliferation was determined using flow cytometry where one CFSE dilution was 
equivalent to one round of cell proliferation.  Top-left graph is without BMDCs. Each 
sample shown was performed in triplicate.  Error bars represent the standard error of the 
mean.     
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5.3  Loading BMDCs with apoptotic cells in the presence 
of DN-MFG-E8 or DN-MFG-E8-Fc protein reduces 
their ability to stimulate CD8+ T cell proliferation in 
vivo. 
 
5.3.1  Apoptotic cells administered to mice intravenously are cleared 
by APCs, permitting cross-presentation of cell-associated antigen to 
CD8+ T cells. 
 
To establish whether apoptotic cells cleared through Fcγ receptors (using 
DN-MFG-E8-Fc protein) or via blockade of PS (using DN-MFG-E8 
protein) would result in enhanced antigen cross-presentation to CD8+ T 
cells in vivo, OVA-loaded apoptotic bm.1 splenocytes were treated with 
either DN-MFG-E8 or DN-MFG-E8-Fc protein, prior to being 
administered intravenously into syngeneic mice.  As shown in figure 5.5, 
cell-associated OVA was efficiently processed and presented in vivo to 
adoptively transferred CFSE-labelled OT-I cells, promoting CD8+ T cell 
proliferation in a dose-dependent manner.  The effect of the two 
recombinant MFG-E8 proteins did not however appear to have any 
significant difference in the cross-presentation of the antigen in this model. 
 
Apoptotic cells injected alone are not directed to a particular phagocyte and 
could therefore have been cleared by alternative scavenger phagocytes such 
as macrophages, unable to efficiently cross-present antigen and migrate to 
draining lymph nodes.  Alternatively, the DN-MFG-E8 or DN-MFG-E8-Fc 
proteins may not have remained bound to the apoptotic cells once in vivo 
due to potential competition between other PS-binding proteins (as 
discussed in chapter 1, section 1.4.5).  
 
To try and overcome this, the loading of apoptotic cells to dendritic cells 
was orchestrated in a more controlled fashion by using cultured BMDCs 
and loading them with apoptotic cells in vitro, prior to their administration.   
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Figure 5.5 Cross-presentation of antigen to CD8+ T cells in vivo.   2 x 10
6 CFSE-
labelled OT-I cells were administered i.v per C57Bl/6 mouse.  24 later, OVA-loaded 
apoptotic bm.1 cells treated with or without DN-MFG-E8 or DN-MFG-E8-Fc protein 
were administered at either 10
5 or 10
6 cells / mouse.   After 72 h, the spleen from each 
mouse was removed and the percentage of OVA-specific CD8+ T cells was determined by 
staining the cells with 10 μg/ml APC-labelled anti-CD8 antibody and 20 μg/ml PE-
labelled tetramer.  Cells which stained double positive are indicated on the graph.  Results 
represent data from triplicate values.  Error bars represent the standard error of the mean.     
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5.3.2  CD8+ T cells show reduced accumulation in the spleen after 
stimulation with BMDCs loaded with apoptotic cells via a PS-
independent clearance pathway. 
 
BMDCs cultured in vitro have the ability to phagocytose apoptotic cells 
and cross-present the cell-associated antigen to antigen-specific CD8+ T 
cells (see section 5.2.2).  To determine whether this could also be achieved 
in an in vivo setting, BMDCs were loaded with apoptotic cells in vitro in 
the presence of either DN-MFG-E8 or DN-MFG-E8-Fc proteins, prior to 
their administration in vivo.  Their ability to migrate to the spleen and 
cross-present the antigen to CD8+ T cells in vivo was then determined by 
measuring CFSE dilution of OT-I T cells.   
 
As shown in figure 5.6, BMDCs loaded in vitro with OVA-loaded 
apoptotic cells were efficient at migrating to the lymphoid organs and 
cross-presenting antigen to transgenic OT-I cells in vivo, as determined by 
their ability to promote both accumulation and proliferation of OT-I T cells 
in the spleen.  Interestingly, the loading of BMDCs with apoptotic cells in 
the presence of both DN-MFG-E8 or DN-MFG-E8-Fc protein caused 
inhibition of antigen cross-presentation as determined by both OT-I 
accumulation (which showed a reduction by 60% and 71%, respectively) 
and proliferation (which showed a reduction by 41% and 46%, 
respectively) in the spleen.   
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Figure 5.6 CD8+ T cell accumulation and proliferation is inhibited by recombina
representative of 3 different mice in each group. 
nt 
MFG-E8 proteins.   2 x 10
6 CFSE-labelled OT-I cells were adoptively transferred i.v per 
C57Bl/6 mouse.  CD11c+ BMDCs, loaded with OVA-loaded apoptotic bm.1 cells in the 
presence or absence of 100 μg/ml DN-MFG-E8 or DN-MFG-E8-Fc protein for 3 h, after 
which 5 x 10
5 CD11c+ BMDCs were administered i.v per mouse.  On day 3, spleens were 
harvested and OVA-specific CD8+ T cell accumulation and proliferation was determined 
by analysis using flow cytometry.   A:  Left panel shows flow cytometry dot plot, gating 
double positive CD8+ and tetramer + cell population.  Right panel shows CFSE-dilution 
of gated double positive cells from left panel.  B:  Graph representing data obtained from 
gated cells from left panel from A.  C:  Graph representing data obtained from gated cells 
from right panel from A.  P value is representative of a two-tailed paired t-test. Graph is 
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As only 25-30% of apoptotic cells were phagocytosed by BMDCs in this 
assay within 3 h (see chapter 4, figure 4.7), this resulted in the co-
ithin the spleen 3 days post stimulation with BMDCs was markedly 
administration of ‘free’ OVA-loaded apoptotic cells that have not been 
internalised by the BMDCs.  To confirm the previous result (figure 5.6) 
and to eliminate any effect observed by apoptotic cells injected alone, the 
assay was repeated, however after BMDCs were loaded with apoptotic 
cells, they were purified by CD11c+ selection prior to their administration. 
 
As shown in figure 5.7, the accumulation of antigen-specific CD8+ T cells 
w
reduced when BMDCs were loaded with apoptotic cells in the presence of 
either DN-MFG-E8 or DN-MFG-E8-Fc proteins. 
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Figure 5.7 Cross-presentation of antigen to CD8+ T cells is orchestrated primarily by 
dendritic cells loaded ex vivo.  2 x 10
6 CFSE-labelled OT-I cells were adoptively 
transferred i.v per C57Bl/6 mouse.  CD11c+ BMDCs, loaded with OVA-loaded apoptotic 
bm.1 cells in the presence or absence of 100 μg/ml DN-MFG-E8 or DN-MFG-E8-Fc 
protein for 3 h.  After which BMDCs were purified to remove non-phagocytosed apoptotic 
cells and 5 x 10
5 CD11c+ BMDCs were administered i.v per mouse.  On day 3, spleens 
were harvested and OVA-specific CD8+ T cell accumulation was determined by analysis 
using flow cytometry.   Graph represents data from flow cytometry analysis showing the 
total percentage of CD8+ tetramer + T cells present in the spleen. P-value is representative 
of a two-tailed paired t-test. Graph represents 3 mice in each group. 
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144 
tic cells directly to 
is that the clearance mechanism 
tilised did not promote a state of DC activation sufficient to induce 
It was clear from the results obtained that the loading of apoptotic cells 
either via a mechanism other than PS or targeting apopto
Fcγ receptors caused a reduction in the ability of DCs to cross present 
antigen to CD8+ T cells in the spleen.  As shown in chapter 4 (figure 4.7), 
apoptotic cell clearance by BMDCs was enhanced in the presence of both 
DN-MFG-E8 and DN-MFG-E8-Fc proteins.  The observation seen here 
was therefore not as a result of insufficient antigen loading.  One possible 
explanation is that the route of antigenic uptake using these alternative 
clearance pathways inhibited access of antigen into the cross-presentation 
pathway and was transferred to highly acidic lysosomal compartments for 
rapid degradation.  Alternatively, this method may have favoured loading 
antigen onto MHC class II molecules for presentation to CD4+ T cells; a 
theory that was not tested in this model.   
 
An additional explanation for this result 
u
homing of the DCs to the secondary lymphoid organs upon their 
administration in vivo [205].  This explanation is explored further in the 
discussion.    
5.4  Apoptotic cell clearance via Fcγ receptors in the 
absence of the inhibitory FcγRIIb induces DC 
maturation in vitro. 
 
5.4.1 FcγR-mediated clearance of apoptotic cells by FcγRIIb-
deficient DCs induces expression of costimulatory molecules, 
CD86 and CD70. 
 
Previous studies have shown that FcγR-engagement on dendritic cells by 
IgG-immune complexes induces DC activation as determined by their 
increased surface expression of MHC, CD40, CD80 and CD86 [52].  It is 
widely accepted that the expression of costimulatory molecules on 
dendritic cells is required for priming T cell responses.  More recently, it 
has been shown that CD70, a member of the TNF family is induced upon 
activation of DCs by CD40 and TLR engagement.  Interestingly, CD70 
was not induced following activation of DCs by type I interferon, a 
stimulant that upregulates CD86 expression [206].  Furthermore, CD70 
expression on dendritic cells was shown to be important for CD40 and 
TLR-mediated priming of antigen specific CD8+ cytotoxic T cells [207].  
In light of those findings, I sought to investigate the effect of uptake of 
apoptotic cells by different receptors on the expression of the costimulatory 
proteins CD70 and CD86.  Because FcγRIIb can inhibit DC maturation 
induced by Fcγ receptors, the effect of the route of uptake of apoptotic cells 
on DC maturation was compared in BMDC cultures obtained from FcγRIIb 
deficient and sufficient mice.      
 
As a positive control, LPS was used in the following DC maturation 
assays.  LPS is a well characterised stimulator of dendritic cells, inducing 
DC maturation as determined by the increased expression of costimulatory 
molecules, as well as inducing inflammatory cytokine secretion [208].  
 
Wild type (WT) and FcγRIIb
-/- BMDCs were grown and cultured as 
described previously.  After 6 days in culture, CD11c+ BMDCs were 
145    
purified and loaded in vitro with apoptotic thymocytes either alone, or 
treated with DN-MFG-E8 or DN-MFG-E8-Fc protein. Additionally, it was 
also important to ensure that there was no presence of endotoxin which 
would favour DC maturation, hence syngeneic thymocytes were used as a 
source of apoptotic cell which were therefore were free from exogenously 
loaded antigen.   
 
The surface expression of CD86 and CD70 on BMDCs from WT or 
FcγRIIb
-/- BMDCs was determined after 18 h in vitro in the presence of 
apoptotic cells treated with or without DN-MFG-E8 or DN-MFG-E8-Fc 
protein.  As shown in figure 5.8, the incubation of cells with the DN-MFG-
E8-Fc protein caused further upregulation of CD86 in wt DCs and to a 
greater extent in CD32KO DCs.  The most striking data, however, was that 
DN-MFG-E8-Fc coated apoptotic cells induced a clear increase in CD70 
expression, but only in CD32KO DCs.  This assay provides strong 
evidence in which the presence of the inhibitory Fcγ receptor is able to 
control dendritic cell maturation, and suggests for the first time that 
upregulation of CD70 expression on the cell surface can be controlled by 
the engagement of Fcγ receptors; another mechanism which could mediate 
effective CD8+ T cell priming.  
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Figure 5.8 FcγR-mediated clearance of apoptotic cells induces full maturation of 
FcγRIIb
-/- DCs but not WT-DCs.  A:  FACs histograms indicating expression of CD86 
and CD70 as detected using 10 μg/ml fluorescently-labelled anti-CD86 (FL-1) or anti-
CD70 (FL-2) antibodies.  Closed histogram represents control, non-treated BMDCs.   
Open histogram represents BMDCs treated with either LPS or apoptotic cells +/- DN-
MFG-E8 or DN-MFG-E8-Fc proteins.  B: Bar graphs show the increase of the geometric 
mean fluorescence intensity (GMFI) from duplicate results in 2 independent experiments. 
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As a matter of caution, it was important to determine that the effect of 
dendritic cell maturation upon removal of the inhibitory Fcγ receptor was 
as a result of apoptotic cells being cleared through activating Fcγ receptors 
in its absence and not due to the cross-linking of the Fcγ receptors by the 
presence of the DN-MFG-E8-Fc protein on the cell surface.  Previous 
studies have shown that targeting antigens to Fcγ receptors on mouse bone 
marrow-derived dendritic cells leads to the significant enhancement of 
cross-presentation [209].  To confirm this, and eliminate the possibility that 
the result shown in this study was not due to the effect of cross-linking the 
DN-MFG-E8-Fc on BMDC, BMDCs were treated in the presence of DN-
MFG-E8-Fc which had been immobilised onto a tissue culture plate.   
 
As shown in figure 5.9, DN-MFG-E8-Fc protein efficiently bound to the 
tissue culture plate surface, the saturated concentration (30 μg/ml) was then 
used in the subsequent maturation assay. 
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Figure 5.9 Saturation binding curve of DN-MFG-E8-Fc to a tissue culture plate. 
Graph showing the results of a sandwich ELISA performed to determine the concentration 
of DN-MFG-E8-Fc protein required to saturate a 24 well tissue culture plate.     
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Both WT and FcγRIIb
-/- BMDCs were placed onto immobilised DN-MFG-
E8-Fc protein for 18 h, after which they were then analysed for the surface 
expression of both CD86 and CD70 using flow cytometry.  Cross-linking 
the Fcγ receptors on either WT or FcγRIIb
-/- BMDCs using immobilised 
DN-MFG-E8-Fc protein was unable to induce a significant change in either 
CD86 or CD70 surface expression (figure 5.10).   
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Figure 5.10 Effect of cross-linking Fcγ receptors on BMDCs with DN-MFG-E8-Fc 
protein  in vitro.  Histograms representing the effect of cross-linked DN-MFG-E8-Fc 
protein on surface expression of CD86 and CD86 on both CF57BL/6 and CD32b
-/- 
CD11c+ BMDCs in vitro. 10 μg/ml fluorescently labelled anti CD11c (FL-4), anti-CD86 
(FL-1) and anti-CD70 (FL-2) was used in the assay.  Top number indicates geometric 
mean fluorescence (GMFI) of control BMDC histogram.  Bottom number indicates GMFI 
of treated BMDC histogram.   
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5.5  Immunising mice with apoptotic cells suppresses 
antibody production in mice. 
 
The exposure of PS on apoptotic cells is a key factor in inhibiting 
inflammation, a response which is required for the survival of antigen-
specific T cells and the subsequent activation of the adaptive immune 
response [210].  Additionally, the clearance of apoptotic cells via PS has 
also been shown to have an effect on the humoral immune response, where 
by the presence of apoptotic cells dampens the production of serum IgG 
antibodies; a response which is eliminated upon blockade of PS on 
apoptotic cells with annexin V [167].  The clearance of apoptotic cells via 
PS induces anti-inflammatory responses including the release of TGFβ.  
Studies by Hoffman et al [178] have shown that mice immunised with PS 
liposomes prior to antigenic challenge showed a reduction in the amount of 
antibody produced against the antigen by approximately 1.5 fold.   
Similarly, work by Gray et al [211] demonstrated that the administration of 
apoptotic thymocytes up to 4 weeks prior to challenge with collagen-
induced arthritis, showed enhanced protection against disease severity 
through the generation of regulatory B cells and subsequent IL-10 
production.  These studies would suggest that the presence of PS is, alone, 
able to suppress an inflammatory response against an antigen and as 
consequence promotes the release of anti-inflammatory cytokines, leading 
to a reduced humoral response.   
 
To observe the effect of blocking PS on apoptotic cells using either DN-
MFG-E8 or DN-MFG-E8-Fc protein on the levels of serum IgG generated 
in response to antigen, BALB/c mice were immunised with a strong 
immunogen, KLH (Keyhole limpet Haemocyanin) which was suspended in 
complete Freund’s adjuvant (CFA).  Syngeneic apoptotic thymocytes were 
then either left untreated or were treated with 100 μg/ml DN-MFG-E8 or 
DN-MFG-E8-Fc protein.  2 x 10
7 thymocytes were then administered 
intravenously per BALB/c mouse, whilst at the same time being challenged 
with KLH in CFA.  Days 1 and 2 post challenge, mice were again treated 
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with apoptotic thymocytes as described for day 0.  On days 10 and 20, the 
serum was then analysed for anti-KLH antibodies.   
 
As shown in figure 5.11, by day 10 the blockade of PS on apoptotic cells 
with either DN-MFG-E8 or DN-MFG-E8-Fc proteins promoted enhanced 
anti-KLH antibody production compared to the control or apoptotic cells 
alone.  This was further enhanced by day 20, where by the treatment of 
mice with apoptotic cells alone lead to reduced antibody production 
compared to the treatment of KLH alone, or upon PS blockade.  
 
There is a non-significant trend observed in this experiment which supports 
that PS exposure on apoptotic cells is able to dampen the humoral response 
against a model antigen.  Additionally, the blockade of PS on apoptotic 
cells is able to alleviate this response, and in fact suggests that a modestly 
enhanced antibody response against a non-specific antigen can be achieved 
by simple blockade of PS alone. 
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Figure 5.11 Influence of PS blockade on apoptotic cells on the primary humoral 
immune response.  Graphs representing the relative titre of anti-KLH antibodies in the 
serum detected by anti-KLH sandwich ELISA day 10 and day 20 post KLH challenge 
where BALB/c had been injected on day 0, 1 and 2 with apoptotic cells either untreated or 
treated with DN-MFG-E8 or DN-MFG-E8-Fc protein in 200 μl PBS per BALB/c mouse.  
Graphs show comparable levels of anti-KLH antibodies at a standard absorbance (0.15 on 
day 10 and 0.210 on day 20 at 490nm).  Each point represents one mouse. 
 
 
152                 
5.6 Discussion 
A potentially important role of dendritic cells for use as a vaccine in cancer 
immunotherapy is attributed to their ability to process and present cell-
associated antigens, including those associated with tumours [212].   
Depending on the milieu of costimulatory molecules and cytokine profile, 
dendritic cells have the capacity to either promote or inhibit tumour 
immunity [29, 199].  One of the caveats when designing a dendritic cell-
based vaccine is the requirement for an adjuvant (either endogenous or 
exogenous) to be present at the time of antigen capture and presentation, to 
ensure that the balance between tolerance and immunity is tipped towards 
the latter.  Matzinger, among others, initially proposed the danger 
hypothesis, where by immunity only ensues when there is a risk to the host 
[213].  This includes the presence of factors such as inflammatory 
cytokines, CD40L, or viral and microbial products [44].  Although this is 
not optimal when generating cancer vaccines, it is of key importance to the 
host in maintaining peripheral tolerance to self antigens.  
 
This chapter investigated whether an immune response against a cell-
associated antigen could be generated in the absence of an adjuvant by the 
manipulation of the classical immune tolerance pathway, used primarily to 
remove apoptotic cells, with the aim of applying this technique to apoptotic 
tumour cell removal; thereby enhancing their immunogenicity. 
 
To examine the effect of re-directing apoptotic cell clearance via a pathway 
other than phosphatidylserine, initial experiments were performed to 
establish a system in which the ability of cell-associated antigen to be 
cross-presented to antigen-specific CD8+ T cells could be determined.  In 
the first instance, apoptotic OVA-expressing tumour cells (EG.7) which 
were treated with DN-MFG-E8-Fc were presented more efficiently via 
splenic antigen presenting cells to OVA-specific CD8+ T cells in vitro 
when compared to apoptotic tumour cells alone (figure 5.1 and 5.2).  As 
explained previously, this assay did not eliminate the possibility of direct 
antigen presentation, nor could the number or type of cells which were 
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processing and presenting the antigen be accurately determined.  There 
may have in fact been no dendritic cells present in this assay, suggesting 
that this not an appropriate model for this study.  To improve this assay 
further the rest of this study focused on the use of targeting apoptotic cells 
specifically to dendritic cells for use as a source of antigen presenting cell.  
Only a small number of dendritic cells can be found within lymphoid 
organs, skin and mucosa.  It is therefore difficult to isolate a sufficient 
quantity of dendritic cells to be used as effective vaccines.  For this reason, 
murine bone marrow was cultured in the presence GM-CSF in vitro.  This 
generated a large number of dendritic cells derived from haematopoietic 
stem cell precursors which are capable of cross-presenting antigen to 
cytotoxic CD8+ T cells [214].   
 
As shown in section 5.2.2, BMDCs loaded with apoptotic cells were able to 
effectively cross-present apoptotic cell-associated antigen to CD8+ T cells 
in vitro when loaded with apoptotic cells via either PS or PS-independent 
pathways; however in contrast to the first experiment, the level of CD8+ T 
cell proliferation was not enhanced in the presence of either DN-MFG-E8 
or DN-MFG-E8-Fc protein.  One possible explanation for this is that the 
splenic APCs used in section 5.2.1 had a more immature phenotype 
compared to cultured BMDCs used in this assay, allowing more antigen 
loading and subsequent presentation to the T cells.  Further investigation 
showed that the loading of BMDCs in the absence of the Fcγ receptors (γ-
chain knockout mice) still conferred effective antigen cross-presentation of 
apoptotic cell associated antigen when apoptotic cells were treated with 
DN-MFG-E8-Fc protein (figure 5.4).  This suggested that the clearance 
pathway being utilised could in fact be via the interaction with the only 
remaining Fcγ receptor, inhibitory FcγRIIb.   
 
To examine what effect both proteins would have on MHC class I-
restricted antigen presentation in an in vivo setting, apoptotic cells were 
treated with either DN-MFG-E8 or DN-MFG-E8-Fc protein prior to their 
administration in vivo.  Their ability to then be processed and presented by 
endogenous APCs was however unaffected when compared to the injection 
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of apoptotic cells alone, as determined upon comparison between the 
proliferation of adoptively transferred OT-I CD8+ T cells (figure 5.5).  It is 
possible within this setting that there may have been competition with PS 
on the apoptotic cells with other PS binding proteins upon administration in 
vivo.  As explained in chapter 4, apoptotic cell clearance in the peritoneal 
cavity after treatment with DN-MFG-E8 protein was unable to inhibit 
phagocytosis for a sustained period of time, suggesting the displacement of 
the protein with other high affinity proteins such as TIM-4, which is 
expressed by resident peritoneal macrophages [96].  To overcome this 
problem, BMDCs were loaded with apoptotic cells in vitro prior to their 
administration in vivo, thereby ensuring that re-direction of the apoptotic 
cells in the presence of both recombinant proteins was unaffected by other 
PS-binding proteins. 
 
Upon transfer of apoptotic cell-loaded BMDCs in vivo it was apparent that 
the loading of apoptotic cells via a PS-independent pathway (using DN-
MFG-E8) or via Fcγ receptors (using DN-MFG-E8-Fc) caused inhibition 
of effective T cell stimulation (figure 5.6 and 5.7).  This suggested that 
either the route of antigen processing and presentation utilised via different 
clearance receptors altered the ability for the dendritic cells to stimulate the 
CD8+ T cells, or that by changing the receptors used for apoptotic cell 
clearance, caused a phenotypical change in the DC leading to their loss of 
ability to migrate to lymphoid organs. 
 
DCs capture antigens through multiple endocytic pathways such as 
phagocytosis and macropinocytosis; both of these pathways of which are 
reliant on the rearrangement of the actin cytoskeleton [215].  In addition to 
endocytosis, the actin cytoskeleton is also required for DC migration [216] 
where by actin polymerisation and depolymerisation generates extensions, 
called podosomes, which induce DC movement towards the advancing 
edge of the cell [217, 218].  Upon DC maturation, podosome formation is 
lost [30], because they have assumingly reached their destination for 
antigen presentation.      
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DC migration is imperative for the activation of lymphocytes within 
secondary lymphoid organs with antigenic material that has been captured 
and processed from the periphery (as reviewed in [205]).  The access of 
CD8α+ DCs into the spleen occurs upon their maturation by their increased 
expression of the chemokine receptor, CCR7 [219], which promotes their 
migration towards CCL19 and CCL21 gradients, produced by stromal cells 
within the T cell zone [220].  Although it is not possible to determine from 
the experimental data obtained thus far, a potential hypothesis for the 
results observed here could suggest that apoptotic cell clearance in the 
presence of either DN-MFG-E8 or DN-MFG-E8-Fc protein inhibited an 
essential cell-cell interaction which is vital for the upregulation of 
chemokine receptors, such as CCR7.  
 
An  in vitro experiment investigating the upregulation of costimulatory 
molecules on dendritic cells (figure 5.8) confirmed that apoptotic cells 
cleared via Fcγ receptors in the presence FcγRIIb exhibited a lower 
maturation phenotype, as determined by a reduction in the level of both 
CD86 and CD70 surface expression; which could be rescued by the 
removal of FcγRIIb.  T cells which are primed by mature dendritic cells, as 
determined by their increased surface expression of MHC and 
costimulatory molecules, are able to proliferate and survive more 
efficiently than those stimulated by immature dendritic cells [26].  The 
signalling through TLRs or the ligation of CD40 on dendritic cells with 
CD40L, provided by CD4+ T cell help, has shown to promote the 
upregulation of costimulatory molecules including CD80, CD86, CD70, 4-
1BBL, and OX40L on the surface of APCs.  Studies have also shown that 
the expression of CD70 on dendritic cells through either CD40 or TLR 
stimulation is also able to promote CD8+ T cell responses without the 
requirement for CD4+ T cell help [221].  This study now suggests that the 
upregulation of both CD86 and CD70 can be controlled by the balance 
between the surface expression of activating and inhibitory Fcγ receptors 
when apoptotic cells are targeted through these receptors. 
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CD86 binds to CD28 on T cells and promotes cell-cycle progression and 
survival of primed T cells whilst CD70 interacts with the CD27 receptor on 
T cells, promoting their survival during successive divisions.  This is 
supported by evidence where CD70 blockade leads of the inhibition of both 
primary and memory CD40-mediated CD8+ T cell responses [200].  CD28 
and CD27 are constitutively present on naïve CD8+ T cells, highlighting 
their importance in T cell priming.  Together these signalling pathways are 
complementary in determining the magnitude of both effector and memory 
CD8+ T cell responses [222]. 
 
Finally, this study focused on the role of apoptotic cell clearance on the 
humoral immune response.  Previous studies have shown that the masking 
of PS on apoptotic cells with a dominant-negative MFG-E8 protein 
promoted a reduction in apoptotic cell clearance and lead to the production 
of autoantibodies against phospholipids and DNA [134].  It is clear from 
this data and work by others, that the exposure of PS on apoptotic cells is, 
alone, able to prevent inflammation and suppress the development of 
antibodies against self or a model antigen.  The results in this study also 
suggest a similar phenomenon, where by the blockade of PS on apoptotic 
cells with either DN-MFG-E8 or DN-MFG-E8-Fc proteins reduced the 
immunosuppressive effect of using apoptotic cells alone to suppress the 
development of antibodies against a model antigen (KLH). (figure 5.11). 
 
It is clear from the results obtained in this chapter that the type of apoptotic 
cell clearance pathway utilised by dendritic cells is able to have numerous 
and unpredictable outcomes.  The concept that simple blockade of PS alone 
is sufficient to enhance the immunogenicity of apoptotic cells does not 
account for a number of factors which have been encountered here when 
this system is tested in vivo.  The manipulation of antigen processing, 
presentation, subsequent DC maturation and migration to secondary 
lymphoid organs weaves a complex web of pathways, the control of which 
requires that each pathway behaves in a predictable fashion.  The use of 
dendritic cells as potential cancer vaccines must therefore account for all of 
these processes, as each one is critical in obtaining a therapeutic result. 
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General Discussion 
 
The clearance of apoptotic cells is a highly controlled process of removing 
unwanted, unnecessary, or potentially dangerous cells without invoking an 
inflammatory response.  This essential function of the immune system only 
becomes obvious when this understated, yet complex process is disrupted.  
Defective apoptotic cell clearance is strongly associated with the 
pathogenesis of a number of diseases such as systemic lupus erythematosus 
(SLE) [70], type I diabetes, cystic fibrosis [223], and obstructive 
pulmonary disease (COPD) [224].      
 
Ensuring that cells which undergo apoptosis are cleared by phagocytes 
both efficiently and rapidly is the shared responsibility between a number 
of  ligands and opsonising bridging proteins [225].  MFG-E8 has been 
characterised in detail as a protein secreted by a sub population of 
macrophages and immature dendritic cells [196] that acts to provide a 
bridge between phosphatidylserine on apoptotic cells and integrins on 
phagocytes to facilitate their uptake [98].  An early event in apoptosis is the 
exposure of phosphatidylserine on the outer plasma membrane [177].   
Removal of cells via this pathway promotes tolerance, whereby cell-
associated antigens which are processed and presented by APCs to CD4+ 
and CD8+ T cells in the absence of costimulation, whilst also in the 
presence of anti-inflammatory cytokines such as IL-10 and TGF-β, 
promotes T celldeletion or anergy.  Whilst this favours protection from 
autoimmunity, this immunosuppressive environment highly favours the 
success and advancement of tumours by preventing effective anti-tumour 
immunity [199].  
 
Mice deficient in receptors which engage with PS on apoptotic cells and 
mediate their clearance have highly variable and contrasting outcomes.   
Whilst MFG-E8-/- mice develop auto-antibodies and splenomegaly in an 
age-dependent manner [126], CD14-/- mice which are also deficient in 
apoptotic cell clearance do not develop an obvious autoimmune response, 
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owing to the compensatory anti-inflammatory cytokines which are released 
by macrophages as a result [106].  Similarly CD36-/- mice have no signs of 
defective phagocytosis or antigen cross-presentation [193], clearly 
suggesting a redundancy in this clearance pathway.  However, in stark 
contrast to these models is the role of the complement protein, C1q.  C1q 
binds to calreticulin on apoptotic cells and facilitates their phagocytosis 
through the interaction with CD91 [87].  Additionally, C1q also binds 
complement where IgM antibodies bind to apoptotic cells which then 
recruit C1q.  C1q-deficiency, both in mice and humans, leads to excessive 
inflammation and the onset of SLE-like autoimmunity [226].  Whilst the 
mannose-binding lectin, MBL, also interacts with CD91 to mediate 
apoptotic cell clearance, its deficiency, unlike C1q deficient mice, does not 
lead to autoimmunity.  It appears therefore in this model that the binding of 
complement could be important in the role of preventing autoimmunity as 
opposed to the successful clearance of apoptotic cell bodies  [87, 194].  
 
The therapeutic potential of using proteins which abrogate the normal 
clearance pathway of apoptotic cells has been discussed in the scientific 
community for over a decade, the ultimate aim being to provide 
improvement of cancer immunotherapy techniques and to allow a clearer 
understanding of autoimmune disease models.  Interfering with the 
recognition of PS on apoptotic cells promotes the reduction of 
phagocytosis by macrophages, a relative increase in their clearance by 
dendritic cells, and modulates inflammatory responses, all of which suggest 
a potential therapeutic benefit in the development of effective cancer 
vaccines.  Previous studies have shown that interference of this pathway 
with annexin V abrogates effective clearance of apoptotic tumour cells and 
as a consequence, enhances their immunogenicity [167].   
 
The advantage of using apoptotic tumour cells in the development of 
cancer immunotherapy is owing to the fact that whole cells contain a 
milieu of cancer epitopes specific for their unique mutated sequences.   
They also have the added advantage of being able to generate both CD4+ 
and CD8+ T cell responses without the need to know which epitope is 
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responsible.  The aim of this study was to elucidate the potential role of 
MFG-E8 protein in the clearance of apoptotic cells, and if proven to be 
important, attempt to manipulate this system in a manner which could be 
used to render apoptotic tumour cells immunogenic.   
 
The use of a dominant-negative MFG-E8 protein to study the effect of PS-
mediated apoptotic cell clearance was first accomplished by Asana et al 
[134].  In this study they generated a dominant-negative MFG-E8 protein 
which had a mutation in the RGD motif which is required to bind to 
integrins on phagocytes.  Here the masking of PS on apoptotic cells lead to 
defective apoptotic cell clearance and the development of antibodies 
against DNA and phospholipids.  Inspiration from their study initiated the 
hypothesis for this study, in which the blockade of PS on apoptotic cells 
could lead to the development of an immune response against a cell-
associated antigen.   
 
It is widely accepted that the immunisation with an antigen alone is not 
sufficient to stimulate an immune response against the antigen, and can 
instead induce a state of tolerance.  To elicit an effective immune response 
the presence of an adjuvant, whether it be exogenous or endogenous, is 
typically required at the time of antigen exposure [227].  It has been 
postulated that cell necrosis may explain how activation of the adaptive 
immune system occurs in an apparently pathogen-free environment, such 
as allograft transplantation or in therapy-induced tumour rejection [228].  
Apoptotic cells which are not cleared rapidly lose their cellular integrity 
and release their contents into the local environment; a process referred to 
as secondary necrosis.  Necrotic cells release danger signals into the local 
environment that provide a source of endogenous adjuvant which are 
absent from apoptotic cells.  HMGB1, uric acid, gelectins, S100 proteins, 
thioredoxin, and heat shock proteins (HSPs) are all released from necrotic 
cells and activate the innate immune system [62, 227, 229, 230].   
Additionally, HMGB1 and HSPs have also been shown to stimulate the 
adaptive immune system via signaling through TLR2 and TLR4 [231, 
232]. 
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More recent data have now suggested that late apoptotic/secondary necrotic 
cells express a ligand which binds to dendritic cells and promotes effective 
antigen cross-presentation.  This ligand, identified as a cytoplasmic 
ubiquitous preformed acid-labile protein-associated ligand, becomes 
accessible upon cell necrosis for binding to a C-type lectin on CD8α+ 
murine dendritic cells called DNGR1 (also called CLEC9A).  The 
signaling through DNGR1, like the mannose receptor [21], was shown to 
divert antigenic cargo away from lysosomal compartments to allow their 
retrieval for cross-presentation [233].  This data would support the 
hypothesis that apoptotic cell blockade, which induces secondary necrosis, 
would promote enhanced cross-presentation of antigen to generate a cell-
associated antigen immune response. 
 
In the first part of this study, recombinant dominant-negative MFG-E8 
protein was generated so that it could bind to PS on apoptotic cells but no 
longer encoded the domains required for binding to integrins on 
phagocytes.  As a result, DN-MFG-E8 protein inhibited PS-mediated 
apoptotic cell uptake by macrophages by up to 44% in a dose-dependent 
manner (Figure 4.2 and 4.3), whilst showing a slight enhancement of 
apoptotic cell clearance by BMDCs (figure 4.7).  This blockade was 
however only transient in vivo and could not abolish this clearance pathway 
completely.  Similar observations have also been observed in studies which 
examined the blockade of apoptotic cell clearance by TIM-4-deficient mice 
(as discussed by Gordon Freeman, British Society of Immunology, 2008).  
This suggested that in vivo, there is likely to be competition between other 
PS binding proteins.  Inducing enhanced immunity to apoptotic cells may 
therefore only be achievable if one were to develop a DN-MFG-E8 
construct that has a much higher avidity for PS than other PS binding 
proteins, thereby removing this limiting step.   
 
In parallel, the uptake of apoptotic cells through an alternative clearance 
pathway was also investigated.  The targeting of Fcγ receptors on dendritic 
cells using antigen complexed to IgG molecules (IgG immune complexes) 
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has already been shown to be an effective method at eliciting tumour 
immunity.  This finding arose from initial studies which demonstrated that 
the coating of myeloma cells with tumour-specific antibodies promoted 
cross-presentation of cellular antigens by DCs that would then elicit a 
strong CD8+ T cell response, the T cells of which were specific for the 
cancer-testis antigens expressed in the tumour.  This method of generating 
tumour-specific immunity proved more effective than the use of DCs 
loaded with peptides or apoptotic tumour cells alone [56].  Further 
investigation has shown that it is the selective engagement of activating 
Fcγ receptors on dendritic cells which promotes enhanced antigen cross-
presentation [234].  This was supported by data which showed that DCs 
which were deficient for the inhibitory FcγR, FcγRIIb, which were pulsed 
ex-vivo with immune complexes, were able to generate antigen-specific 
CD8 T cells in vivo specific against a murine melanoma model [46].    
 
With this in mind, a second recombinant DN-MFG-E8 protein was also 
generated which had the additional capability of binding to Fcγ receptors 
on APCs, referred to as DN-MFG-E8-Fc.  Treatment of apoptotic cells 
with DN-MFG-E8-Fc protein conferred significantly enhanced uptake by 
both macrophages and BMDCs in vitro (figure 4.5 and 4.7, respectively).   
 
The subsequent treatment of apoptotic cells with either DN-MFG-E8 or 
DN-MFG-E8-Fc proteins was unable to augment antigen cross-
presentation by BMDCs in vitro compared to the use of apoptotic cells 
alone  (figure 5.3).  The treatment of apoptotic cells with either protein 
which were then administered in vivo was also unable to mask or promote 
antigen cross-presentation to transgenic OT-I cells when this system was 
reliant on endogenous APCs.  A possible explanation for this is that the 
transient ability of either DN-MFG-E8 or DN-MFG-E8-Fc protein to block 
PS recognition on apoptotic cells in vivo was not sufficient to augment 
antigen uptake and cross-presentation to CD8+ T cells due to competition 
with other PS binding proteins.  Interestingly however was that BMDCs 
which were loaded firstly in vitro with apoptotic cells via either a PS-
independent pathway or through Fcγ receptors, caused a dramatic reduction 
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in their ability to cross-present antigen to CD8+ T cell responses in vivo 
(figure 5.6 and 5.7) as determined by the ability of transgenic OT-I cells to 
both accumulate and proliferate within the spleen.  As was postulated in 
chapter 5, this apparent inhibition of antigen cross-presentation could have 
been the result of alternative antigen processing within the DC which 
meant that less antigen was available for cross-presentation.  This however 
would not account for the fact that BMDCs were able to promote OT-I 
proliferation  in vitro in the presence of absence of either DN-MFG-E8 
proteins.  This suggested therefore that the loading of apoptotic cells via 
these alternative pathways may have had an effect on the activation status 
of the dendritic cells and their subsequent ability to migrate to the spleen.   
 
After much speculation, a possible explanation for the inhibition of CD8+ 
T cell responses observed in this study came to light by the comparison of 
dendritic cell maturation upon apoptotic cell loading in either the presence 
or absence of the inhibitory Fcγ receptor (FcγRIIb).  Whilst activating Fcγ 
receptors on dendritic cells have been shown to be effective targets for 
enhancement of antigen loading and presentation, research has also shown 
that the presence of the inhibitory Fcγ receptor is able to determine whether 
this response ensues or is rendered tolerant [202].   
 
It was clear from phagocytosis studies that γ-chain deficient BMDCs which 
only express the inhibitory Fcγ receptor were still able to phagocytose 
apoptotic cells more readily in the presence of DN-MFG-E8-Fc protein 
(figure 4.9) and additionally were still able to cross-present antigen to OT-I 
cells  in vitro (figure 5.4).  To evaluate whether the balance between 
activation and inhibitory signals through FcγRs on dendritic cells is 
important in determining dendritic cell maturation, DCs were generated 
from bone marrow-derived from either C57BL/6 WT or FcγRIIb-deficient 
mice.   
 
In comparison to LPS-induced maturation, WT BMDCs were inefficiently 
matured in response to apoptotic cells cleared in the presence of DN-MFG-
E8-Fc protein (figure 5.8) as determined by their surface expression of 
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CD86 and CD70.  This is consistent with previous reports which target IgG 
immune complexes to WT BMDCs in vitro and examine their maturation 
[46].  However, FcγRIIb-/- BMDCs displayed a maturation phenotype that 
was comparable to that seen with LPS when apoptotic cells were 
phagocytosed in the presence of DN-MFG-E8-Fc protein, showing 
upregulation of both CD86 and CD70 surface expression (figure 5.8).  The 
possibility that FcγRIIb-/- BMDCs were more sensitive to maturation in 
general could be excluded by the fact that FcγRIIb-/- BMDCs showed 
equivalent maturation in response to LPS compared to WT controls. 
 
Although the main focus of this study was to determine whether a CD8+ T 
cell response could be generated against apoptotic cell-associated antigens 
without the requirement of additional exogenous adjuvants, it was also of 
interest to examine what effect these proteins could have on the humoral 
immune response which can also be manipulated by the presence of 
apoptotic cells.  The exposure of PS on apoptotic cells has been shown to 
alleviate both inflammation and the generation of antibodies against self or 
model antigens [178, 211].  In support of this, the blockade of PS with 
either DN-MFG-E8 or DN-MFG-E8-Fc protein alleviated the ability of 
apoptotic cells to suppress the generation of antibodies against the model 
antigen, KLH (figure 5.11).  
 
This study, with the corroboration of others, signifies the ever apparent 
stark contrast between an immune response observed in vitro to that 
observed in vivo.  The loading of dendritic cells ex vivo with apoptotic 
tumour cells for use as tumour vaccines will eradicate the potential 
interference of macrophages and other phagocytes, whilst also ensuring 
that dendritic cells are functionally mature before being administered, so as 
to limit the risk of inducing further tumour tolerance.  It is clear that the 
route of antigen uptake, the amount of antigen load and the subsequent 
dendritic cell maturation, are all vital components for generating immunity. 
In particular, this study, again supported by other groups [46] has shown 
that Fcγ receptor-mediated DC maturation in vitro is critically dependent 
on the balance between opposing activating and inhibitory receptors.  The 
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pivotal role of FcγRIIb in this process is clearly paramount where by 
studies which involve loading of DCs ex vivo with tumour antigens prior to 
administration in vivo have only been successful using either DCs from 
FcγRIIb-deficient mice [46], or when an additional adjuvant such as TLR 
ligand or anti-CD40 has been used to ensure activate DC maturation [235].  
Research has already started to focus; the aim of a particular study was to 
identify IgG1 Fc domains which showed improved binding to the low-
affinity activating Fc receptor FcγRIIIa and reduced binding to the low-
affinity FcγRIIb [236].   
 
In order to safely and effectively use apoptotic tumour cells as a source of 
antigen for cross-priming by dendritic cells in tumour therapy, further 
investigation into mechanisms which control receptor-mediated clearance 
must be further investigated.  The milieu of factors which can influence the 
immune outcome in vivo must also raise caution when trying to make 
predictions from in vitro data. 
 
Future work 
 
This work, supported strongly by a recently published study [237] would 
suggest that the application of either DN-MFG-E8 or DN-MFG-E8-Fc 
proteins is, alone, likely to prove difficult in generating an effective cancer 
immunotherapy.  This does not however rule out their potential use in 
combination with other cancer therapeutic regimens such as chemotherapy.  
A recent study has shown that an anti-MFG-E8 antibody used in 
combination with the chemotherapy drug, gemcitabine, worked effectively 
in a murine colon carcinoma model, showing long term protection in a 
synergistic manner.  Interestingly, its effectiveness was most dramatic 
when anti-MFG-E8 antibody was administered either at the same time, 3 or 
7 days post treatment with gemcitabine [237].  Their study, as well as the 
results obtained within this study suggests that a cohort of different 
variables in vivo dictate the immune outcome.   
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In order to take this research forward, it would be of key interest to 
determine whether the treatment of either DN-MFG-E8 or DN-MFG-E8-Fc 
proteins used in parallel with a chemotherapy drug in a murine tumour 
model is able to synergistically induce tumour regression and potentially 
long term survival.  A question which immediately arises from the study 
using an anti-MFG-E8 antibody with gemcitabine, is why the combination 
therapy is only successful when the antibody is used at particular time 
points throughout the experiment.   
The amount or type of tumour cell death caused in response to the 
chemotherapy drug will affect the level of binding of the MFG-E8 protein 
to bind to phosphatidylserine on apoptotic cells.  Similarly, the plethora of 
cytokines and chemokines which are present during the treatment course 
are also likely to vary, again, influencing the possible effectiveness of 
either PS blockade or the clearance of tumour cells through Fcγ receptors 
on phagocytes. 
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